Michael J. Keating, M.B., B.S.

Peer-Reviewed Articles

1. Zhang R, Khare P, Banerjee P, Ivan C, Schneider S, Barbaglio F, Clise-Dwyer K, Jensen VB, Thompson E, Mendoza M, Chiorazzi N, Chen SS, Yan XJ, Jain N, Ghia P, Caligaris-Cappio F, Mendonsa R, Kasimsetty S, Swoboda R, Bayraktar R, Wierda W, Gandhi V, Calin GA, Keating MJ, Bertilaccio MTS. The DLEU2/miR-15a/miR-16-1 cluster shapes the immune microenvironment of chronic lymphocytic leukemia. Blood Cancer J 14(1):168, 2024. e-Pub 2024. PMID: 39438453.
2. Liu P, Wang K, Li J, Ogasawara MA, Xia Z, Wierda WG, Keating MJ, Li Y, Huang P. Global miRNA profiling reveals key molecules that contribute to different chronic lymphocytic leukemia incidences in Asian and Western populations. Haematologica 109(2):479-492, 2024. e-Pub 2024. PMID: 37646669.
3. Thompson PA, Bazinet A, Wierda WG, Tam CS, O'Brien SM, Saha S, Peterson CB, Plunkett W, Keating MJ. Sustained remissions in CLL after frontline FCR treatment with very long-term follow-up. Blood 142(21):1784-1788, 2023. e-Pub 2023. PMID: 37595283.
4. Corvigno S, Badal S, Spradlin ML, Keating M, Pereira I, Stur E, Bayraktar E, Foster KI, Bateman NW, Barakat W, Darcy KM, Conrads TP, Maxwell GL, Lorenzi PL, Lutgendorf SK, Wen Y, Zhao L, Thaker PH, Goodheart MJ, Liu J, Fleming N, Lee S, Eberlin LS, Sood AK. In situ profiling reveals metabolic alterations in the tumor microenvironment of ovarian cancer after chemotherapy. NPJ Precis Oncol 7(1):115, 2023. e-Pub 2023. PMID: 37923835.
5. Gordon MJ, Jones JE, George B, Peterson C, Burger JA, Jain N, Keating M, Wierda WG, Durand JB, Ferrajoli A. Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity. Cancer 129(14):2192-2200, 2023. e-Pub 2023. PMID: 37016930.
6. Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, Basu S, Kadia T, Daver N, Borthakur G, Konopleva M, Pemmaraju N, Parry E, Wu CJ, Khoury J, Bueso-Ramos C, Garg N, Wang X, Lopez W, Ayala A, O'Brien S, Kantarjian H, Keating M, Allison J, Sharma P, Wierda W. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Adv 7(10):1958-1966, 2023. e-Pub 2023. PMID: 36287248.
7. Thompson PA, Keating MJ, Ferrajoli A, Jain N, Peterson CB, Garg N, Wang SA, Jorgensen JL, Kadia TM, Bose P, Pemmaraju N, Short NJ, Wierda WG. Venetoclax consolidation in high-risk CLL treated with ibrutinib for =1 year achieves a high rate of undetectable MRD. Leukemia. e-Pub 2023. PMID: 37138019.
8. Boddu PC, Senapati J, Ravandi-Kashani F, Jabbour EJ, Jain N, Ayres M, Chen Y, Keating MJ, Kantarjian HM, Gandhi V, Kadia TM. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies. Cancer 129(4):580-589, 2023. e-Pub 2023. PMID: 36448227.
9. Rozovski U, Veletik I, Harris D, Li P, Liu Z, Jain P, Manshouri T, Ferrajoli A, Burger J, Bose P, Thompson P, Jain N, Wierda W, Verstovsek S, Keating M, Estrov Z. CLL-162 PTX3 is Constitutively Active in CLL Cells. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S271, 2022. e-Pub 2022. PMID: 36163878.
10. Thompson PA, Jiang X, Banerjee P, Basar R, Garg N, Chen K, Kaplan M, Nandivada V, Cortes AKN, Ferrajoli A, Keating MJ, Peterson CB, Andreeff M, Rezvani K, Wierda WG. A phase two study of high dose blinatumomab in Richter's syndrome. Leukemia 36(9):2228-2232, 2022. e-Pub 2022. PMID: 35941212.
11. Cherng HJ, Khwaja R, Kanagal-Shamanna R, Tang G, Burger J, Thompson P, Ferrajoli A, Estrov Z, Sasaki K, Sampath D, Wang X, Kantarjian H, Keating M, Wierda WG, Jain N. TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis. Am J Hematol 97(8):1005-1012, 2022. e-Pub 2022. PMID: 35567779.
12. Tettamanti S, Rotiroti MC, Giordano Attianese GMP, Arcangeli S, Zhang R, Banerjee P, Galletti G, McManus S, Mazza M, Nicolini F, Martinelli G, Ivan C, Veliz Rodriguez T, Barbaglio F, Scarfò L, Ponzoni M, Wierda W, Gandhi V, Keating M, Biondi A, Caligaris-Cappio F, Biagi E, Ghia P, Bertilaccio MTS. Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia. Leuk Lymphoma 63(7):1-14, 2022. e-Pub 2022. PMID: 35259043.
13. Rozovski U, Veletic I, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Verstovsek S, Keating MJ, Estrov Z. STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells. J Immunol 208(12):2847-2855, 2022. e-Pub 2022. PMID: 35595309.
14. Chen R, Chen Y, Xiong P, Zheleva D, Blake D, Keating MJ, Wierda WG, Plunkett W. Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells. Leukemia 36(6):1596-1608, 2022. e-Pub 2022. PMID: 35383271.
15. Sivina M, Kim E, Wierda WG, Ferrajoli A, Jain N, Thompson P, Kantarjian H, Keating M, Burger JA. Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion/TP53 mutations. Blood 138(24):2589-2592, 2021. e-Pub 2021. PMID: 34521099.
16. Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia 35(12):3421-3429, 2021. e-Pub 2021. PMID: 34007049.
17. Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol 7(8):1213-1219, 2021. e-Pub 2021. PMID: 34110383.
18. Cherng HJ, Jammal N, Paul S, Wang X, Sasaki K, Thompson P, Burger J, Ferrajoli A, Estrov Z, O'Brien S, Keating M, Wierda WG, Jain N. Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia. Br J Haematol 194(1):61-68, 2021. e-Pub 2021. PMID: 33973230.
19. Sivina M, Xiao L, Kim E, Vaca A, Chen SS, Keating MJ, Ferrajoli A, Estrov Z, Jain N, Wierda WG, Huang X, Chiorazzi N, Burger JA. CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia. Leukemia 35(6):1610-1620, 2021. e-Pub 2021. PMID: 33087831.
20. Assi R, Kantarjian H, Keating M, Pemmaraju N, Verstovsek S, Garcia-Manero G, Ravandi F, Borthakur G, Dahl J, Jabbour E, Cortes JE. Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience. Leuk Lymphoma 62(4):1-14, 2021. e-Pub 2021. PMID: 33283580.
21. Chen R, Tsai J, Thompson PA, Chen Y, Xiong P, Liu C, Burrows F, Sivina M, Burger JA, Keating MJ, Wierda WG, Plunkett W. The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action. Blood Cancer J 11(3):57, 2021. e-Pub 2021. PMID: 33714981.
22. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Veletic I, Ferrajoli A, Bose P, Thompson P, Jain N, Verstovsek S, Wierda W, Keating MJ, Estrov Z. STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells. Oncotarget 12(5):401-411, 2021. e-Pub 2021. PMID: 33747356.
23. Yi X, Sarkar A, Kismali G, Aslan B, Ayres M, Iles LR, Keating MJ, Wierda WG, Long JP, Bertilaccio MTS, Gandhi V. AMG-176, an Mcl-1 antagonist, shows preclinical efficacy in chronic lymphocytic leukemia. Clin Cancer Res 26(14):3856-3867, 2020. e-Pub 2020. PMID: 31937611.
24. Kim E, Ten Hacken E, Sivina M, Clarke A, Thompson PA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG, Bhalla KN, Burger JA. The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. Leukemia 34(6):1588-1598, 2020. e-Pub 2020. PMID: 31862959.
25. Strati P, Schlette EJ, Solis Soto LM, Duenas DE, Sivina M, Kim E, Keating MJ, Wierda WG, Ferrajoli A, Kantarjian H, Estrov Z, Jain N, Thompson PA, Wistuba II, Burger JA. Achieving Complete Remission in CLL Patients Treated with Ibrutinib: Clinical Significance and Predictive Factors. Blood 135(7):510-513, 2020. e-Pub 2020. PMID: 31895947.
26. Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med 382(6):545-553, 2020. e-Pub 2020. PMID: 32023374.
27. Vitale C, Falchi L, Ciccone M, Burger J, Pemmaraju N, Borthakur G, Wierda WG, Keating MJ, Ferrajoli A. Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies. J Geriatr Oncol 11(1):19-23, 2020. e-Pub 2020. PMID: 31005650.
28. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Uziel O, Keating MJ, Estrov Z. STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage. J Immunol 203(11):3078-3085, 2019. e-Pub 2019. PMID: 31645416.
29. Banerjee P, Zhang R, Ivan C, Galletti G, Clise-Dwyer K, Barbaglio F, Scarfò L, Aracil M, Klein C, Wierda W, Plunkett W, Caligaris-Cappio F, Gandhi V, Keating MJ, Bertilaccio MTS. Trabectedin reveals a strategy of immunomodulation in chronic lymphocytic leukemia. Cancer Immunol Res 7(12):2036-2051, 2019. e-Pub 2019. PMID: 31530560.
30. Chen LS, Keating MJ, Wierda WG, Gandhi V. Induction of apoptosis by MCL-1 inhibitors in chronic lymphocytic leukemia cells. Leuk Lymphoma 60(12):1-4, 2019. e-Pub 2019. PMID: 31161836.
31. Thompson PA, Srivastava J, Peterson C, Strati P, Jorgensen JL, Hether T, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Wierda WG. Undetectable MRD Using Next Generation Sequencing is Associated With Improved PFS After Treatment with FCR for CLL. Blood 134(22):1951-1959, 2019. e-Pub 2019. PMID: 31537528.
32. Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur GM, Takahashi K, Estrov ZE, Fowler NH, Kadia TM, Konopleva MY, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang SA, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). Blood 134(Supplement_1):34, 2019. e-Pub 2019. PMID: 31724006.
33. Herling CD, Coombes KR, Benner A, Bloehdorn J, Barron LL, Abrams ZB, Majewski T, Bondaruk JE, Bahlo J, Fischer K, Hallek M, Stilgenbauer S, Czerniak BA, Oakes CC, Ferrajoli A, Keating MJ, Abruzzo LV. Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study. Lancet Oncol 20(11):1576-1586, 2019. e-Pub 2019. PMID: 31582354.
34. Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating M, Wierda WG. Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol 187(3):307-318, 2019. e-Pub 2019. PMID: 31243771.
35. Strati P, Wang F, Tambaro FP, Thompson PA, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Futreal A, Takahashi K, Wierda WG. The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. Br J Haematol 187(1):e1-e4, 2019. e-Pub 2019. PMID: 31344256.
36. Zucker MR, Abruzzo LV, Herling CD, Barron LL, Keating MJ, Abrams ZB, Heerema N, Coombes KR. Inferring Clonal Heterogeneity in Cancer using SNP Arrays and Whole Genome Sequencing. Bioinformatics 35(17):2924-2931, 2019. e-Pub 2019. PMID: 30689715.
37. Zucker MR, Abruzzo LV, Herling CD, Barron LL, Keating MJ, Abrams ZB, Heerema N, Coombes KR. Inferring clonal heterogeneity in cancer using SNP arrays and whole genome sequencing. Bioinformatics 35(17):3216, 2019. e-Pub 2019. PMID: 31161200.
38. Giacopelli B, Zhao Q, Ruppert AS, Agyeman A, Weigel C, Wu YZ, Gerber MM, Rabe KG, Larson MC, Lu J, Blachly JS, Rogers KA, Wierda WG, Brown JR, Rai KR, Keating M, Rassenti LZ, Kipps TJ, Zenz T, Shanafelt TD, Kay NE, Abruzzo LV, Coombes KR, Woyach JA, Byrd JC, Oakes CC. Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia. Blood 134(8):688-698, 2019. e-Pub 2019. PMID: 31292113.
39. Hu B, Patel KP, Chen HC, Wang X, Wang F, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Wierda WG. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol 185(5):852-864, 2019. e-Pub 2019. PMID: 30924136.
40. Gruber M, Bozic I, Leshchiner I, Livitz D, Stevenson K, Rassenti L, Rosebrock D, Taylor-Weiner A, Olive O, Goyetche R, Fernandes SM, Sun J, Stewart C, Wong A, Cibulskis C, Zhang W, Reiter JG, Gerold JM, Gribben JG, Rai KR, Keating MJ, Brown JR, Neuberg D, Kipps TJ, Nowak MA, Getz G, Wu CJ. Growth dynamics in naturally progressing chronic lymphocytic leukaemia. Nature 570(7762):474-479, 2019. e-Pub 2019. PMID: 31142838.
41. Strati P, Takahashi K, Peterson CB, Keating MJ, Thompson PA, Daver NG, Jain N, Burger JA, Estrov Z, O'Brien SM, Kantarjian HM, Wierda WG, Futreal PA, Ferrajoli A. Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Adv 3(9):1533-1539, 2019. e-Pub 2019. PMID: 31076409.
42. Paul S, Jain N, Ferrajoli A, O'Brien S, Burger J, Keating M, Wierda W. A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia. Br J Haematol 185(3):606-608, 2019. e-Pub 2019. PMID: 30406944.
43. Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 380(22):2095-2103, 2019. e-Pub 2019. PMID: 31141631.
44. Van Roosbroeck K, Bayraktar R, Calin S, Bloehdorn J, Dragomir MP, Okubo K, Bertilaccio MTS, Zupo S, You MJ, Gaidano G, Rossi D, Chen SS, Chiorazzi N, Thompson PA, Ferrajoli A, Bertoni F, Stilgenbauer S, Keating MJ, Calin GA. miRNAs involvement in the pathogenesis of Richter's syndrome. Haematologica 104(5):1004-1015, 2019. e-Pub 2019. PMID: 30409799.
45. Cervantes-Gomez F, Stellrecht CM, Ayres ML, Keating MJ, Wierda WG, Gandhi V. PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells. Oncotarget 10(29):2793-2809, 2019. e-Pub 2019. PMID: 31073371.
46. Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, Nogueras-Gonzalez GM, Huang X, Jorgensen J, Li J, Cheng M, Clow F, Ohanian M, Andreeff M, Mathew T, Thompson P, Kantarjian H, O'Brien S, Wierda WG, Ferrajoli A, Keating MJ. Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood 133(10):1011-1019, 2019. e-Pub 2019. PMID: 30530801.
47. Kanagal-Shamanna R, Jain P, Patel KP, Routbort M, Bueso-Ramos C, Alhalouli T, Khoury JD, Luthra R, Ferrajoli A, Keating M, Jain N, Burger J, Estrov Z, Wierda W, Kantarjian HM, Medeiros LJ. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer 125(4):559-574, 2019. e-Pub 2019. PMID: 30508305.
48. Abruzzo LV, Herling CD, Calin GA, Oakes C, Barron LL, Banks HE, Katju V, Keating MJ, Coombes KR. Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways. Haematologica 103(12):2069-2078, 2018. e-Pub 2018. PMID: 29976738.
49. Chen LS, Bose P, Cruz ND, Jiang Y, Wu Q, Thompson PA, Feng S, Kroll MH, Qiao W, Huang X, Jain N, Wierda WG, Keating MJ, Gandhi V. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood 132(21):2249-2259, 2018. e-Pub 2018. PMID: 30254130.
50. Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo CD, Daver N, Jabbour E, Wierda WG. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia 32(11):2388-2398, 2018. e-Pub 2018. PMID: 29769624.
51. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia. Leuk Lymphoma 59(11):2686-2691, 2018. e-Pub 2018. PMID: 29465264.
52. Strati P, Ferrajoli A, Wierda WG, Jain N, Thompson PA, O'Brien SM, Rezvani K, Kantarjian HM, Burger JA, Hinojosa CO, Keating MJ, Estrov Z. Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia. Leukemia 32(10):2278-2281, 2018. e-Pub 2018. PMID: 29479067.
53. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells. Oncotarget 9(72):33710-33718, 2018. e-Pub 2018. PMID: 30263097.
54. Kantarjian HM, DiNardo CD, Nogueras-Gonzalez GM, Kadia TM, Jabbour E, Bueso-Ramos CE, O'Brien SM, Konopleva M, Jain NB, Daver NG, Shpall EJ, Champlin RE, Simkins A, Garcia-Manero G, Keating MJ, Huang X, Cortes JE, Pierce SA, Ravandi F, Freireich EJ. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer 124(12):2534-2540, 2018. e-Pub 2018. PMID: 29645075.
55. Vangapandu HV, Chen H, Wierda WG, Keating MJ, Korkut A, Gandhi V. Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells. Leuk Lymphoma 59(6):1-12, 2018. e-Pub 2018. PMID: 28971726.
56. Vangapandu HV, Alston B, Morse J, Ayres ML, Wierda WG, Keating MJ, Marszalek JR, Gandhi V. Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cells. Oncotarget 9(38):24980-24991, 2018. e-Pub 2018. PMID: 29861847.
57. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells. Oncotarget 9(30):21268-21280, 2018. e-Pub 2018. PMID: 29765537.
58. Takahashi K, Hu B, Wang F, Yan Y, Kim E, Vitale C, Patel KP, Strati P, Gumbs C, Little L, Tippen S, Song X, Zhang J, Jain N, Thompson P, Garcia-Manero G, Kantarjian H, Estrov Z, Do KA, Keating M, Burger JA, Wierda WG, Futreal PA, Ferrajoli A. Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood 131(16):1820-1832, 2018. e-Pub 2018. PMID: 29358183.
59. Patel VK, Lamothe B, Ayres ML, Gay J, Cheung JP, Balakrishnan K, Ivan C, Morse J, Nelson M, Keating MJ, Wierda WG, Marszalek JR, Gandhi V. Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia 32(4):920-930, 2018. e-Pub 2018. PMID: 29099493.
60. Sivina M, Werner L, Rassenti L, Ferrajoli A, Wierda WG, Keating MJ, O'Brien S, Neuberg D, Kipps T, Burger JA. Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation. Br J Haematol 180(4):597-600, 2018. e-Pub 2018. PMID: 27766619.
61. Jain P, Nogueras González GM, Kanagal-Shamanna R, Rozovski U, Sarwari N, Tam C, Wierda WG, Thompson PA, Jain N, Luthra R, Quesada A, Sanchez-Petitto G, Ferrajoli A, Burger J, Kantarjian H, Cortes J, O'Brien S, Keating MJ, Estrov Z. The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. Br J Haematol 180(1):33-40, 2018. e-Pub 2018. PMID: 29164608.
62. Schliffke S, Sivina M, Kim E, von Wenserski L, Thiele B, Akyüz N, Falker-Gieske C, Statovci D, Oberle A, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Jain N, Estrov Z, Ferrajoli A, Wierda W, Keating M, Burger JA, Binder M. Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy. Oncoimmunology 7(4):e1417720, 2018. e-Pub 2018. PMID: 29632735.
63. Lu W, Hu Y, Chen G, Chen Z, Zhang H, Wang F, Feng L, Pelicano H, Wang H, Keating MJ, Liu J, McKeehan W, Wang H, Luo Y, Huang P. Correction: Novel Role of NOX in Supporting Aerobic Glycolysis in Cancer Cells with Mitochondrial Dysfunction and as a Potential Target for Cancer Therapy. PLoS Biol 15(12):e1002616, 2017. e-Pub 2017. PMID: 29227990.
64. Vangapandu HV, Havranek O, Ayres ML, Kaipparettu BA, Balakrishnan K, Wierda WG, Keating MJ, Davis RE, Stellrecht CM, Gandhi V. B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia. Mol Cancer Res 15(12):1692-1703, 2017. e-Pub 2017. PMID: 28835371.
65. Strati P, Keating MJ, Burger JA, O'Brien SM, Wierda WG, Estrov Z, Zacharian G, Ferrajoli A. Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia. Haematologica 102(12):e494-e496, 2017. e-Pub 2017. PMID: 28798068.
66. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Activation of the B-cell receptor successively activates NF-κB and STAT3 in chronic lymphocytic leukemia cells. Int J Cancer 141(10):2076-2081, 2017. e-Pub 2017. PMID: 28722170.
67. Vangapandu HV, Ayres ML, Bristow CA, Wierda WG, Keating MJ, Balakrishnan K, Stellrecht CM, Gandhi V. The Stromal Microenvironment Modulates Mitochondrial Oxidative Phosphorylation in Chronic Lymphocytic Leukemia Cells. Neoplasia 19(10):762-771, 2017. e-Pub 2017. PMID: 28863345.
68. Stellrecht CM, Chen LS, Ayres ML, Dennison JB, Shentu S, Chen Y, Keating MJ, Wierda WG, Gandhi V. Chlorinated adenosine analogue induces AMPK and autophagy in chronic lymphocytic leukaemia cells during therapy. Br J Haematol 179(2):266-271, 2017. e-Pub 2017. PMID: 28737232.
69. Hacken ET, Gounari M, Back JW, Shimanovskaya E, Scarfò L, Kim E, Burks J, Ponzoni M, Ramirez GA, Wierda WG, Estrov Z, Keating MJ, Ferrajoli A, Stamatopoulos K, Ghia P, Burger JA. Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia. Haematologica 102(10):e394-e396, 2017. e-Pub 2017. PMID: 28751563.
70. Jain P, Kanagal-Shamanna R, Wierda W, Ferrajoli A, Keating M, Jain N. Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab. Hematol Oncol Stem Cell Ther 10(3):151-154, 2017. e-Pub 2017. PMID: 27352257.
71. Patel V, Balakrishnan K, Bibikova E, Ayres M, Keating MJ, Wierda WG, Gandhi V. Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells. Clin Cancer Res 23(14):3734-3743, 2017. e-Pub 2017. PMID: 28034907.
72. Jain P, Thompson PA, Keating M, Estrov Z, Ferrajoli A, Jain N, Kantarjian H, Burger JA, O'Brien S, Wierda WG. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer 123(12):2268-2273, 2017. e-Pub 2017. PMID: 28171709.
73. Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez-Aguayo C, Fuentes-Mattei E, Xiao L, Vannini I, Redis RS, D'Abundo L, Zhang X, Nicoloso MS, Rossi S, Gonzalez-Villasana V, Rupaimoole R, Ferracin M, Morabito F, Neri A, Ruvolo PP, Ruvolo VR, Pecot CV, Amadori D, Abruzzo L, Calin S, Wang X, You MJ, Ferrajoli A, Orlowski R, Plunkett W, Lichtenberg TM, Davuluri RV, Berindan-Neagoe I, Negrini M, Wistuba II, Kantarjian HM, Sood AK, Lopez-Berestein G, Keating MJ, Fabbri M, Calin GA. Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. Clin Cancer Res 23(11):2891-2904, 2017. e-Pub 2017. PMID: 27903673.
74. Fuentes-Mattei E, Giza DE, Shimizu M, Ivan C, Manning JT, Tudor S, Ciccone M, Kargin OA, Zhang X, Mur P, do Amaral NS, Chen M, Tarrand JJ, Lupu F, Ferrajoli A, Keating MJ, Vasilescu C, Yeung SJ, Calin GA. Plasma Viral miRNAs Indicate a High Prevalence of Occult Viral Infections. EBioMedicine 20:182-192, 2017. e-Pub 2017. PMID: 28465156.
75. Abou Zahr A, Bose P, Keating MJ. Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia. Expert Opin Pharmacother 18(9):1-17, 2017. e-Pub 2017. PMID: 28446054.
76. Jain P, Keating MJ, Wierda WG, Sivina M, Thompson PA, Ferrajoli A, Estrov Z, Kantarjian H, O'Brien S, Burger JA. Long term follow up of treatment with ibrutinib and rituximab (IR) in patients with high-risk Chronic Lymphocytic Leukemia (CLL). Clin Cancer Res 23(9):2154-2158, 2017. e-Pub 2017. PMID: 27797975.
77. Thompson PA, Stingo F, Keating MJ, Wierda WG, O'Brien SM, Estrov Z, Ledesma C, Rezvani K, Qazilbash M, Shah N, Parmar S, Popat U, Anderlini P, Yago N, Ciurea SO, Kebriaei P, Champlin R, Shpall EJ, Hosing CM. Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. Br J Haematol 177(4):567-577, 2017. e-Pub 2017. PMID: 28295181.
78. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, O'Brien S, Bose P, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex. Mol Cancer Res 15(5):610-618, 2017. e-Pub 2017. PMID: 28130399.
79. Jain N, Balakrishnan K, Ferrajoli A, O'Brien SM, Burger JA, Kadia TM, Cortes JE, Ayres ML, Tambaro FP, Keating MJ, Gandhi V, Wierda WG. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. Oncotarget 8(13):22104-22112, 2017. e-Pub 2017. PMID: 27655665.
80. Modi P, Balakrishnan K, Yang Q, Wierda WG, Keating MJ, Gandhi V. Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells. Oncotarget 8(10):16259-16274, 2017. e-Pub 2017. PMID: 28187444.
81. Yin Q, Sivina M, Robins H, Yusko E, Vignali M, O'Brien S, Keating MJ, Ferrajoli A, Estrov Z, Jain N, Wierda WG, Burger JA. Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia. J Immunol 198(4):1740-1747, 2017. e-Pub 2017. PMID: 28077600.
82. Jain P, Keating M, Renner S, Cleeland C, Xuelin H, Gonzalez GN, Harris D, Li P, Liu Z, Veletic I, Rozovski U, Jain N, Thompson P, Bose P, DiNardo C, Ferrajoli A, O'Brien S, Burger J, Wierda W, Verstovsek S, Kantarjian H, Estrov Z. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol 4(2):e67-e74, 2017. e-Pub 2017. PMID: 28089238.
83. Burger JA, Li KW, Keating MJ, Sivina M, Amer AM, Garg N, Ferrajoli A, Huang X, Kantarjian H, Wierda WG, O'Brien S, Hellerstein MK, Turner SM, Emson CL, Chen SS, Yan XJ, Wodarz D, Chiorazzi N. Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib. JCI Insight 2(2):e89904, 2017. e-Pub 2017. PMID: 28138560.
84. Chen Q, Jain N, Ayer T, Wierda WG, Flowers CR, O'Brien SM, Keating MJ, Kantarjian HM, Chhatwal J. Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. J Clin Oncol 35(2):JCO2016682856, 2017. e-Pub 2017. PMID: 27870563.
85. Cramer SL, Saha A, Liu J, Tadi S, Tiziani S, Yan W, Triplett K, Lamb C, Alters SE, Rowlinson S, Zhang YJ, Keating MJ, Huang P, DiGiovanni J, Georgiou G, Stone E. Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth. Nat Med 23(1):120-127, 2017. e-Pub 2017. PMID: 27869804.
86. Shaim H, Estrov Z, Harris D, Hernandez Sanabria M, Liu Z, Ruvolo P, Thompson PA, Ferrajoli A, Daher M, Burger J, Muftuoglu M, Imahashi N, Li L, Liu E, Alsuliman AS, Basar R, Nassif Kerbauy L, Sobieski C, Gokdemir E, Kondo K, Wierda W, Keating M, Shpall EJ, Rezvani K. The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide. Front Immunol 8:1773, 2017. e-Pub 2017. PMID: 29379494.
87. Ryan CE, Sahaf B, Logan AC, O'Brien S, Byrd JC, Hillmen P, Brown JR, Dyer MJ, Mato AR, Keating MJ, Jaglowski S, Clow F, Rezvani AR, Styles L, Coutre SE, Miklos DB. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood 128(25):2899-2908, 2016. e-Pub 2016. PMID: 27802969.
88. Liu J, Chen G, Pelicano H, Liao J, Huang J, Feng L, Keating MJ, Huang P. Targeting p53-deficient chronic lymphocytic leukemia cells in vitro and in vivo by ROS-mediated mechanism. Oncotarget 7(44):71378-71389, 2016. e-Pub 2016. PMID: 27655686.
89. Jain P, Kanagal-Shamanna R, Wierda W, Keating M, Sarwari N, Rozovski U, Thompson P, Burger J, Kantarjian H, Patel KP, Medeiros LJ, Luthra R, Estrov Z. Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. Am J Hematol 91(11):E478-E479, 2016. e-Pub 2016. PMID: 27468087.
90. Thompson PA, Lévy V, Tam CS, Al Nawakil C, Goudot FX, Quinquenel A, Ysebaert L, Michallet AS, Dilhuydy MS, Van Den Neste E, Dupuis J, Keating MJ, Meune C, Cymbalista F. Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study. Br J Haematol 175(3):462-466, 2016. e-Pub 2016. PMID: 27611233.
91. Ogasawara MA, Liu J, Pelicano H, Hammoudi N, Croce CM, Keating MJ, Huang P. Alterations of mitochondrial biogenesis in chronic lymphocytic leukemia cells with loss of p53. Mitochondrion 31:33-39, 2016. e-Pub 2016. PMID: 27650502.
92. Bose P, Gandhi VV, Keating MJ. Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses. Expert Opin Drug Metab Toxicol 12(11):1-12, 2016. e-Pub 2016. PMID: 27686109.
93. Liu PP, Liu J, Jiang WQ, Carew JS, Ogasawara MA, Pelicano H, Croce CM, Estrov Z, Xu RH, Keating MJ, Huang P. Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline. Oncogene 35(43):5663-5673, 2016. e-Pub 2016. PMID: 27065330.
94. O'Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, Österborg A, Siddiqi T, Thirman MJ, Furman RR, Ilhan O, Keating MJ, Call TG, Brown JR, Stevens-Brogan M, Li Y, Clow F, James DF, Chu AD, Hallek M, Stilgenbauer S. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol 17(10):1409-1418, 2016. e-Pub 2016. PMID: 27637985.
95. Ten Hacken E, Sivina M, Kim E, O'Brien S, Wierda WG, Ferrajoli A, Estrov Z, Keating MJ, Oellerich T, Scielzo C, Ghia P, Caligaris-Cappio F, Burger JA. Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia. J Immunol 197(6):2522-31, 2016. e-Pub 2016. PMID: 27534555.
96. Lamothe B, Wierda WG, Keating MJ, Gandhi V. Carfilzomib triggers cell death in chronic lymphocytic leukemia by inducing proapoptotic and endoplasmic reticulum stress responses. Clin Cancer Res 22(18):4712-26, 2016. e-Pub 2016. PMID: 27026200.
97. Jiang Y, Chen HC, Su X, Thompson PA, Liu X, Do KA, Wierda W, Keating MJ, Plunkett W. ATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion (11q22.3-23.2). Blood Cancer J 6(9):e465, 2016. e-Pub 2016. PMID: 27588518.
98. Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, Jena B, Dawson MJ, Kumaresan PR, Su S, Maiti S, Dai J, Moriarity B, Forget MA, Senyukov V, Orozco A, Liu T, McCarty J, Jackson RN, Moyes JS, Rondon G, Qazilbash M, Ciurea S, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Kantarjian H, Keating M, Wierda W, Do KA, Largaespada DA, Lee DA, Hackett PB, Champlin RE, Cooper LJ. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest 126(9):3363-76, 2016. e-Pub 2016. PMID: 27482888.
99. Chihara D, Kantarjian H, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Poku R, Jain P, Thompson P, Brandt M, Luthra R, Burger J, Keating M, Ravandi F. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol 174(5):760-6, 2016. e-Pub 2016. PMID: 27301277.
100. Thompson PA, Stingo F, Keating MJ, Ferrajoli A, Burger JA, Wierda WG, Kadia TM, O'Brien SM. Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity. Cancer 122(16):2505-11, 2016. e-Pub 2016. PMID: 27182988.
101. Jain N, Keating MJ. Richter transformation of CLL. Expert Rev Hematol 9(8):1-9, 2016. e-Pub 2016. PMID: 27351634.
102. Balakrishnan K, Fu M, Onida F, Wierda WG, Keating MJ, Gandhi V. Reactivation of smac-mediated apoptosis in chronic lymphocytic leukemia cells: mechanistic studies of smac mimetic. Oncotarget 7(26):39458-39472, 2016. e-Pub 2016. PMID: 27223062.
103. Vitale C, Ahn IE, Sivina M, Ferrajoli A, Wierda WG, Estrov Z, Konoplev SN, Jain N, O'Brien S, Farooqui M, Keating MJ, Wiestner A, Burger JA. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica 101(6):e254-8, 2016. e-Pub 2016. PMID: 27013651.
104. Falchi L, Vitale C, Keating MJ, Lerner S, Wang X, Elhor Gbito KY, Strom S, Wierda WG, Ferrajoli A. Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia. Ann Oncol 27(6):1100-1106, 2016. e-Pub 2016. PMID: 26912560.
105. Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K, Wang L, Stewart C, Fan J, Hoellenriegel J, Sivina M, Dubuc AM, Fraser C, Han Y, Li S, Livak KJ, Zou L, Wan Y, Konoplev S, Sougnez C, Brown JR, Abruzzo LV, Carter SL, Keating MJ, Davids MS, Wierda WG, Cibulskis K, Zenz T, Werner L, Dal Cin P, Kharchencko P, Neuberg D, Kantarjian H, Lander E, Gabriel S, O'Brien S, Letai A, Weitz DA, Nowak MA, Getz G, Wu CJ. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun 7:11589, 2016. e-Pub 2016. PMID: 27199251.
106. Vitale C, Falchi L, Ten Hacken E, Gao H, Shaim H, Van Roosbroeck K, Calin G, O'Brien S, Faderl S, Wang X, Wierda WG, Rezvani K, Reuben JM, Burger JA, Keating MJ, Ferrajoli A. Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation Between Responses and Immune Characteristics. Clin Cancer Res 22(10):2359-67, 2016. e-Pub 2016. PMID: 26733610.
107. Rozovski U, Harris DM, Li P, Liu Z, Wu JY, Grgurevic S, Faderl S, Ferrajoli A, Wierda WG, Martinez M, Verstovsek S, Keating MJ, Estrov Z. At High Levels, Constitutively Activated STAT3 Induces Apoptosis of Chronic Lymphocytic Leukemia Cells. J Immunol 196(10):4400-9, 2016. e-Pub 2016. PMID: 27076684.
108. Todisco G, Manshouri T, Verstovsek S, Masarova L, Pierce SA, Keating MJ, Estrov Z. Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics. Leuk Lymphoma 57(5):1-6, 2016. e-Pub 2016. PMID: 26402369.
109. Sharman JP, Mato AR, Keating MJ. Ibrutinib for Chronic Lymphocytic Leukemia. N Engl J Med 374(16):1592-3, 2016. e-Pub 2016. PMID: 27096595.
110. Thompson PA, O'Brien SM, Xiao L, Wang X, Burger JA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG. β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. Cancer 122(4):565-73, 2016. e-Pub 2016. PMID: 26588193.
111. Tambaro FP, Garcia-Manero G, O'Brien SM, Faderl SH, Ferrajoli A, Burger JA, Pierce S, Wang X, Do KA, Kantarjian HM, Keating MJ, Wierda WG. Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome. Leukemia 30(2):325-30, 2016. e-Pub 2016. PMID: 26290497.
112. Cervantes-Gomez F, Lavergne B, Keating MJ, Wierda WG, Gandhi V. Combination of Pim kinase inhibitors and Bcl-2 antagonists in chronic lymphocytic leukemia cells. Leuk Lymphoma 57(2):1-23, 2016. e-Pub 2016. PMID: 26088877.
113. Thompson PA, Tam CS, O'Brien SM, Wierda WG, Stingo F, Plunkett W, Smith SC, Kantarjian HM, Freireich EJ, Keating MJ. Fludarabine, cyclophosphamide and rituximab achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 127(3):303-9, 2016. e-Pub 2016. PMID: 26492934.
114. Kellner J, Wierda W, Shpall E, Keating M, McNiece I. Isolation of a novel chronic lymphocytic leukemic (CLL) cell line and development of an in vivo mouse model of CLL. Leuk Res 40:54-9, 2016. e-Pub 2016. PMID: 26601610.
115. Patel V, Keating MJ, Wierda WG, Gandhi V. Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase activating compound with ibrutinib in chronic lymphocytic leukemia. Leuk Lymphoma 57(6):1-11, 2016. e-Pub 2016. PMID: 26440741.
116. Rozovski U, Hazan-Halevy I, Barzilai M, Keating MJ, Estrov Z. Metabolism pathways in chronic lymphocytic leukemia. Leuk Lymphoma 57(4):1-8, 2016. e-Pub 2016. PMID: 26643954.
117. O'Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, Keating M, Mitra S, Holes L, Yu AS, Johnson DM, Miller LL, Kim Y, Dansey RD, Dubowy RL, Coutre SE. A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood 126(25):2686-94, 2015. e-Pub 2015. PMID: 26472751.
118. Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O'Brien S, Davis RE, Burger JA. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. Br J Haematol 171(5):726-35, 2015. e-Pub 2015. PMID: 26358140.
119. Short NJ, Keating MJ, Wierda WG, Faderl S, Ferrajoli A, Estrov Z, Smith SC, O'Brien SM. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia. Cancer 121(21):3869-76, 2015. e-Pub 2015. PMID: 26218678.
120. Stephens DM, Ruppert AS, Weirda WG, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Tam C, O'Brien S, Keating MJ, Muthusamy N, Abruzzo LV, Heerema NA, Byrd JC. Externally Validated Predictive Clinical Model for Untreated Del(17p13.1) Chronic Lymphocytic Leukemia Patients. Am J Hematol 90(11):967-9, 2015. e-Pub 2015. PMID: 26202978.
121. Thompson PA, O'Brien SM, Wierda WG, Ferrajoli A, Stingo F, Smith SC, Burger JA, Estrov Z, Jain N, Kantarjian HM, Keating MJ. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer 121(20):3612-21, 2015. e-Pub 2015. PMID: 26193999.
122. Coutré SE, Barrientos JC, Brown JR, de Vos S, Furman RR, Keating MJ, Li D, O'Brien SM, Pagel JM, Poleski MH, Sharman JP, Yao NS, Zelenetz AD. Management of adverse events associated with idelalisib treatment - expert panel opinion. Leuk Lymphoma 56(10):1-20, 2015. e-Pub 2015. PMID: 25726955.
123. Thompson PA, Rozovski U, Keating MJ, Stingo F, Smith SC, Wierda WG, Falchi L, O'Brien SM, Estrov Z, Burger JA, Ferrajoli A. The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience. Br J Haematol 171(2):281-284, 2015. e-Pub 2015. PMID: 25824652.
124. Balakrishnan K, Peluso M, Fu M, Rosin NY, Burger JA, Wierda WG, Keating MJ, Faia K, O'Brien S, Kutok JL, Gandhi V. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. Leukemia 29(9):1811-22, 2015. e-Pub 2015. PMID: 25917267.
125. Cervantes-Gomez F, Lamothe B, Woyach JA, Wierda WG, Keating MJ, Balakrishnan K, Gandhi V. Pharmacological and protein profiling suggest ABT-199 as optimal partner with ibrutinib in chronic lymphocytic leukemia. Clin Cancer Res 21(16):3705-15, 2015. e-Pub 2015. PMID: 25829398.
126. Yin CC, Tang G, Lu G, Feng X, Keating MJ, Medeiros LJ, Abruzzo LV. Del(20q) in patients with chronic lymphocytic leukemia: a therapy-related abnormality involving lymphoid or myeloid cells. Mod Pathol 28(8):1130-7, 2015. e-Pub 2015. PMID: 25953391.
127. Chakhachiro Z, Yin CC, Abruzzo LV, Aladily TN, Barron LL, Banks HE, Thomas DA, Keating M, Medeiros LJ, Huh YO. B-Lymphoblastic Leukemia in Patients With Chronic Lymphocytic Leukemia: A Report of Four Cases. Am J Clin Pathol 144(2):333-40, 2015. e-Pub 2015. PMID: 26185320.
128. Thompson PA, Ferrajoli A, O'Brien S, Wierda WG, Keating MJ, Burger JA. Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia. Br J Haematol 170(1):125-8, 2015. e-Pub 2015. PMID: 25522014.
129. Strati P, Abruzzo LV, Wierda WG, O'Brien S, Ferrajoli A, Keating MJ. Second Cancers and Richter Transformation Are the Leading Causes of Death in Patients With Trisomy 12 Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk 15(7):420-7, 2015. e-Pub 2015. PMID: 25800543.
130. Jain P, Keating M, Thompson PA, Trinh L, Wang X, Wierda W, Ferrajoli A, Burger J, Kantarjian H, Estrov Z, Abruzzo L, O'Brien S. High FISH percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome. Am J Hematol 90(6):471-7, 2015. e-Pub 2015. PMID: 25683856.
131. Strati P, Tong WG, Vitale C, Wierda WG, O'Brien S, Brown JR, Weng WK, Kipps T, Keating MJ, Ferrajoli A. A Phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia. Leuk Lymphoma 56(6):1-9, 2015. e-Pub 2015. PMID: 25311497.
132. Benjamini O, Jain P, Trinh L, Qiao W, Strom SS, Lerner S, Wang X, Burger J, Ferrajoli A, Kantarjian H, O'Brien S, Wierda W, Estrov Z, Keating M. Second cancers in patients with Chronic Lymphocytic Leukemia who received frontline FCR therapy - Distribution and clinical outcomes. Leuk Lymphoma 56(6):1-28, 2015. e-Pub 2015. PMID: 25308294.
133. Ferrajoli A, Ivan C, Ciccone M, Shimizu M, Kita Y, Ohtsuka M, D'Abundo L, Qiang J, Lerner S, Nouraee N, Rabe KG, Rassenti LZ, Van Roosbroeck K, Manning JT, Yuan Y, Zhang X, Shanafelt TD, Wierda WG, Sabbioni S, Tarrand JJ, Estrov Z, Radovich M, Liang H, Negrini M, Kipps TJ, Kay NE, Keating M, Calin GA. Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival. EBioMedicine 2(6):572-82, 2015. e-Pub 2015. PMID: 26288818.
134. Rozovski U, Benjamini O, Jain P, Thompson PA, Wierda WG, O'Brien S, Burger JA, Ferrajoli A, Faderl S, Shpall E, Hosing C, Khouri IF, Champlin R, Keating MJ, Estrov Z. Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure. J Clin Oncol 33(14):1557-63, 2015. e-Pub 2015. PMID: 25847930.
135. Rozovski U, Grgurevic S, Bueso-Ramos C, Harris DM, Li P, Liu Z, Wu JY, Jain P, Wierda W, Burger J, O'Brien S, Jain N, Ferrajoli A, Keating MJ, Estrov Z. Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells. Mol Cancer Res 13(5):944-53, 2015. e-Pub 2015. PMID: 25733697.
136. Kamel S, Horton L, Ysebaert L, Levade M, Burbury K, Tan S, Cole-Sinclair M, Reynolds J, Filshie R, Schischka S, Khot A, Sandhu S, Keating MJ, Nandurkar H, Tam CS. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia 29(4):783-7, 2015. e-Pub 2015. PMID: 25138588.
137. Jain P, Keating M, Wierda W, Estrov Z, Ferrajoli A, Jain N, George B, James D, Kantarjian H, Burger J, O'Brien S. Outcomes of patients with chronic lymphocytic leukemia (CLL) after discontinuing ibrutinib. Blood 125(13):2062-7, 2015. e-Pub 2015. PMID: 25573991.
138. Londin E, Loher P, Telonis AG, Quann K, Clark P, Jing Y, Hatzimichael E, Kirino Y, Honda S, Lally M, Ramratnam B, Comstock CE, Knudsen KE, Gomella L, Spaeth GL, Hark L, Katz LJ, Witkiewicz A, Rostami A, Jimenez SA, Hollingsworth MA, Yeh JJ, Shaw CA, McKenzie SE, Bray P, Nelson PT, Zupo S, Van Roosbroeck K, Keating MJ, Calin GA, Yeo C, Jimbo M, Cozzitorto J, Brody JR, Delgrosso K, Mattick JS, Fortina P, Rigoutsos I. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proc Natl Acad Sci U S A 112(10):E1106-15, 2015. e-Pub 2015. PMID: 25713380.
139. Patel V, Balakrishnan K, Keating MJ, Wierda WG, Gandhi V. Expression of executioner procaspases and their activation by a procaspase activating compound in chronic lymphocytic leukemia cells. Blood 125(7):1126-36, 2015. e-Pub 2015. PMID: 25538042.
140. Lamothe B, Cervantes-Gomez F, Sivina M, Wierda WG, Keating MJ, Gandhi V. Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia. Blood 125(2):407-10, 2015. e-Pub 2015. PMID: 25573971.
141. Thompson PA, Shpall EJ, Keating MJ. Shifting paradigms in the treatment of chronic lymphocytic leukemia. Future Oncol 11(4):641-57, 2015. e-Pub 2015. PMID: 25686119.
142. Alattar ML, Ciccone M, Gaballa MR, Vitale C, Badoux XC, Manoukian G, Keating MJ, Kroll MH, Ferrajoli A. Bleeding diathesis associated with acquired von Willebrand Syndrome in three patients with chronic lymphocytic leukemia. Leuk Lymphoma 56(12):1-9, 2015. e-Pub 2015. PMID: 25926060.
143. McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood 124(25):3829-30, 2014. e-Pub 2014. PMID: 25498454.
144. Jain P, Lee HJ, Qiao W, Wierda W, Benjamini O, Burger J, Ferrajoli A, Estrov Z, Kantarjian H, Keating M, O'Brien S. FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia. Cancer 120(22):3494-501, 2014. e-Pub 2014. PMID: 25043749.
145. Tam CS, O'Brien S, Plunkett W, Wierda W, Ferrajoli A, Wang X, Do KA, Cortes J, Khouri I, Kantarjian H, Lerner S, Keating MJ. Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). Blood 124(20):3059-64, 2014. e-Pub 2014. PMID: 25281606.
146. Ciccone M, Ferrajoli A, Keating MJ, Calin GA. SnapShot: Chronic Lymphocytic Leukemia. Cancer Cell 26(5):770-770.e1, 2014. e-Pub 2014. PMID: 25517752.
147. Tsimberidou AM, Keating MJ, Jabbour EJ, Ravandi-Kashani F, O'Brien S, Estey E, Bekele N, Plunkett WK, Kantarjian H, Borthakur G. A Phase I Study of Fludarabine, Cytarabine, and Oxaliplatin Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 14(5):395-400.e1, 2014. e-Pub 2014. PMID: 24637132.
148. Rozovski U, Hazan-Halevy I, Keating MJ, Estrov Z. Personalized medicine in CLL: Current status and future perspectives. Cancer Lett 352(1):4-14, 2014. e-Pub 2014. PMID: 23879961.
149. Freireich EJ, Kantarjian H, Keating MJ. The proceedings of the initial meeting of the Society of Hematologic Oncology 2013. Clin Lymphoma Myeloma Leuk 14 Suppl:S1, 2014. e-Pub 2014. PMID: 25486946.
150. Li P, Harris D, Liu Z, Rozovski U, Ferrajoli A, Wang Y, Bueso-Ramos C, Hazan-Halevy I, Grgurevic S, Wierda W, Burger J, O'Brien S, Faderl S, Keating M, Estrov Z. STAT3-Activated GM-CSFRalpha Translocates to the Nucleus and Protects CLL Cells from Apoptosis. Mol Cancer Res 12(9):1267-82, 2014. e-Pub 2014. PMID: 24836891.
151. Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, de Weerdt I, Jeyakumar G, Ferrajoli A, Cardenas-Turanzas M, Lerner S, Jorgensen JL, Nogueras-González GM, Zacharian G, Huang X, Kantarjian H, Garg N, Rosenwald A, O'Brien S. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol 15(10):1090-9, 2014. e-Pub 2014. PMID: 25150798.
152. Chen LS, Keating MJ, Gandhi V. Blood collection methods affect cellular protein integrity: implications for clinical trial biomarkers and ZAP-70 in CLL. Blood 124(7):1192-5, 2014. e-Pub 2014. PMID: 25124785.
153. Strati P, Keating MJ, O'Brien SM, Ferrajoli A, Burger J, Faderl S, Tambaro FP, Jain N, Wierda WG. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica 99(8):1350-5, 2014. e-Pub 2014. PMID: 24859876.
154. Wodarz D, Garg N, Komarova NL, Benjamini O, Keating MJ, Wierda WG, Kantarjian H, James D, O'Brien S, Burger JA. Kinetics of chronic lymphocytic leukemia (CLL) cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. Blood 123(26):4132-5, 2014. e-Pub 2014. PMID: 24829205.
155. El-Mabhouh AA, Ayres ML, Shpall EJ, Baladandayuthapani V, Keating MJ, Wierda WG, Gandhi V. Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells. Blood 123(24):3780-9, 2014. e-Pub 2014. PMID: 24747434.
156. Rozovski U, Wu JY, Harris DM, Liu Z, Li P, Hazan-Halevy I, Ferrajoli A, Burger JA, O'Brien S, Jain N, Verstovsek S, Wierda WG, Keating MJ, Estrov Z. Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. Blood 123(24):3797-802, 2014. e-Pub 2014. PMID: 24778152.
157. Strati P, Keating MJ, O'Brien SM, Burger J, Ferrajoli A, Jain N, Tambaro FP, Estrov Z, Jorgensen J, Challagundla P, Faderl SH, Wierda WG. Eradication of bone marrow minimal residual disease with first-line chemoimmunotherapy may prompt early treatment discontinuation in chronic lymphocytic leukemia. Blood 123(24):3727-32, 2014. e-Pub 2014. PMID: 24705492.
158. Mehta RS, Di Stasi A, Hosing C, Shah N, Rezvani K, Alousi A, O'Brien S, Wierda W, Keating M, Shpall EJ. Lenalidomide-Induced Graft-Vs.-Leukemia Effect in a Patient With Chronic Lymphocytic Leukemia Who Relapsed After Allogeneic Stem Cell Transplant. Clin Lymphoma Myeloma Leuk 14(3):e105-9, 2014. e-Pub 2014. PMID: 24502832.
159. Falchi L, Keating MJ, Marom EM, Truong MT, Schlette EJ, Sargent RL, Trinh L, Wang X, Smith SC, Jain N, Estrov Z, O'Brien S, Wierda WG, Lerner S, Ferrajoli A. Correlation between FDG/PET findings, histological features, clinical characteristics and survival in 332 patients with chronic lymphocytic leukemia. Blood 123(18):2783-2790, 2014. e-Pub 2014. PMID: 24615780.
160. Strati P, Ferrajoli A, Lerner S, O'Brien S, Wierda W, Keating MJ, Faderl S. Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia. Leuk Lymphoma 55(4):828-33, 2014. e-Pub 2014. PMID: 23808813.
161. Sandoval MR, Balakrishnan K, Luthra R, Keating M, Gandhi V. DNA Repair Initiation Induces Expression of Ribonucleotide Reductase in Human Chronic Lymphocytic Leukemia Cells. Leuk Lymphoma 55(4):876-83, 2014. e-Pub 2014. PMID: 23772636.
162. Jain P, Baez-Vallecillo L, Huh YO, Benjamini O, Abruzzo L, O'Brien S, Pemmaraju N, Keating M, Gagel RF, Estrov Z. Atypical chronic lymphocytic leukemia (CLL) with polyglandular autoimmune endocrinopathy (PGA) type II - a complex profile. Leuk Lymphoma 55(4):944-6, 2014. e-Pub 2014. PMID: 23829280.
163. Nazha A, Kantarjian HM, Bhatt VR, Nogueras-Gonzalez G, Cortes JE, Kadia T, Garcia-Manero G, Abruzzo L, Daver N, Pemmaraju N, Quintas-Cardama A, Ravandi F, Keating M, Borthakur G. Prognostic Implications of Chromosome 17 Abnormalities in the Context of Monosomal Karyotype in Patients With Acute Myeloid Leukemia and Complex Cytogenetics. Clin Lymphoma Myeloma Leuk 14(2):163-71, 2014. e-Pub 2014. PMID: 24461514.
164. Chae YK, Trinh L, Jain P, Wang X, Rozovski U, Wierda WG, Keating MJ, Estrov Z. Statin and aspirin use is associated with improved outcome of FCR therapy in relapsed/refractory chronic lymphocytic leukemia. Blood 123(9):1424-6, 2014. e-Pub 2014. PMID: 24578497.
165. Hoellenriegel J, Zboralski D, Maasch C, Rosin NY, Wierda WG, Keating MJ, Kruschinski A, Burger JA. The Spiegelmer(R) NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemo-sensitization. Blood 123(7):1032-9, 2014. e-Pub 2014. PMID: 24277076.
166. Liu J, Chen G, Feng L, Zhang W, Pelicano H, Wang F, Ogasawara MA, Lu W, Amin HM, Croce CM, Keating MJ, Huang P. Loss of p53 and altered miR15-a/16-1short right arrowMCL-1 pathway in CLL: insights from TCL1-Tg:p53(-/-) mouse model and primary human leukemia cells. Leukemia 28(1):118-28, 2014. e-Pub 2014. PMID: 23608884.
167. Rozovski U, Keating MJ, Estrov Z. Targeting inflammatory pathways in chronic lymphocytic leukemia. Crit Rev Oncol Hematol 88(3):655-66, 2013. e-Pub 2013. PMID: 23941728.
168. Strati P, Wierda W, Burger J, Ferrajoli A, Tam C, Lerner S, Keating MJ, O'Brien S. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: Analysis of persistent and new-onset cytopenia. Cancer 119(21):3805-11, 2013. e-Pub 2013. PMID: 23943357.
169. Tsimberidou AM, Wierda WG, Wen S, Plunkett W, O'Brien S, Kipps TJ, Jones JA, Badoux X, Kantarjian H, Keating MJ, Research Consortium CLL. Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Therapy in Aggressive Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome. Clin Lymphoma Myeloma Leuk 13(5):568-74, 2013. e-Pub 2013. PMID: 23810245.
170. Benjamini O, Jain P, Konoplev SN, Yin CC, Abruzzo L, Wotherspoon AC, Dearden C, Shpall EJ, Estrov Z, Keating MJ. CD4(-)/CD8(-) Variant of T-Cell Large Granular Lymphocytic Leukemia or Hepatosplenic T-Cell Lymphoma: A Clinicopathologic Dilemma. Clin Lymphoma Myeloma Leuk 13(5):610-3, 2013. e-Pub 2013. PMID: 23800602.
171. Ferrajoli A, Shanafelt TD, Ivan C, Shimizu M, Rabe KG, Nouraee N, Ikuo M, Ghosh AK, Lerner S, Rassenti LZ, Xiao L, Hu J, Reuben JM, Calin S, You MJ, Manning JT, Wierda WG, Estrov Z, O'Brien S, Kipps TJ, Keating MJ, Kay NE, Calin GA. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B-chronic lymphocytic leukemia. Blood 122(11):1891-9, 2013. e-Pub 2013. PMID: 23821659.
172. Falchi L, Keating MJ, Wang X, Coombs CC, Lanasa MC, Strom S, Wierda WG, Ferrajoli A. Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia: Joint experience of the MD Anderson Cancer Center and Duke University Medical Center. Cancer 119(17):3177-85, 2013. e-Pub 2013. PMID: 24022787.
173. Freireich EJ, Kantarjian H, Keating MJ. Retrospect of hematological malignancies 2012. Clin Lymphoma Myeloma Leuk 13 Suppl 2:S271, 2013. e-Pub 2013. PMID: 24290211.
174. Strati P, Keating MJ, Wierda WG, Badoux XC, Calin S, Reuben JM, O'Brien S, Kornblau SM, Kantarjian HM, Gao H, Ferrajoli A. Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. Blood 122(5):734-7, 2013. e-Pub 2013. PMID: 23801633.
175. Kontoyiannis DP, Georgiadou SP, Wierda WG, Wright S, Albert ND, Ferrajoli A, Keating M, Lewis RE. Impaired bactericidal but not fungicidal activity of polymorphonuclear neutrophils in patients with chronic lymphocytic leukemia. Leuk Lymphoma 54(8):1730-3, 2013. e-Pub 2013. PMID: 23163595.
176. Rozovski U, Keating M, Estrov Z. The significance of spliceosome mutations in chronic lymphocytic leukemia. Leuk Lymphoma 54(7):1364-6, 2013. e-Pub 2013. PMID: 23270583.
177. Rozovski U, Calin GA, Setoyama T, D'Abundo L, Harris DM, Li P, Liu Z, Grgurevic S, Ferrajoli A, Faderl S, Burger JA, O'Brien S, Wierda WG, Keating MJ, Estrov Z. Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells. Mol Cancer 12:50, 2013. e-Pub 2013. PMID: 23725032.
178. Malik A, Shoukier M, Garcia-Manero G, Wierda W, Cortes J, Bickel S, Keating MJ, Estrov Z. Azacitidine in Fludarabine-Refractory Chronic Lymphocytic Leukemia: A Phase II Study. Clin Lymphoma Myeloma Leuk 13(3):292-5, 2013. e-Pub 2013. PMID: 23265768.
179. Benjamini O, Jain P, Schlette E, Sciffman JS, Estrov Z, Keating M. Chronic Lymphocytic Leukemia With Central Nervous System Involvement: A High-Risk Disease?. Clin Lymphoma Myeloma Leuk 13(3):338-41, 2013. e-Pub 2013. PMID: 23332395.
180. Tam CS, Keating MJ. Selection of rituximab dosage in chronic lymphocytic leukemia: where is the evidence?. Leuk Lymphoma 54(5):934-939, 2013. e-Pub 2013. PMID: 22966877.
181. Schweighofer CD, Coombes KR, Majewski T, Barron LL, Lerner S, Sargent RL, O'Brien S, Ferrajoli A, Wierda WG, Czerniak BA, Medeiros LJ, Keating MJ, Abruzzo LV. Genomic Variation by Whole-Genome SNP Mapping Arrays Predicts Time-to-Event Outcome in Patients with Chronic Lymphocytic Leukemia: A Comparison of CLL and HapMap Genotypes. J Mol Diagn 15(2):196-209, 2013. e-Pub 2013. PMID: 23273604.
182. Badoux XC, Keating MJ, Wen S, Wierda WG, O'Brien SM, Faderl S, Sargent R, Burger JA, Ferrajoli A. Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol 31(5):584-591, 2013. e-Pub 2013. PMID: 23270003.
183. Yuan S, Wang F, Chen G, Zhang H, Feng L, Wang L, Colman H, Keating MJ, Li X, Xu RH, Wang J, Huang P. Effective Elimination of Cancer Stem Cells by a Novel Drug Combination Strategy. Stem Cells 31(1):23-34, 2013. e-Pub 2013. PMID: 23132831.
184. Nazha A, Bueso-Ramos C, Estey E, Faderl S, O'Brien S, Fernandez MH, Nguyen M, Koller C, Freireich E, Beran M, Pierce S, Keating M, Cortes J, Kantarjian H, Ravandi F. The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia. Front Oncol 3:218, 2013. e-Pub 2013. PMID: 24032106.
185. Li P, Grgurevic S, Liu Z, Harris D, Rozovski U, Calin GA, Keating MJ, Estrov Z. Signal Transducer and Activator of Transcription-3 Induces MicroRNA-155 Expression in Chronic Lymphocytic Leukemia. PLoS One 8(6):e64678, 2013. e-Pub 2013. PMID: 23750211.
186. Fiorcari S, Brown WS, McIntyre BW, Estrov Z, Maffei R, O'Brien S, Sivina M, Hoellenriegel J, Wierda WG, Keating MJ, Ding W, Kay NE, Lannutti BJ, Marasca R, Burger JA. The PI3-Kinase Delta Inhibitor Idelalisib (GS-1101) Targets Integrin-Mediated Adhesion of Chronic Lymphocytic Leukemia (CLL) Cell to Endothelial and Marrow Stromal Cells. PLoS One 8(12):e83830, 2013. e-Pub 2013. PMID: 24376763.
187. Pillai RN, Chen LS, Ayres ML, Nowak BJ, Thomas MW, Shpall EJ, Keating MJ, Gandhi V. Multifaceted actions of 8-amino-adenosine kill BCR-ABL positive cells. Leuk Lymphoma 53(10):2024-32, 2012. e-Pub 2012. PMID: 22448923.
188. Sivina M, Hartmann E, Vasyutina E, Boucas JM, Breuer A, Keating MJ, Wierda WG, Rosenwald A, Herling M, Burger JA. Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia. Leukemia 26(8):1812-20, 2012. e-Pub 2012. PMID: 22460735.
189. Garg R, Wierda W, Ferrajoli A, Abruzzo L, Pierce S, Lerner S, Keating M, O'Brien S. The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia. Cancer 118(14):3531-7, 2012. e-Pub 2012. PMID: 22139735.
190. Hoellenriegel J, Coffey GP, Sinha U, Pandey A, Sivina M, Ferrajoli A, Ravandi F, Wierda WG, O'Brien S, Keating MJ, Burger JA. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia 26(7):1576-83, 2012. e-Pub 2012. PMID: 22362000.
191. Zenz T, Gribben JG, Hallek M, Döhner H, Keating MJ, Stilgenbauer S. Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood 119(18):4101-7, 2012. e-Pub 2012. PMID: 22394601.
192. Bazargan A, Tam CS, Keating MJ. Predicting survival in chronic lymphocytic leukemia. Expert Rev Anticancer Ther 12(3):393-403, 2012. e-Pub 2012. PMID: 22369330.
193. Zhang W, Trachootham D, Liu J, Chen G, Pelicano H, Garcia-Prieto C, Lu W, Burger JA, Croce CM, Plunkett W, Keating MJ, Huang P. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol 14(3):276-86, 2012. e-Pub 2012. PMID: 22344033.
194. Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O'Brien S, Chiorazzi N, Burger JA. Bruton's tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119(5):1182-9, 2012. e-Pub 2012. PMID: 22180443.
195. Hu Y, Lu W, Chen G, Wang P, Chen Z, Zhou Y, Ogasawara M, Trachootham D, Feng L, Pelicano H, Chiao PJ, Keating MJ, Garcia-Manero G, Huang P. K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Res 22(2):399-412, 2012. e-Pub 2012. PMID: 21876558.
196. Zhou Y, Tang G, Medeiros LJ, McDonnell TJ, Keating MJ, Wierda WG, Wang SA. Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Mod Pathol 25(2):237-45, 2012. e-Pub 2012. PMID: 22080061.
197. Sampath D, Liu C, Vasan K, Sulda M, Puduvalli VK, Wierda WG, Keating MJ. Histone deacetylases mediate the silencing of miR-15a, miR-16 and miR-29b in chronic lymphocytic leukemia. Blood 119(5):1162-1172, 2012. e-Pub 2012. PMID: 22096249.
198. Hornberger J, Reyes C, Shewade A, Lerner S, Friedmann M, Han L, Gutierrez H, Satram-Hoang S, Keating MJ. Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia. Leuk Lymphoma 53(2):225-234, 2012. e-Pub 2012. PMID: 21824050.
199. Lu W, Hu Y, Chen G, Chen Z, Zhang H, Wang F, Feng L, Pelicano H, Wang H, Keating MJ, Liu J, McKeehan W, Wang H, Luo Y, Huang P. Novel Role of NOX in Supporting Aerobic Glycolysis in Cancer Cells with Mitochondrial Dysfunction and as a Potential Target for Cancer Therapy. PLoS Biol 10(5):e1001326, 2012. e-Pub 2012. PMID: 22589701.
200. Decker WK, Shah N, Xing D, Lapushin R, Li S, Robinson SN, Yang H, Parmar S, Halpert MM, Keating MJ, Gribben JG, Molldrem JJ, Shpall EJ, Wierda WG. Generation of Functional CLL-Specific Cord Blood CTL Using CD40-Ligated CLL APC. PLoS One 7(12):e51390, 2012. e-Pub 2012. PMID: 23284688.
201. Badoux X, Bueso-Ramos C, Harris D, Li P, Liu Z, Burger J, O'Brien S, Ferrajoli A, Keating MJ, Estrov Z. Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3. Hum Pathol 42(12):1989-2000, 2011. e-Pub 2011. PMID: 21733558.
202. Tong WG, Estrov Z, Wang Y, O'Brien S, Faderl S, Harris DM, Van Pham Q, Hazan-Halevy I, Liu Z, Koch P, Kantarjian H, Keating MJ, Ferrajoli A. The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells. Invest New Drugs 29(6):1206-12, 2011. e-Pub 2011. PMID: 20533075.
203. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller CA, Burger JA, Lerner S, Schlette E, Abruzzo L, Kantarjian HM, Keating MJ. Multivariable Model for Time to First Treatment in Patients With Chronic Lymphocytic Leukemia. J Clin Oncol 29(31):4088-4095, 2011. e-Pub 2011. PMID: 21969505.
204. Khouri IF, Bassett R, Poindexter N, O'Brien S, Bueso-Ramos CE, Hsu Y, Ferrajoli A, Keating MJ, Champlin R, Fernandez-Vina M. Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: Long-Term Follow-Up, Prognostic Factors, and Effect of Human Leukocyte Histocompatibility Antigen Subtype on Outcome. Cancer 117(20):4679-88, 2011. e-Pub 2011. PMID: 21455998.
205. Ravandi F, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Koller C, Challagundla P, York S, Brandt M, Luthra R, Burger J, Thomas D, Keating M, Kantarjian H. Phase II study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood 118(14):3818-23, 2011. e-Pub 2011. PMID: 21821712.
206. Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, Giese N, O'Brien S, Yu A, Miller LL, Lannutti BJ, Burger JA. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 118(13):3603-12, 2011. e-Pub 2011. PMID: 21803855.
207. Badoux XC, Keating MJ, Wen S, Lee BN, Sivina M, Reuben J, Wierda WG, O'Brien SM, Faderl S, Kornblau SM, Burger JA, Ferrajoli A. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 118(13):3489-98, 2011. e-Pub 2011. PMID: 21725050.
208. Zhou Y, Zhou Y, Shingu T, Feng L, Chen Z, Ogasawara M, Keating MJ, Kondo S, Huang P. Metabolic alterations in highly tumorigenic glioblastoma cells: preference for hypoxia and high dependency on glycolysis. J Biol Chem 286(37):32843-53, 2011. e-Pub 2011. PMID: 21795717.
209. Lee BN, Gao H, Cohen EN, Badoux X, Wierda WG, Estrov Z, Faderl SH, Keating MJ, Ferrajoli A, Reuben JM. Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer 117(17):3999-4008, 2011. e-Pub 2011. PMID: 21858802.
210. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Cyclophosphamide, fludarabine, rituximab and alemtuzumab (CFAR) as salvage therapy for heavily pre-treated patients with chronic lymphocytic leukemia. Blood 118(8):2085-93, 2011. e-Pub 2011. PMID: 21670470.
211. Parikh SA, Keating MJ, O'Brien S, Wang X, Ferrajoli A, Faderl S, Burger J, Koller C, Estrov Z, Badoux X, Lerner S, Wierda WG. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood 118(8):2062-8, 2011. e-Pub 2011. PMID: 21750315.
212. Ferrajoli A, Keating MJ, O'Brien S, Cortes J, Thomas DA. Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia. Cancer 117(14):3182-86, 2011. e-Pub 2011. PMID: 21246526.
213. Schweighofer CD, Huh YO, Luthra R, Sargent RL, Ketterling RP, Knudson RA, Barron LL, Medeiros LJ, Keating MJ, Abruzzo LV. The B cell antigen receptor in atypical chronic lymphocytic leukemia with t(14;19)(q32;q13) demonstrates remarkable stereotypy. Int J Cancer 128(11):2759-2764, 2011. e-Pub 2011. PMID: 20715110.
214. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, Kamble RT, Bollard CM, Gee AP, Mei Z, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, Dotti G. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 121(5):1822-1826, 2011. e-Pub 2011. PMID: 21540550.
215. Huh YO, Schweighofer CD, Ketterling RP, Knudson RA, Vega F, Kim JE, Luthra R, Keating MJ, Medeiros LJ, Abruzzo LV. Chronic Lymphocytic Leukemia With t(14;19)(q32;q13) Is Characterized by Atypical Morphologic and Immunophenotypic Features and Distinctive Genetic Features. Am J Clin Pathol 135(5):686-696, 2011. e-Pub 2011. PMID: 21502423.
216. Duzkale H, Schweighofer CD, Coombes KR, Barron LL, Ferrajoli A, O'Brien S, Wierda WG, Pfeifer J, Majewski T, Czerniak BA, Jorgensen JL, Medeiros LJ, Freireich EJ, Keating MJ, Abruzzo LV. LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts over-all survival in untreated patients. Blood 117(15):4076-4084, 2011. e-Pub 2011. PMID: 21310924.
217. Liu Z, Hazan-Halevy I, Harris DM, Li P, Ferrajoli A, Faderl S, Keating MJ, Estrov Z. Signal Transducer and Activator of Transcription (STAT)-3 Activates Nuclear Factor (NF)-{kappa}B in Chronic Lymphocytic Leukemia Cells. Mol Cancer Res 9(4):507-515, 2011. e-Pub 2011. PMID: 21364020.
218. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 117(11):3016-3024, 2011. e-Pub 2011. PMID: 21245487.
219. Badoux XC, Keating MJ, Wierda WG. What is the Best Frontline Therapy for Patients with CLL and 17p Deletion?. Curr Hematol Malig Rep 6(1):36-46, 2011. e-Pub 2011. PMID: 21153774.
220. Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, LaPushin R, Xiao L, Huang X, Werner L, Neuberg D, Kantarjian H, O'Brien S, Wierda WG, Keating MJ, Rosenwald A, Burger JA. CCL3 (MIP-1{alpha}) plasma levels and the risk for disease progression in chronic lymphocytic leukemia (CLL). Blood 117(5):1662-1669, 2011. e-Pub 2011. PMID: 21115978.
221. Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso MS, Rossi S, Barbarotto E, Cimmino A, Adair B, Wojcik SE, Valeri N, Calore F, Sampath D, Fanini F, Vannini I, Musuraca G, Dell'Aquila M, Alder H, Davuluri RV, Rassenti LZ, Negrini M, Nakamura T, Amadori D, Kay NE, Rai KR, Keating MJ, Kipps TJ, Calin GA, Croce CM. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA 305(1):59-67, 2011. e-Pub 2011. PMID: 21205967.
222. Wierda WG, Kipps TJ, Keating MJ, Brown JR, Gribben JG, Browning M, Rassenti LZ, Greaves AW, Neuberg D, O'Brien SM, Consortium CLL. Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer 117(1):116-124, 2011. e-Pub 2011. PMID: 20806349.
223. Schweighofer CD, Coombes KR, Barron LL, Diao L, Newman RJ, Ferrajoli A, O'Brien S, Wierda WG, Luthra R, Medeiros LJ, Keating MJ, Abruzzo LV. A Two-Gene Signature, SKI and SLAMF1, Predicts Time-to-Treatment in Previously Untreated Patients with Chronic Lymphocytic Leukemia. PLoS One 6(12):e28277, 2011. e-Pub 2011. PMID: 22194822.
224. Admirand JH, Knoblock RJ, Coombes KR, Tam C, Schlette EJ, Wierda WG, Ferrajoli A, O'Brien S, Keating MJ, Luthra R, Medeiros LJ, Abruzzo LV. Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression. Mod Pathol 23(11):1518-1523, 2010. e-Pub 2010. PMID: 20657554.
225. Kantarjian H, Ravandi F, O'Brien S, Cortes J, Faderl S, Garcia-Manero G, Jabbour E, Wierda W, Kadia T, Pierce S, Shan J, Keating M, Freireich EJ. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 116(22):4422-4429, 2010. e-Pub 2010. PMID: 20668231.
226. Hu Y, Lu W, Chen G, Zhang H, Jia Y, Wei Y, Yang H, Zhang W, Fiskus W, Bhalla K, Keating M, Huang P, Garcia-Manero G. Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate. Blood 116(15):2732-41, 2010. e-Pub 2010. PMID: 20566897.
227. Bruey JM, Kantarjian H, Ma W, Estrov Z, Yeh C, Donahue A, Sanders H, O'Brien S, Keating M, Albitar M. Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia. Leuk Res 34(10):1320-4, 2010. e-Pub 2010. PMID: 20362333.
228. Tam CS, Keating MJ. Chemoimmunotherapy of chronic lymphocytic leukemia. Nat Rev Clin Oncol 7(9):521-532, 2010. e-Pub 2010. PMID: 20603650.
229. Konoplev SN, Fritsche HA, O'Brien S, Wierda WG, Keating MJ, Gornet TG, St Romain S, Wang X, Inamdar K, Johnson MR, Medeiros LJ, Bueso-Ramos CE. High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia. Am J Clin Pathol 134(3):472-477, 2010. e-Pub 2010. PMID: 20716805.
230. Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Ravandi F, Verstovsek S, Jorgensen JL, Bueso-Ramos C, Andreeff M, Pierce S, Garris R, Keating MJ, Cortes J, Kantarjian HM. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 28(24):3880-3889, 2010. e-Pub 2010. PMID: 20660823.
231. Tong WG, Wierda WG, Lin E, Kuang SQ, Bekele BN, Estrov Z, Wei Y, Yang H, Keating MJ, Garcia-Manero G. Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. Epigenetics 5(6):499-508, 2010. e-Pub 2010. PMID: 20484983.
232. Balakrishnan K, Verma D, O'Brien S, Kilpatrick JM, Chen Y, Tyler BF, Bickel S, Bantia S, Keating MJ, Kantarjian H, Gandhi V, Ravandi F. Phase II and pharmacodynamic study of oral forodesine in patients with advanced and/or fludarabine-treated chronic lymphocytic leukemia. Blood 116(6):886-892, 2010. e-Pub 2010. PMID: 20427701.
233. Rossi S, Shimizu M, Barbarotto E, Nicoloso MS, Dimitri F, Sampath D, Fabbri M, Lerner S, Barron LL, Rassenti LZ, Jiang L, Xiao L, Hu J, Secchiero P, Zauli G, Volinia S, Negrini M, Wierda W, Kipps TJ, Plunkett W, Coombes KR, Abruzzo LV, Keating MJ, Calin GA. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood 116(6):945-952, 2010. e-Pub 2010. PMID: 20393129.
234. Tsimberidou AM, Keating MJ. Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options. Leuk Lymphoma 51(7):1188-1199, 2010. e-Pub 2010. PMID: 20545582.
235. Faderl S, Ferrajoli A, Wierda W, O'Brien S, Lerner S, Keating MJ. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence. Cancer 116(10):2360-2365, 2010. e-Pub 2010. PMID: 20225334.
236. Verma D, Kantarjian H, Faderl S, O'Brien S, Pierce S, Vu K, Freireich E, Keating M, Cortes J, Ravandi F. Late relapses in acute myeloid leukemia: analysis of characteristics and outcome. Leuk Lymphoma 51(5):778-782, 2010. e-Pub 2010. PMID: 20196624.
237. Hazan-Halevy I, Harris D, Liu Z, Liu J, Li P, Chen X, Shanker S, Ferrajoli A, Keating MJ, Estrov Z. STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood 115(14):2852-2863, 2010. e-Pub 2010. PMID: 20154216.
238. Faderl S, Wierda W, O'Brien S, Ferrajoli A, Lerner S, Keating MJ. Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years. Leuk Res 34(3):284-288, 2010. e-Pub 2010. PMID: 19646755.
239. Tarrand JJ, Keating MJ, Tsimberidou AM, O'Brien S, LaSala RP, Han XY, Bueso-Ramos CE. Epstein-Barr virus latent membrane protein 1 mRNA is expressed in a significant proportion of patients with chronic lymphocytic leukemia. Cancer 116(4):880-887, 2010. e-Pub 2010. PMID: 20052729.
240. Wojcik SE, Rossi S, Shimizu M, Nicoloso MS, Cimmino A, Alder H, Herlea V, Rassenti LZ, Rai KR, Kipps TJ, Keating MJ, Croce CM, Calin GA. Non-codingRNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer. Carcinogenesis 31(2):208-215, 2010. e-Pub 2010. PMID: 19926640.
241. Alatrash G, Albitar M, O'Brien S, Wang X, Manshouri T, Faderl S, Ferrajoli A, Burger J, Garcia-Manero G, Kantarjian HM, Lerner S, Keating MJ, Wierda WG. Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). Br J Haematol 148(3):386-393, 2010. e-Pub 2010. PMID: 19895616.
242. Keating MJ, Dritselis A, Yasothan U, Kirkpatrick P. Ofatumumab. Nat Rev Drug Discov 9(2):101-102, 2010. e-Pub 2010. PMID: 20118960.
243. Li P, Harris D, Liu Z, Liu J, Keating M, Estrov Z. Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells. PLoS One 5(7):e11859, 2010. e-Pub 2010. PMID: 20686606.
244. Al-Kali A, Wierda W, Keating M, O'Brien S. Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL). J Blood Med 1:115-122, 2010. e-Pub 2010. PMID: 22282690.
245. Tam CS, Kantarjian H, Cortes J, Lynn A, Pierce S, Zhou L, Keating MJ, Thomas DA, Verstovsek S. Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis. J Clin Oncol 27(33):5587-5593, 2009. e-Pub 2009. PMID: 19786661.
246. Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, Sivina M, Wierda WG, Estrov Z, Keating MJ, Shehata M, Jäger U, Gandhi V, Kay NE, Plunkett W, Burger JA. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 114(20):4441-4450, 2009. e-Pub 2009. PMID: 19762485.
247. Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol 27(32):5425-5430, 2009. e-Pub 2009. PMID: 19805674.
248. Herling M, Patel KA, Weit N, Lilienthal N, Hallek M, Keating MJ, Jones D. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. Blood 114(21):4675-4686, 2009. e-Pub 2009. PMID: 19770358.
249. Jain N, Wierda W, Ferrajoli A, Wong F, Lerner S, Keating M, O'Brien S. A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia. Cancer 115(19):4533-4539, 2009. e-Pub 2009. PMID: 19637351.
250. Schlette EJ, Admirand J, Wierda W, Abruzzo L, Lin KI, O'Brien S, Lerner S, Keating MJ, Tam C. p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy. Leuk Lymphoma 50(10):1597-1605, 2009. e-Pub 2009. PMID: 19863337.
251. Gunn SR, Bolla AR, Barron LL, Gorre ME, Mohammed MS, Bahler DW, Mellink CH, van Oers MH, Keating MJ, Ferrajoli A, Coombes KR, Abruzzo LV, Robetorye RS. Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME gene. Leuk Res 33(9):1276-1281, 2009. e-Pub 2009. PMID: 19027161.
252. Tam CS, Shanafelt TD, Wierda WG, Abruzzo LV, Van Dyke DL, O'Brien S, Ferrajoli A, Lerner SA, Lynn A, Kay NE, Keating MJ. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the MD Anderson and Mayo Clinic experience. Blood 114(5):957-964, 2009. e-Pub 2009. PMID: 19414856.
253. Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG, Gandhi V, Burger JA. B cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migrationa nd survival: specific targeting with a novel Syk inhibitor, R406. Blood 114(5):1029-1037, 2009. e-Pub 2009. PMID: 19491390.
254. Thomas DA, O'Brien S, Jorgensen JL, Cortes J, Faderl S, Garcia-Manero G, Verstovsek S, Koller C, Pierce S, Huh Y, Wierda W, Keating MJ, Kantarjian HM. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood 113(25):6330-6337, 2009. e-Pub 2009. PMID: 18703706.
255. Tsai CY, Ray AS, Tumas DB, Keating MJ, Reiser H, Plunkett W. Targeting DNA repair in chronic lymphocytic leukemia cells with a novel acyclic nucleotide analogue, GS-9219. Clin Cancer Res 15(11):3760-3769, 2009. e-Pub 2009. PMID: 19435836.
256. Chen R, Wierda WG, Chubb S, Hawtin RE, Fox JA, Keating MJ, Gandhi V, Plunkett W. Mechanism of action of SNS-032, a novel cyclin dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 113(19):4637-4645, 2009. e-Pub 2009. PMID: 19234140.
257. Niedermeier M, Hennessy BT, Knight ZA, Henneberg M, Hu J, Kurtova AV, Wierda WG, Keating MJ, Shokat KM, Burger JA. Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 113(22):5549-5557, 2009. e-Pub 2009. PMID: 19318683.
258. Yin CC, Lin KI, Ketterling RP, Knudson RA, Medeiros LJ, Barron LL, Huh YO, Luthra R, Keating MJ, Abruzzo LV. Chronic lymphocytic leukemia with t(2;14)(p16;q32) involves the BCL11A and IgH genes and is associated with atypical morphologic features and unmutated IgVH genes. Am J Clin Pathol 131(5):663-670, 2009. e-Pub 2009. PMID: 19369625.
259. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller C, Burger J, Lerner S, Kantarjian H, Keating M. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol 27(10):1637-1643, 2009. e-Pub 2009. PMID: 19224852.
260. Sampath D, Calin GA, Puduvalli VK, Gopisetty G, Taccioli C, Liu CG, Ewald B, Liu C, Keating MJ, Plunkett W. Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. Blood 113(16):3744-3753, 2009. e-Pub 2009. PMID: 19096009.
261. Miller CP, Rudra S, Keating MJ, Wierda WG, Palladino M, Chandra J. Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells. Blood 113(18):4289-4299, 2009. e-Pub 2009. PMID: 19182209.
262. Lin KI, Tam CS, Keating MJ, Wierda WG, O'Brien S, Lerner S, Coombes KR, Schlette E, Ferrajoli A, Barron LL, Kipps TJ, Rassenti L, Faderl S, Kantarjian H, Abruzzo LV. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood 113(14):3168-3171, 2009. e-Pub 2009. PMID: 19050308.
263. Tam CS, Abruzzo LV, Lin KI, Cortes J, Lynn A, Keating MJ, Thomas DA, Pierce S, Kantarjian H, Verstovsek S. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: Applicability at the time of diagnosis and later during disease course. Blood 113(18):4171-4178, 2009. e-Pub 2009. PMID: 19131547.
264. Burger JA, Quiroga MP, Hartmann E, Bürkle A, Wierda WG, Keating MJ, Rosenwald A. High-level expression of the T cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell co-cultures and after BCR stimulation. Blood 113(13):3050-3058, 2009. e-Pub 2009. PMID: 19074730.
265. Tsimberidou AM, Wen S, McLaughlin P, O'Brien S, Wierda WG, Lerner S, Strom S, Freireich EJ, Medeiros LJ, Kantarjian HM, Keating MJ. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol 27(6):904-910, 2009. e-Pub 2009. PMID: 19114699.
266. Ault P, Cortes J, Lynn A, Keating M, Verstovsek S. Pregnancy in a patient with hypereosinophilic syndrome. Leukemia Research 33(1):186-187, 2009. e-Pub 2009. PMID: 18597844.
267. Tsimberidou AM, Tam C, Abruzzo LV, O'Brien S, Wierda WG, Lerner S, Kantarjian HM, Keating MJ. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer 115(2):373-380, 2009. e-Pub 2009. PMID: 19117034.
268. O'Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ, Viallet J, Cheson BD. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 113(2):299-305, 2009. e-Pub 2009. PMID: 18931344.
269. Sargent R, Jones D, Abruzzo LV, Yao H, Bonderover J, Cisneros M, Wierda WG, Keating MJ, Luthra R. Customized Oligonucleotide Array-based Comparative Genomic Hybridization as a Clinical Assay for Genomic Profiling of Chronic Lymphocytic Leukemia. J Mol Diagn 11(1):25-34, 2009. e-Pub 2009. PMID: 19074592.
270. Burger JA, Quiroga MP, Balakrishnan K, Gandhi V, Kurtova A, Wierda WG, Keating MJ. The SYK inhibitor R406 blocks BCR signaling, cell adhesion and migration, and induces apoptosis in CLL cells: an explanation for the clinical activity of R406 in chronic lymphocytic leukemia. Haematologica 94:135, 2009. e-Pub 2009.
271. Ma W, Kantarjian H, Zhang X, Jilani I, Sheikholeslami MR, Donahue AC, Ravandi F, Estey E, O'Brien S, Keating M, Giles FJ, Albitar M. Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications. Cancer Biomarker 5(1):51-58, 2009. e-Pub 2009.
272. Ma W, Kantarjian H, Bekele B, Donahue AC, Zhang X, Zhang ZJ, O'Brien S, Estey E, Estrov Z, Cortes J, Keating M, Giles F, Albitar M. Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome. Clin Cancer Res 15(11):3820-3826, 2009. e-Pub 2009. PMID: 19458051.
273. Yeh CH, Tseng R, Zhang Z, Cortes J, O'Brien S, Giles F, Hannah A, Estrov Z, Keating M, Kantarjian H, Albitar M. Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia. Leuk Res 33(2):212-217, 2009. e-Pub 2009. PMID: 18715642.
274. Jilani I, Wei C, Bekele BN, Zhang ZJ, Keating M, Wierda W, Ferrajoli A, Estrov Z, Kantarjian H, O'Brien SM, Giles FJ, Albitar M. Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia. International Journal of Laboratory Hematology 31(1):97-105, 2009. e-Pub 2009. PMID: 18190591.
275. Inamdar KV, O'Brien S, Sen S, Keating M, Nguyen MH, Wang X, Fernandez M, Thomazy V, Medeiros LJ, Bueso-Ramos CE. Aurora-A kinase nuclear expression in chronic lymphocytic leukemia. Mod Pathol 21(12):1428-1435, 2008. e-Pub 2008. PMID: 18931650.
276. Caraway NP, Thomas E, Khanna A, Payne L, Zhang HZ, Lin E, Keating MJ, Katz RL. Chromosomal abnormalities detected by multicolor fluorescence in situ hybridization in fine-needle aspirates from patients with small lymphocytic lymphoma are useful for predicting survival. Cancer 114(5):315-322, 2008. e-Pub 2008. PMID: 18683215.
277. Balakrishnan K, Wierda WG, Keating MJ, Gandhi V. Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood 112(5):1971-1980, 2008. e-Pub 2008. PMID: 18566329.
278. Rassenti LZ, Jain S, Keating MJ, Wierda WG, Grever MR, Byrd JC, Kay NE, Brown JR, Gribben JG, Neuberg DS, He F, Greaves AW, Rai KR, Kipps TJ. Relative value Of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 112(5):1923-1930, 2008. e-Pub 2008. PMID: 18577710.
279. Tsimberidou AM, Kantarjian HM, Wen S, Keating MJ, O'Brien S, Brandt M, Pierce S, Freireich EJ, Medeiros LJ, Estey E. Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia. Cancer 113(6):1370-1378, 2008. e-Pub 2008. PMID: 18623376.
280. Trachootham D, Zhang H, Zhang W, Feng L, Du M, Zhou Y, Chen Z, Pelicano H, Plunkett W, Wierda WG, Keating MJ, Huang P. Effective Elimination of Fludarabine-Resistant CLL Cells by PEITC through a Redox-Mediated Mechanism. Blood 112(5):1912-1922, 2008. e-Pub 2008. PMID: 18574029.
281. Gunn SR, Mohammed MS, Gorre ME, Cotter PD, Kim J, Bahler DW, Preobrazhensky SN, Higgins RA, Bolla AR, Ismail SH, de Jong D, Eldering E, van Oers MH, Mellink CH, Keating MJ, Schlette EJ, Abruzzo LV, Robetorye RS. Whole-Genome Scanning by Array Comparative Genomic Hybridization as a Clinical Tool for Risk Assessment in Chronic Lymphocytic Leukemia. J Mol Diagn 10(5):442-451, 2008. e-Pub 2008. PMID: 18687794.
282. Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA, Thomas DA, Cortes J, Lerner S, Keating MJ. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112(4):975-980, 2008. e-Pub 2008. PMID: 18411418.
283. Huh YO, Lin KI, Vega F, Schlette E, Yin CC, Keating MJ, Luthra R, Medeiros LJ, Abruzzo LV. MYC translocation in chronic lymphocytic leukaemia is associated with increased prolymphocytes and a poor prognosis. Br J Haematol 142(1):36-44, 2008. e-Pub 2008. PMID: 18477041.
284. Safdar A, Rodriguez GH, Rueda AM, Wierda WG, Ferrajoli A, Musher DM, O'Brien S, Koller CA, Bodey GP, Keating MJ. Multiple-dose granulocyte-macrophage-colony-stimulating factor plus 23-valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia: a prospective, randomized trial of safety and immunogenicity. Cancer 113(2):383-387, 2008. e-Pub 2008. PMID: 18470901.
285. Zhang H, Trachootham D, Lu W, Carew J, Giles FJ, Keating MJ, Arlinghaus RB, Huang P. Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia 22(6):1191-1199, 2008. e-Pub 2008. PMID: 18385754.
286. Keating MJ, Bach C, Yasothan U, Kirkpatrick P. Bendamustine. Nat Rev Drug Discov 7(6):473-474, 2008. e-Pub 2008. PMID: 18511926.
287. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ, Lymphocytic Leukemia IWOC. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111(12):5446-5456, 2008. e-Pub 2008. PMID: 18216293.
288. Ferrajoli A, Lee BN, Schlette EJ, O'Brien SM, Gao H, Wen S, Wierda WG, Estrov Z, Faderl S, Cohen EN, Li C, Reuben JM, Keating MJ. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111(11):5291-5297, 2008. e-Pub 2008. PMID: 18334676.
289. Tam CS, Otero-Palacios J, Abruzzo LV, Jorgensen JL, Ferrajoli A, Wierda WG, Lerner S, O'Brien S, Keating MJ. Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients. Br J Haematol 141(1):36-40, 2008. e-Pub 2008. PMID: 18324964.
290. Tsimberidou AM, Kantarjian HM, Wen S, O'Brien S, Cortes J, Wierda WG, Koller C, Pierce S, Brandt M, Freireich EJ, Keating MJ, Estey EH. The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients. Clin Cancer Res 14(3):721-30, 2008. e-Pub 2008. PMID: 18245532.
291. O'Brien S, Ravandi F, Riehl T, Wierda W, Huang X, Tarrand J, O'Neal B, Kantarjian H, Keating M. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 111(4):1816-1819, 2008. e-Pub 2008. PMID: 18039954.
292. Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 26(2):196-203, 2008. e-Pub 2008. PMID: 18182662.
293. Khouri IF, Saliba RM, Admirand J, O'Brien S, Lee MS, Korbling M, Samuels BI, Giralt S, Lima de M, Keating MJ, Champlin RE, Bueso-Ramos C. Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol 137(4):355-363, 2007. e-Pub 2007. PMID: 17456058.
294. Nimmanapalli R, Lyu MA, Du M, Keating MJ, Rosenblum MG, Gandhi V. The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R positive CLL cells. Blood 109(6):2557-2564, 2007. e-Pub 2007. PMID: 17119117.
295. Safdar A, Rodriguez G, Rolston KV, O'Brien S, Khouri IF, Shpall EJ, Keating MJ, Kantarjian HM, Champlin RE, Raad II, Kontoyiannis DP. High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. Bone Marrow Transplant 39(3):157-164, 2007. e-Pub 2007. PMID: 17245424.
296. Huh YO, Abruzzo LV, Rassidakis GZ, Parry-Jones N, Schlette E, Brito-Bapabulle V, Matutes E, Wotherspoon A, Keating MJ, Medeiros LJ, Catovsky D. The t(14;19)(q32;q13)-positive small B-cell leukaemia: a clinicopathologic and cytogenetic study of seven cases. Br J Haematol 136(2):220-228, 2007. e-Pub 2007. PMID: 17129229.
297. Albitar M, Johnson M, Do KA, Day A, Jilani I, Pierce S, Estey E, Kantarjian H, Keating M, Verstovsek S, O'Brien S, Giles FJ. Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy. Leukemia 21(3):480-488, 2007. e-Pub 2007. PMID: 17215857.
298. Aribi A, Huh Y, Keating M, O'Brien S, Ferrajoli A, Faderl S, Wierda W, Kantarjian H, Ravandi F. T-cell large granular lymphocytic (T-LGL) leukemia: Experience in a single institution over 8 years. Leuk Res 31(7):939-945, 2007. e-Pub 2007. PMID: 17045649.
299. Ma W, Tseng R, Gorre M, Jilani I, Keating M, Kantarjian H, Cortes J, O'Brien S, Giles F, Albitar M. Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia. Haematologica 92(2):170-175, 2007. e-Pub 2007. PMID: 17296565.
300. Ravandi F, Jilani I, Estey E, Kantarjian H, Dey A, Aguilar C, Jitkaroon C, Giles F, O'Brien S, Keating M, Albitar M. Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML). Leuk Res 31(6):791-797, 2007. e-Pub 2007. PMID: 17156841.
301. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Cortes J, Thomas D, Garcia-Manero G, Koller C, Beran M, Giles F, Ravandi F, Lerner S, Kantarjian H, Keating M. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 109(11):4679-4685, 2007. e-Pub 2007. PMID: 17299097.
302. Borthakur G, O'Brien S, Wierda WG, Thomas DA, Cortes JE, Giles FJ, Kantarjian HM, Lerner S, Keating MJ. Immune anaemias in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide and rituximab - incidence and predictors. Br J Haematol 136(6):800-805, 2007. e-Pub 2007.
303. Ahmed B, Estey E, Manning J, David C, Keating MJ, Kantarjian H, Tsimberidou AM. Anaplastic large cell lymphoma with involvement of the pancreas presenting as panniculitis in a patient with a history of acute myeloid leukemia - case report and review of the literature. Haematologica 91(12 Suppl):ECR55, 2006. e-Pub 2006. PMID: 17194661.
304. Pelicano H, Xu RH, Du M, Feng L, Sasaki R, Carew JS, Hu Y, Ramdas L, Hu L, Keating MJ, Zhang W, Plunkett W, Huang P. Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol 175(6):913-923, 2006. e-Pub 2006. PMID: 17158952.
305. Moufarij MA, Sampath D, Keating MJ, Plunkett W. Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal. Blood 108(13):4187-4193, 2006. e-Pub 2006. PMID: 16954499.
306. Morabito F, Damle RN, Deaglio S, Keating M, Ferrarini M, Chiorazzi N. The CD38 ectoenzyme family: advances in basic science and clinical practice. Mol Med 12(11-12):342-344, 2006. e-Pub 2006. PMID: 17380202.
307. Balakrishnan K, Nimmanapalli R, Ravandi F, Keating MJ, Gandhi V. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood 108(7):2392-2398, 2006. e-Pub 2006. PMID: 16778146.
308. Belov L, Mulligan SP, Barber N, Woolfson A, Scott M, Stoner K, Chrisp JS, Sewell WA, Bradstock KF, Bendall L, Pascovici DS, Thomas M, Erber W, Huang P, Sartor M, Young GA, Wiley JS, Juneja S, Wierda WG, Green AR, Keating MJ, Christopherson RI. Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray. Br J Haematol 135(2):184-197, 2006. e-Pub 2006. PMID: 16939496.
309. Faderl S, Rai K, Gribben J, Byrd JC, Flinn IW, O'Brien S, Sheng S, Esseltine DL, Keating MJ. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. Cancer 107(5):916-924, 2006. e-Pub 2006. PMID: 16832816.
310. Chemaly RF, Ghosh S, Bodey GP, Rohatgi N, Safdar A, Keating MJ, Champlin RE, Aguilera EA, Tarrand JJ, Raad II. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore) 85(5):278-287, 2006. e-Pub 2006. PMID: 16974212.
311. Tsimberidou AM, O'Brien S, Kantarjian HM, Koller C, Hagemeister FB, Fayad L, Lerner S, Bueso-Ramos CE, Keating MJ. Hodgkin's transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer 107(6):1294-1302, 2006. e-Pub 2006. PMID: 16902984.
312. Bruzzi JF, Macapinlac H, Tsimberidou AM, Truong MT, Keating MJ, Marom EM, Munden RF. Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med 47(8):1267-1273, 2006. e-Pub 2006. PMID: 16883004.
313. Gandhi V, Plunkett W, Bonate PL, Du M, Nowak B, Lerner S, Keating MJ. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment. Clin Cancer Res 12(13):4011-4017, 2006. e-Pub 2006. PMID: 16818700.
314. Tsimberidou AM, Catovsky D, Schlette E, O'Brien S, Wierda WG, Kantarjian H, Garcia-Manero G, Wen S, Do KA, Lerner S, Keating MJ. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer 107(1):125-135, 2006. e-Pub 2006. PMID: 16700034.
315. Tibes R, Keating MJ, Ferrajoli A, Wierda W, Ravandi F, Garcia-Manero G, O'Brien S, Cortes J, Verstovsek S, Browning ML, Faderl S. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer 106(12):2645-2651, 2006. e-Pub 2006. PMID: 16688777.
316. Ravandi F, Jorgensen JL, O'Brien SM, Verstovsek S, Koller CA, Faderl S, Giles FJ, Ferrajoli A, Wierda WG, Odinga S, Huang X, Thomas DA, Freireich EJ, Jones D, Keating MJ, Kantarjian HM. Eradication of minimal residual disease in hairy cell leukemia. Blood 107(12):4658-4662, 2006. e-Pub 2006. PMID: 16497968.
317. Ma W, Jilani I, Gorre M, Keating M, Chan H, Tseng R, Kantarjian H, O'Brien S, Giles FJ, Albitar M. Plasma as a source of mRNA for determining IgV(H) mutation status in patients with chronic lymphocytic leukaemia. British Journal of Haematology 133(6):690-2, 2006. e-Pub 2006. PMID: 16704448.
318. Thomas DA, Giles FJ, Albitar M, Cortes JE, Verstovsek S, Faderl S, O'Brien SM, Garcia-Manero G, Keating MJ, Pierce S, Zeldis J, Kantarjian HM. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer 106(9):1974-1984, 2006. e-Pub 2006. PMID: 16583431.
319. Tsimberidou AM, Keating MJ, Bueso-Ramos CE, Kurzrock R. Epstein-Barr virus in patients with chronic lymphocytic leukemia: a pilot study. Leuk Lymphoma 47(5):827-836, 2006. e-Pub 2006. PMID: 16753866.
320. Tsimberidou AM, O'Brien S, Khouri I, Giles FJ, Kantarjian HM, Champlin R, Wen S, Do KA, Smith SC, Lerner S, Freireich EJ, Keating MJ. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol 24(15):2343-2351, 2006. e-Pub 2006. PMID: 16710033.
321. Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106(7):1569-1580, 2006. e-Pub 2006. PMID: 16502413.
322. Pelicano H, Carew JS, McQueen TJ, Andreeff M, Plunkett W, Keating MJ, Huang P. Targeting Hsp90 by 17-AAG in leukemia cells: Mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C. Leukemia 20(4):610-619, 2006. e-Pub 2006. PMID: 16482209.
323. Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E, Garcia-Manero G. Adult acute megakaryocytic leukemia: An analysis of 37 patients treated at M. D. Anderson Cancer Center. Blood 107(3):880-884, 2006. e-Pub 2006. PMID: 16123215.
324. Carew JS, Nawrocki ST, Krupnik YV, Dunner K, McConkey DJ, Keating MJ, Huang P. Targeting endoplasmic reticulum protein transport: A novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL. Blood 107(1):222-231, 2006. e-Pub 2006. PMID: 16144803.
325. Ault P, Kantarjian H, O'Brien S, Faderl S, Beran M, Rios MB, Koller C, Giles F, Keating M, Talpaz M, Cortes J. Pregnancy among patients with chronic myeloid leukemia treated with imatinob. Journal of Clinical Oncology 24(7):1204-1208, 2006. e-Pub 2006.
326. Kantarjian H, Beran M, Cortes J, O'Brien S, Giles F, Pierce S, Shan J, Plunkett W, Keating M, Estey E. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer 106(5):1099-1109, 2006. e-Pub 2006.
327. Gandhi V, Keating MJ, Bate G, Kirkpatrick P. Nelarabine. Nature reviews. Drug Discovery 5(1):17-18, 2006. e-Pub 2006.
328. Ma W, Kantarjian H, Verstovsek S, Jilani I, Gorre M, Giles F, Cortes J, O'Brien S, Keating M, Albitar M. Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behavior. British Journal of Haematology 134(3):341-343, 2006. e-Pub 2006.
329. Wierda W, O’Brien S, Faderl S, Ferrajoli A, Wang X, Do KA, Garcia-Manero G, Thomas D, Cortes J, Ravandi-Kashani F, Giles F, Lerner S, Kantarjian H, Keating M. A retrospective comparison of three sequential groups of patients with recurrent/refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer 106(2):337-345, 2006. e-Pub 2006.
330. Koller C, Bekele BN, Zhou X, Park C, Estrov Z, O’Brien S, Keating M, Jilani I, Giles FJ, Kantarjian HM, Albitar M. Plasma thrombopoietin compared to immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia. Blood 108(3):1001-1006, 2006. e-Pub 2006.
331. Binet JL, Caligaris-Cappio F, Catovsky D, Cheson B, Davis T, Dighiero G, Dohner H, Hallek M, Hillmen P, Keating M, Montserrat E, Kipps TJ, Rai K. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 107(3):859-861, 2006. e-Pub 2006.
332. Tsimberidou AM, Tirado-Gomez M, Andreeff M, O'Brien S, Kantarjian H, Keating M, Lopez-Berestein G, Estey E. Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series. Leukemia and Lymphoma 47(6):1062-1068, 2006. e-Pub 2006. PMID: 16840198.
333. Sheikholeslami MR, Jilani I, Keating M, Uyeji J, Chen K, Kantarjian H, O'Brien S, Giles F, Albitar M. Variations in the detection of ZAP-70 in chronic lymphocytic leukemia: Comparison with IgV(H) mutation analysis. Cytometry. Part B. Clinical Cytometry 70(4):270-275, 2006. e-Pub 2006. PMID: 16906585.
334. Ruiz S, Krupnik Y, Keating M, Chandra J, Palladino M, McConkey D. The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Molecular Cancer Therapeutics 5(7):1836-1843, 2006. e-Pub 2006. PMID: 16891470.
335. Jilani I, Keating M, Day A, William W, Kantarjian H, O'Brien S, Giles FJ, Albitar M. Simplified sensitive method for the detection of B-cell clonality in lymphoid malignancies. Clinical and Laboratory Haematology 28(5):325-331, 2006. e-Pub 2006. PMID: 16999724.
336. Zhou Y, Garcia-Prieto C, Carney DA, Xu RH, Pelicano H, Kang Y, Yu W, Lou C, Kondo S, Liu J, Harris DM, Estrov Z, Keating MJ, Jin Z, Huang P. OSW-1: A natural compound with potent anticancer activity and a novel mechanism of action. J Natl Cancer Inst 97(23):1781-1785, 2005. e-Pub 2005. PMID: 16333034.
337. Xu RH, Pelicano H, Zhang H, Giles FJ, Keating MJ, Huang P. Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells. Leukemia 19(12):2153-8, 2005. e-Pub 2005. PMID: 16193082.
338. Achanta G, Sasaki R, Feng L, Carew JS, Lu W, Pelicano H, Keating MJ, Huang P. Novel role of p53 in maintaining mitochondrial genetic stability through interaction with DNA Pol gamma. EMBO J 24(19):3482-3492, 2005. e-Pub 2005. PMID: 16163384.
339. Chen R, Keating MJ, Gandhi V, Plunkett W. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 106(7):2513-2519, 2005. e-Pub 2005. PMID: 15972445.
340. Motta M, Rassenti L, Shelvin BJ, Lerner S, Kipps TJ, Keating MJ, Wierda WG. Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia 19(10):1788-1793, 2005. e-Pub 2005. PMID: 16094420.
341. Balakrishnan K, Wierda WG, Keating MJ, Gandhi V. Mechanisms of cell death of chronic lymphocytic leukemia lymphocytes by RNA-directed agent, 8-NH2-adenosine. Clin Cancer Res 11(18):6745-6752, 2005. e-Pub 2005. PMID: 16166456.
342. Abruzzo LV, Wang J, Kapoor M, Medeiros LJ, Keating MJ, Edward Highsmith W, Barron LL, Cromwell CC, Coombes KR. Biological validation of differentially expressed genes in chronic lymphocytic leukemia identified by applying multiple statistical methods to oligonucleotide microarrays. J Mol Diagn 7(3):337-345, 2005. e-Pub 2005. PMID: 16049305.
343. Balakrishnan K, Stellrecht CM, Genini D, Ayres M, Wierda WG, Keating MJ, Leoni LM, Gandhi V. Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP. Blood 105(11):4455-4462, 2005. e-Pub 2005. PMID: 15718423.
344. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A, Kantarjian H. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23(18):4079-4088, 2005. e-Pub 2005. PMID: 15767648.
345. Abruzzo LV, Lee KY, Fuller A, Silverman A, Keating MJ, Medeiros LJ, Coombes KR. Validation of oligonucleotide microarray data using microfluidic low-density arrays: a new statistical method to normalize real-time RT-PCR data. Biotechniques 38(5):785-792, 2005. e-Pub 2005. PMID: 15945375.
346. Kurtzberg J, Ernst TJ, Keating MJ, Gandhi V, Hodge JP, Kisor DF, Lager JJ, Stephens C, Levin J, Krenitsky T, Elion G, Mitchell BS. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol 23(15):3396-3403, 2005. e-Pub 2005. PMID: 15908652.
347. Yin CC, Lin P, Carney DA, Handy BC, Rassidakis GZ, Admirand JH, Keating MJ, Medeiros LJ. Chronic lymphocytic leukemia/small lymphocytic lymphoma associated with IgM paraprotein. Am J Clin Pathol 123(4):594-602, 2005. e-Pub 2005. PMID: 15743747.
348. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, Keating MJ, Huang P. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 65(2):613-621, 2005. e-Pub 2005. PMID: 15695406.
349. Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H, Keating M. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. Journal of Clinical Oncology 23(18):4070-4078, 2005. e-Pub 2005. PMID: 15767647.
350. Faderl S, Gandhi V, O'Brien S, Bonate P, Cortes J, Estey E, Beran M, Wierda W, Garcia-Manero G, Ferrajoli A, Estrov Z, Giles FJ, Du M, Kwari M, Keating M, Plunkett W, Kantarjian H. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 105(3):940-947, 2005. e-Pub 2005. PMID: 15486072.
351. Xu RH, Pelicano H, Zhang H, Giles FJ, Keating MJ, Huang P. Synergistic effect of targeting in mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells. Leukemia 19(12):2153-2158, 2005. e-Pub 2005.
352. Faderl S, Do KA, Johnson MM, Keating M, O’Brien S, Jilani I, Ferrajoli A, Ravandi-Kashani F, Aguilar C, Dey A, Thomas DA, Giles FJ, Kantarjian HM, Albitar M. Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia. Blood 106(13):4303-4307, 2005. e-Pub 2005.
353. Faderl S, Coutre S, Byrd JC, Dearden C, Denes A, Dyer MJ, Gregory SA, Gribben JG, Hillmen P, Keating M, Rosen S, Venugopal P, Rai K. The evolving role of alemtuzumab in management of patients with CLL. Leukemia 19(12):2147-2152, 2005. e-Pub 2005.
354. Ravandi F, O’Brien S, Jones D, Lerner S, Faderl S, Ferrajoli A, Wierda W, Garcia-Manero G, Thomas D, Koller C, Verstovsek S, Giles F, Cortes J, Herling M, Kantarjian H, Keating M. T-cell prolymphocytic leukemia: A single-institution experience. Clinical Lymphoma and Myeloma 6(3):234-239, 2005. e-Pub 2005.
355. Ravandi F, Kantarjian H, Jones D, Dearden C, Keating M, O’Brien S. Mature T-cell leukemias. Cancer 104(9):1808-1818, 2005. e-Pub 2005.
356. Giles F, O'Brien S, Cortes J, Verstovsek S, Bueso-Ramos C, Shan J, Pierce S, Garcia-Manero G, Keating M, Kantarjian H. Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer 104(3):547-554, 2005. e-Pub 2005.
357. Carew JS, Nawrocki ST, Xu RH, Dunner K, McConkey DJ, Wierda WG, Keating MJ, Huang P. Increased mitochondrial biogenesis in primary leukemia cells: the role of endogenous nitric oxide and impact on sensitivity to fludarabine. Leukemia 18(12):1934-1940, 2004. e-Pub 2004. PMID: 15483672.
358. Thomas DA, O'Brien S, Cortes J, Giles FJ, Faderl S, Verstovsek S, Ferrajoli A, Koller C, Beran M, Pierce S, Ha CS, Cabanillas F, Keating MJ, Kantarjian H. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 104(6):1624-1630, 2004. e-Pub 2004. PMID: 15178574.
359. Bueso-Ramos CE, Ferrajoli A, Medeiros LJ, Keating MJ, Estrov Z. Aberrant morphology, proliferation, and apoptosis of B-cell chronic lymphocytic leukemia cells. Hematology 9(4):279-286, 2004. e-Pub 2004. PMID: 15621735.
360. Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, Neuberg DS, Flinn IW, Rai KR, Byrd JC, Kay NE, Greaves A, Weiss A, Kipps TJ. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 351(9):893-901, 2004. e-Pub 2004. PMID: 15329427.
361. Herling M, Khoury JD, Washington LT, Duvic M, Keating MJ, Jones D. A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood 104(2):328-335, 2004. e-Pub 2004. PMID: 15044256.
362. Verstovsek S, Giles FJ, O'Brien S, Faderl S, Kantarjian HM, Keating MJ, Albitar M. Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia. Leuk Res 28(7):707-711, 2004. e-Pub 2004. PMID: 15158092.
363. Tsimberidou AM, Keating MJ, Giles FJ, Wierda WG, Ferrajoli A, Lerner S, Beran M, Andreeff M, Kantarjian HM, O'Brien S. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. Cancer 100(12):2583-2591, 2004. e-Pub 2004. PMID: 15197800.
364. Ma Y, Mansour A, Bekele BN, Zhou X, Keating MJ, O'Brien S, Giles FJ, Albitar M. The clinical significance of large cells in bone marrow in patients with chronic lymphocytic leukemia. Cancer 100(10):2167-2175, 2004. e-Pub 2004. PMID: 15139060.
365. Tsimberidou AM, Murray JL, O'Brien S, Wierda WG, Keating MJ. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome. Cancer 100(10):2195-2200, 2004. e-Pub 2004. PMID: 15139064.
366. Khouri IF, Albitar M, Saliba RM, Ippoliti C, Ma YC, Keating MJ, Champlin RE. Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics. Bone Marrow Transplantation 33(8):833-837, 2004. e-Pub 2004. PMID: 14755312.
367. Hileman EO, Liu J, Albitar M, Keating MJ, Huang P. Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemotherapy and Pharmacology 53(3):209-219, 2004. e-Pub 2004. PMID: 14610616.
368. Khouri IF, Lee MS, Saliba RM, Andersson B, Anderlini P, Couriel D, Hosing C, Giralt S, Korbling M, McMannis J, Keating MJ, Champlin RE. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Experimental Hematology 32(1):28-35, 2004. e-Pub 2004. PMID: 14725898.
369. Jilani I, Keating M, Giles FJ, O'Brien S, Kantarjian HM, Albitar M. Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay. Leukemia Research 28(12):1255-1262, 2004. e-Pub 2004. PMID: 15475065.
370. Keating M, Coutre S, Rai K, Osterborg A, Faderl S, Kennedy B, Kipps T, Bodey G, Byrd JC, Rosen S, Dearden C, Dyer MJ, Hillmen P. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clinical Lymphoma 4(4):220-227, 2004. e-Pub 2004. PMID: 15072613.
371. Jeha S, Gandhi V, Chan KW, McDonald L, Ramirez I, Madden R, Rytting M, Brandt M, Keating M, Plunkett W, Kantarjian H. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 103(3):784-789, 2004. e-Pub 2004. PMID: 14551141.
372. Albitar M, Do KA, Johnson MM, Giles FJ, Jilani I, O'Brien S, Cortes J, Thomas D, Rassenti LZ, Kipps TJ, Kantarjian HM, Keating M. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer 101(5):999-1008, 2004. e-Pub 2004. PMID: 15329909.
373. Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, Bueso-Ramos CE, Pierce S, Shan J, Koller C, Beran M, Keating M, Freireich EJ. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 101(12):2788-2801, 2004. e-Pub 2004. PMID: 15481055.
374. Kantarjian H, O'Brien S, Cortes J, Giles F, Shan J, Rios MB, Faderl S, Verstovsek S, Garcia-Manero G, Wierda W, Kornblau S, Ferrajoli A, Keating M, Talpaz M. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. Clinical Cancer Research 10(1 Pt 1):68-75, 2004. e-Pub 2004. PMID: 14734453.
375. Tsimberidou AM, Giles FJ, Kantarjian HM, Keating MJ, O'Brien SM. Anti-B4 blocked ricin post chemotherapy in patients with chronic lymphocytic leukemia--long-term follow-up of a monoclonal antibody-based approach to residual disease. Leuk Lymphoma 44(10):1719-25, 2003. e-Pub 2003. PMID: 14692524.
376. Amin HM, Jilani I, Estey EH, Keating MJ, Dey AL, Manshouri T, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Giles FJ, Albitar M. Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome. Blood 102(5):1866-1868, 2003. e-Pub 2003. PMID: 12730116.
377. Ferrajoli A, O'Brien SM, Cortes JE, Giles FJ, Thomas DA, Faderl S, Kurzrock R, Lerner S, Kontoyiannis DP, Keating MJ. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 98(4):773-778, 2003. e-Pub 2003. PMID: 12910522.
378. Carew JS, Zhou Y, Albitar M, Carew JD, Keating MJ, Huang P. Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: clinical significance and therapeutic implications. Leukemia 17(8):1437-1447, 2003. e-Pub 2003. PMID: 12886229.
379. McCarthy H, Wierda WG, Barron LL, Cromwell CC, Wang J, Coombes KR, Rangel R, Elenitoba-Johnson KS, Keating MJ, Abruzzo LV. High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia. Blood 101(12):4903-4908, 2003. e-Pub 2003. PMID: 12586616.
380. Tsimberidou AM, Kantarjian HM, Estey E, Cortes JE, Verstovsek S, Faderl S, Thomas DA, Garcia-Manero G, Ferrajoli A, Manning JT, Keating MJ, Albitar M, O'Brien S, Giles FJ. Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia 17(6):1100-1103, 2003. e-Pub 2003. PMID: 12764375.
381. Zhou Y, Hileman EO, Plunkett W, Keating MJ, Huang P. Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 101(10):4098-4104, 2003. e-Pub 2003. PMID: 12531810.
382. Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, Andreeff M, Beran M, Cortes J, Wierda W, Tran N, Keating MJ. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101(9):3413-3415, 2003. e-Pub 2003. PMID: 12522009.
383. Giles FJ, Bekele BN, O'Brien S, Cortes JE, Verstovsek S, Balerdi M, Yared M, Zhou X, Kantarjian HM, Keating MJ, Thall P, Albitar M. A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression. Br J Haematol 121(4):578-585, 2003. e-Pub 2003. PMID: 12752098.
384. Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, Verstovsek S, Ferrajoli A, Wierda W, Alvarado Y, O'Brien SM, Albitar M, Keating MJ, Giles FJ. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer 97(7):1711-1720, 2003. e-Pub 2003. PMID: 12655528.
385. Manshouri T, Do KA, Wang X, Giles FJ, O'Brien SM, Saffer H, Thomas D, Jilani I, Kantarjian HM, Keating MJ, Albitar M. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 101(7):2507-2513, 2003. e-Pub 2003. PMID: 12446458.
386. Amin HM, McDonnell TJ, Medeiros LJ, Rassidakis GZ, Leventaki V, O'Connor SL, Keating MJ, Lai R. Characterization of 4 mantle cell lymphoma cell lines. Arch Pathol Lab Med 127(4):424-431, 2003. e-Pub 2003. PMID: 12683869.
387. Kantarjian HM, O'Brien S, Cortes JE, Shan J, Giles FJ, Rios MB, Faderl SH, Wierda WG, Ferrajoli A, Verstovsek S, Keating MJ, Freireich EJ, Talpaz M. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 97(4):1033-1041, 2003. e-Pub 2003. PMID: 12569603.
388. Lu D, Nounou R, Beran M, Estey E, Manshouri T, Kantarjian H, Keating MJ, Albitar M. The prognostic significance of bone marrow levels of neurofibromatosis-1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer 97(2):441-449, 2003. e-Pub 2003. PMID: 12518368.
389. Montillo M, Tedeschi A, O'Brien S, Di Raimondo F, Lerner S, Ferrajoli A, Morra E, Keating MJ. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer 97(1):114-120, 2003. e-Pub 2003. PMID: 12491512.
390. Tsimberidou A, Estey E, Cortes J, Thomas D, Faderl S, Verstovsek S, Garcia-Manero G, Keating M, Albitar M, O'Brien S, Kantarjian H, Giles F. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer 97(6):1481-1487, 2003. e-Pub 2003. PMID: 12627513.
391. Thomas DA, Estey E, Giles FJ, Faderl S, Cortes J, Keating M, O'Brien S, Albitar M, Kantarjian H. Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia. British Journal of Haematology 123(3):436-441, 2003. e-Pub 2003. PMID: 14617002.
392. Cortes J, Kantarjian H, Albitar M, Thomas D, Faderl S, Koller C, Garcia-Manero G, Giles F, Andreeff M, O'Brien S, Keating M, Estey E. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cancer 97(5):1234-1241, 2003. e-Pub 2003. PMID: 12599230.
393. Verstovsek S, Kantarjian H, Manshouri T, Cortes J, Faderl S, Giles FJ, Keating M, Albitar M. Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia. Cancer 97(5):1248-1252, 2003. e-Pub 2003. PMID: 12599232.
394. Ibrahim S, Jilani I, O'Brien S, Rogers A, Manshouri T, Giles F, Faderl S, Thomas D, Kantarjian H, Keating M, Albitar M. Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B-cell chronic lymphocytic leukemia. Cancer 97(8):1914-1919, 2003. e-Pub 2003. PMID: 12673718.
395. Jilani I, Estey E, Manshouri T, Caligiuri M, Keating M, Giles F, Thomas D, Kantarjian H, Albitar M. Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA. Leukemia 17(1):114-119, 2003. e-Pub 2003. PMID: 12529667.
396. Schlette E, Medeiros LJ, Keating M, Lai R. CD79b expression in chronic lymphocytic leukemia. Association with trisomy 12 and atypical immunophenotype. Archives of Pathology and Laboratory Medicine 127(5):561-566, 2003. e-Pub 2003. PMID: 12708898.
397. Kantarjian H, O'Brien S, Cortes J, Giles F, Thomas D, Kornblau S, Shan J, Beth Rios M, Keating M, Freireich E, Talpaz M. Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications. Cancer 98(1):81-85, 2003. e-Pub 2003. PMID: 12833459.
398. Lai R, Rassidakis GZ, Medeiros LJ, Leventaki V, Keating M, McDonnell TJ. Expression of STAT3 and its phosphorylated forms in mantle cell lymphoma cell lines and tumours. Journal of Pathology 199(1):84-89, 2003. e-Pub 2003. PMID: 12474230.
399. Kantarjian HM, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J, O'Brien S, Ibrahim N, Khuri F, Du M, Rios MB, Jeha S, McLaughlin P, Plunkett W, Keating M. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. Journal of Clinical Oncology 21(6):1167-1173, 2003. e-Pub 2003. PMID: 12637486.
400. Wierda WG, Johnson MM, Do KA, Manshouri T, Dey A, O'Brien S, Giles FJ, Kantarjian H, Thomas D, Faderl S, Lerner S, Keating M, Albitar M. Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia. British Journal of Haematology 120(3):452-456, 2003. e-Pub 2003. PMID: 12580959.
401. Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Faderl S, Issa JP, Garcia-Manero G, Rios MB, Shan J, Andreeff M, Keating M, Talpaz M. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 98(3):522-528, 2003. e-Pub 2003. PMID: 12879469.
402. Verstovsek S, Manshouri T, Smith FO, Giles FJ, Cortes J, Estey E, Kantarjian H, Keating M, Jeha S, Albitar M. Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia. Cancer 97(9):2212-2217, 2003. e-Pub 2003. PMID: 12712473.
403. Aguayo A, Kantarjian HM, Estey EH, Giles FJ, Verstovsek S, Manshouri T, Gidel C, O'Brien S, Keating MJ, Albitar M. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer 95(9):1923-1930, 2002. e-Pub 2002. PMID: 12404286.
404. Onida F, Ball G, Kantarjian HM, Smith TL, Glassman A, Albitar M, Scappini B, Rios MB, Keating MJ, Beran M. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia. Cancer 95(8):1673-1684, 2002. e-Pub 2002. PMID: 12365015.
405. Giles FJ, Kantarjian HM, Bekele BN, Cortes JE, Faderl S, Thomas DA, Manshouri T, Rogers A, Keating MJ, Talpaz M, O'Brien S, Albitar M. Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival. Br J Haematol 119(1):38-45, 2002. e-Pub 2002. PMID: 12358901.
406. Keating MJ, O'Brien S, Kontoyiannis D, Plunkett W, Koller C, Beran M, Lerner S, Kantarjian H. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 43(9):1755-1762, 2002. e-Pub 2002. PMID: 12685828.
407. Ferrajoli A, Keating MJ, Manshouri T, Giles FJ, Dey A, Estrov Z, Koller CA, Kurzrock R, Thomas DA, Faderl S, Lerner S, O'Brien S, Albitar M. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood 100(4):1215-1219, 2002. e-Pub 2002. PMID: 12149200.
408. Faderl S, Keating MJ, Do KA, Liang SY, Kantarjian HM, O'Brien S, Garcia-Manero G, Manshouri T, Albitar M. Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia 16(6):1045-1052, 2002. e-Pub 2002. PMID: 12040436.
409. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B, Rai KR. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99(10):3554-3561, 2002. e-Pub 2002. PMID: 11986207.
410. Scappini B, Onida F, Kantarjian HM, Dong L, Verstovsek S, Keating MJ, Beran M. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells. Cancer 94(10):2653-2662, 2002. e-Pub 2002. PMID: 12173333.
411. Abruzzo LV, Rosales CM, Medeiros LJ, Vega F, Luthra R, Manning JT, Keating MJ, Jones D. Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. Am J Surg Pathol 26(5):630-636, 2002. e-Pub 2002. PMID: 11979093.
412. Tsimberidou AM, O'Brien SM, Cortes JE, Faderl S, Andreeff M, Kantarjian HM, Keating MJ, Giles FJ. Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders. Leuk Lymphoma 43(4):767-772, 2002. e-Pub 2002. PMID: 12153163.
413. Oudat R, Keating MJ, Lerner S, O'Brien S, Albitar M. Significance of the levels of bone marrow lymphoid infiltrate in chronic lymphocytic leukemia patients with nodular partial remission. Leukemia 16(4):632-635, 2002. e-Pub 2002. PMID: 11960343.
414. Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH, Glassman AB, Albitar M, Kwari MI, Beran M. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 99(3):840-849, 2002. e-Pub 2002. PMID: 11806985.
415. Yamauchi T, Keating MJ, Plunkett W. UCN-01 (7-hydroxystaurosporine) inhibits DNA repair and increases cytotoxicity in normal lymphocytes and chronic lymphocytic leukemia lymphocytes. Mol Cancer Ther 1(4):287-294, 2002. e-Pub 2002. PMID: 12467224.
416. Keating MJ, Cazin B, Coutré S, Birhiray R, Kovacsovics T, Langer W, Leber B, Maughan T, Rai K, Tjønnfjord G, Bekradda M, Itzhaki M, Hérait P. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 20(1):205-213, 2002. e-Pub 2002. PMID: 11773171.
417. Coombes KR, Zhang L, Bueso-Ramos C, Brisbay S, Logothetis C, Roth J, Keating MJ, McDonnell TJ. TAD: a web interface and database for tissue microarrays. Appl Bioinformatics 1(3):155-8, 2002. e-Pub 2002. PMID: 15130842.
418. Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S, Thomas DA, Garcia-Manero G, Issa JP, Andreeff M, Kornblau SM, Koller C, Beran M, Keating M, Rios MB, Shan J, Resta D, Capdeville R, Hayes K, Albitar M, Freireich EJ, Cortes JE. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clinical Cancer Research 8(7):2177-2187, 2002. e-Pub 2002. PMID: 12114418.
419. Lai R, O'Brien S, Maushouri T, Rogers A, Kantarjian H, Keating M, Albitar M. Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia. Cancer 95(5):1071-1075, 2002. e-Pub 2002. PMID: 12209693.
420. Kantarjian HM, O'Brien S, Cortes JE, Smith TL, Rios MB, Shan J, Yang Y, Giles FJ, Thomas DA, Faderl S, Garcia-Manero G, Jeha S, Wierda W, Issa JP, Kornblau SM, Keating M, Resta D, Capdeville R, Talpaz M. Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clinical Cancer Research 8(7):2167-2176, 2002. e-Pub 2002. PMID: 12114417.
421. DiRaimondo F, Albitar M, Huh Y, O'Brien S, Montillo M, Tedeschi A, Kantarjian H, Lerner S, Giustolisi R, Keating M. The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease. Cancer 94(6):1721-1730, 2002. e-Pub 2002. PMID: 11920534.
422. O'Brien S, Talpaz M, Cortes J, Shan J, Giles FJ, Faderl S, Thomas D, Garcia-Manero G, Mallard S, Beth M, Koller C, Kornblau S, Andreeff M, Murgo A, Keating M, Kantarjian HM. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer 94(7):2024-2032, 2002. e-Pub 2002. PMID: 11932905.
423. Khouri IF, Keating MJ, Saliba RM, Champlin RE. Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy 4(3):217-221, 2002. e-Pub 2002. PMID: 12194718.
424. Tsimberidou AM, Thomas D, O'Brien S, Andreeff M, Kurzrock R, Keating M, Albitar M, Kantarjian H, Giles F. Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies. Cancer Chemotherapy and Pharmacology 50(3):237-242, 2002. e-Pub 2002. PMID: 12203106.
425. Scappini B, Onida F, Kantarjian HM, Dong L, Verstovsek S, Keating MJ, Beran M. Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells. Clin Cancer Res 7(12):3884-3893, 2001. e-Pub 2001. PMID: 11751479.
426. Keating MJ. Progress in CLL, chemotherapy, antibodies and transplantation. Biomed Pharmacother 55(9-10):524-528, 2001. e-Pub 2001. PMID: 11769960.
427. Yamauchi T, Nowak BJ, Keating MJ, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 7(11):3580-3589, 2001. e-Pub 2001. PMID: 11705880.
428. Bullrich F, Fujii H, Calin G, Mabuchi H, Negrini M, Pekarsky Y, Rassenti L, Alder H, Reed JC, Keating MJ, Kipps TJ, Croce CM. Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer Res 61(18):6640-6648, 2001. e-Pub 2001. PMID: 11559527.
429. Huh YO, Keating MJ, Saffer HL, Jilani I, Lerner S, Albitar M. Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia. Am J Clin Pathol 116(3):437-443, 2001. e-Pub 2001. PMID: 11554173.
430. Dabaja BS, O'Brien SM, Kantarjian HM, Cortes JE, Thomas DA, Albitar M, Schlette ES, Faderl S, Sarris A, Keating MJ, Giles FJ. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome. Leuk Lymphoma 42(3):329-337, 2001. e-Pub 2001. PMID: 11699397.
431. Giles FJ, Shen Y, Kantarjian HM, Korbling MJ, O'Brien S, Anderlini P, Donato M, Pierce S, Keating MJ, Freireich EJ, Estey E. Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long-term survival. Leuk Lymphoma 42(1-2):67-73, 2001. e-Pub 2001. PMID: 11699223.
432. Di Raimondo F, Giustolisi R, Lerner S, Cacciola E, O'Brien S, Kantarjian H, Keating MJ. Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine. Ann Oncol 12(5):621-625, 2001. e-Pub 2001. PMID: 11432619.
433. O'Brien SM, Kantarjian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J, Lerner S, Keating MJ. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19(8):2165-2170, 2001. e-Pub 2001. PMID: 11304768.
434. Gandhi V, Plunkett W, Weller S, Du M, Ayres M, Rodriguez CO, Ramakrishna P, Rosner GL, Hodge JP, O'Brien S, Keating MJ. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. J Clin Oncol 19(8):2142-2152, 2001. e-Pub 2001. PMID: 11304766.
435. Ferrajoli A, Manshouri T, Estrov Z, Keating MJ, O'Brien S, Lerner S, Beran M, Kantarjian HM, Freireich EJ, Albitar M. High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia. Clin Cancer Res 7(4):795-799, 2001. e-Pub 2001. PMID: 11309324.
436. Fayad L, Keating MJ, Reuben JM, O'Brien S, Lee BN, Lerner S, Kurzrock R. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 97(1):256-263, 2001. e-Pub 2001. PMID: 11133769.
437. Onciu M, Schlette E, Medeiros LJ, Abruzzo LV, Keating M, Lai R. Cytogenetic findings in mantle cell lymphoma cases with a high level of peripheral blood involvement have a distinct pattern of abnormalities. American Journal Clinical Pathology 116(6):886-892, 2001. e-Pub 2001. PMID: 11764078.
438. Verstovsek S, Manshouri T, Kantarjian H, Giles FJ, Keating M, Estey E, Albitar M. Highly reproducible detection and semi-quantification of telomerase activity. Biotechniques 30(5):930-934, 2001. e-Pub 2001. PMID: 11355351.
439. Verstovsek S, Kantarjian H, Estey E, Aguayo A, Giles FJ, Manshouri T, Koller C, Estrov Z, Freireich E, Keating M, Albitar M. Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome. Leukemia 15(8):1165-1170, 2001. e-Pub 2001. PMID: 11480557.
440. Verstovsek S, Kantarjian H, Aguayo A, Manshouri T, Freireich E, Keating M, Estey E, Albitar M. Significance of angiogenin plasma concentrations in patients with acute myeloid leukaemia and advanced myelodysplastic syndrome. British Journal Haematology 114(2):290-295, 2001. e-Pub 2001. PMID: 11529846.
441. Verstovsek S, Estey E, Manshouri T, Keating M, Kantarjian H, Giles FJ, Albitar M. High expression of the receptor tyrosine kinase Tie-1 in acute myeloid leukemia and myelodysplastic syndrome. Leukemia and Lymphoma 42:511-516, 2001. e-Pub 2001. PMID: 11699417.
442. Aguayo A, Manshouri T, O'Brien S, Keating M, Beran M, Koller C, Kantarjian H, Rogers A, Albitar M. Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL). Leukemia Research 25(4):279-285, 2001. e-Pub 2001. PMID: 11248324.
443. Cortes J, Estey E, O'Brien S, Giles F, Shen Y, Koller C, Beran M, Thomas D, Keating M, Kantarjian H. High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia. Cancer 92(1):7-14, 2001. e-Pub 2001. PMID: 11443603.
444. Cortes J, O'Brien S, Loscertales J, Kantarjian H, Giles F, Thomas D, Koller C, Keating M. Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia. Cancer 92(8):2016-2022, 2001. e-Pub 2001. PMID: 11596014.
445. Faderl S, Gidel C, Kantarjian HM, Manshouri T, Keating M, Albitar M. Loss of heterozygosity on chromosome 5 in adults with acute lymphoblastic leukemia. Leukemia Research 25(1):39-43, 2001. e-Pub 2001. PMID: 11137559.
446. Giles FJ, Kantarjian H, O'Brien S, Rios MB, Cortes J, Beran M, Koller C, Keating M, Talpaz M. Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with Philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase. Leukemia and Lymphoma 41(3-4):309-319, 2001. e-Pub 2001. PMID: 11378543.
447. Ibrahim S, Keating M, Do KA, O'Brien S, Huh YO, Jilani I, Lerner S, Kantarjian HM, Albitar M. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 98(1):181-186, 2001. e-Pub 2001. PMID: 11418478.
448. O'Brien SM, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ, Lerner S, Keating M. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. Journal of Clinical Oncology 19(5):1414-1420, 2001. e-Pub 2001. PMID: 11230486.
449. Keating M, O'Brien S. High-dose rituximab therapy in chronic lymphocytic leukemia. Semin Oncol 27(6 Suppl 12):86-90, 2000. e-Pub 2000. PMID: 11226005.
450. Faderl S, Kantarjian HM, Estey E, Manshouri T, Chan CY, Rahman Elsaied A, Kornblau SM, Cortes J, Thomas DA, Pierce S, Keating MJ, Estrov Z, Albitar M. The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. Cancer 89(9):1976-1982, 2000. e-Pub 2000. PMID: 11064355.
451. Ibrahim S, Estey EH, Pierce S, Glassman A, Keating M, O'Brien S, Kantarjian HM, Albitar M. 11q23 abnormalities in patients with acute myelogenous leukemia and myelodysplastic syndrome as detected by molecular and cytogenetic analyses. Am J Clin Pathol 114(5):793-797, 2000. e-Pub 2000. PMID: 11068555.
452. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, Koller C, Estrov Z, O'Brien S, Keating M, Freireich E, Albitar M. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 96(6):2240-2245, 2000. e-Pub 2000. PMID: 10979972.
453. Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 407(6802):390-395, 2000. e-Pub 2000. PMID: 11014196.
454. Rodriguez J, Keating MJ, O'Brien S, Champlin RE, Khouri IF. Allogeneic haematopoietic transplantation for Richter's syndrome. Br J Haematol 110(4):897-899, 2000. e-Pub 2000. PMID: 11054078.
455. Rodriguez CO, Plunkett W, Paff MT, Du M, Nowak B, Ramakrishna P, Keating MJ, Gandhi V. High-performance liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells. J Chromatogr B Biomed Sci Appl 745(2):421-430, 2000. e-Pub 2000. PMID: 11043760.
456. Huang P, Sandoval A, Van Den Neste E, Keating MJ, Plunkett W. Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine. Leukemia 14(8):1405-1413, 2000. e-Pub 2000. PMID: 10942236.
457. Aguayo A, O'Brien S, Keating M, Manshouri T, Gidel C, Barlogie B, Beran M, Koller C, Kantarjian H, Albitar M. Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. Blood 96(2):768-770, 2000. e-Pub 2000. PMID: 10887147.
458. Albitar M, Beran M, O'Brien S, Kantarjian H, Frieriech E, Keating M, Estey E. Differences between refractory anemia with excess blasts in transformation and acute myeloid leukemia. Blood 96(1):372-373, 2000. e-Pub 2000. PMID: 10939804.
459. Ravandi-Kashani F, O'Brien S, Manshouri T, Lerner S, Sim S, Dodd K, Kantarjian H, Freireich E, Keating M, Albitar M. Variations in the low levels of cyclin D1/BCL1 have prognostic value in chronic lymphocytic leukemia. Leuk Res 24(6):469-474, 2000. e-Pub 2000. PMID: 10781679.
460. Chung CY, Kantarjian H, Haidar M, Starostik P, Manshouri T, Gidel C, Freireich E, Keating M, Albitar M. Deletions in the 13q14 locus in adult lymphoblastic leukemia: rate of incidence and relevance. Cancer 88(6):1359-1364, 2000. e-Pub 2000. PMID: 10717617.
461. Haidar MA, Kantarjian H, Manshouri T, Chang CY, O'Brien S, Freireich E, Keating M, Albitar M. ATM gene deletion in patients with adult acute lymphoblastic leukemia. Cancer 88(5):1057-1062, 2000. e-Pub 2000. PMID: 10699895.
462. Haidar MA, Manshouri T, Keating MJ, Kantarjian HM, Freireich EJ, Mehta K, Albitar M. Downregulation of the p53 tumor suppressor gene and upregulation of the bcl-2 gene in retinoic acid receptor alpha-deficient transgenic mice. Int J Oncol 16(3):561-565, 2000. e-Pub 2000. PMID: 10675490.
463. Estey EH, Pierce S, Keating MJ. Identification of a group of AML/MDS patients with a relatively favorable prognosis who have chromosome 5 and/or 7 abnormalities. Haematologica 85(3):246-249, 2000. e-Pub 2000. PMID: 10702811.
464. Giles FJ, Wong GC, Clark SJ, Pierce S, Kantarjian HM, Keating MJ. Oral idarubicin in patients with late chronic phase chronic myelogenous leukemia or chronic myelomonocytic leukemia. Leuk Lymphoma 37(1-2):87-95, 2000. e-Pub 2000. PMID: 10721772.
465. Keating MJ, Smith TL, Lerner S, O'Brien S, Robertson LE, Kantarjian H, Freireich EJ. Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia. Leuk Lymphoma 37(1-2):71-85, 2000. e-Pub 2000. PMID: 10721771.
466. Kisor DF, Plunkett W, Kurtzberg J, Mitchell B, Hodge JP, Ernst T, Keating MJ, Gandhi V. Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J Clin Oncol 18(5):995-1003, 2000. e-Pub 2000. PMID: 10694549.
467. Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M, Pierce S, Huh Y, Andreeff M, Koller C, Ha CS, Keating MJ, Murphy S, Freireich EJ. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 18(3):547-561, 2000. e-Pub 2000. PMID: 10653870.
468. Cortes J, Estey E, Beran M, O'Brien S, Giles F, Koller C, Keating M, Kantarjian H. Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia. Leuk Lymphoma 36(5-6):479-484, 2000. e-Pub 2000. PMID: 10784392.
469. Sacchi S, Kantarjian HM, O'Brien S, Cortes J, Rios MB, Giles FJ, Beran M, Koller CA, Keating MJ, Talpaz M. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 86(12):2632-2641, 1999. e-Pub 1999. PMID: 10594858.
470. Partyka S, O'Brien S, Podoloff D, Kantarjian H, Keating MJ. The usefulness of high dose (7-10mci) gallium (67Ga) scanning to diagnose Richter's transformation. Leuk Lymphoma 36(1-2):151-155, 1999. e-Pub 1999. PMID: 10613460.
471. Giles FJ, O'Brien SM, Santini V, Gandhi V, Plunkett W, Seymour JF, Robertson LE, Kantarjian HM, Keating MJ. Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study. Leuk Lymphoma 36(1-2):57-65, 1999. e-Pub 1999. PMID: 10613450.
472. Thomas DA, Kantarjian H, Smith TL, Koller C, Cortes J, O'Brien S, Giles FJ, Gajewski J, Pierce S, Keating MJ. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer 86(7):1216-1230, 1999. e-Pub 1999. PMID: 10506707.
473. Hallas C, Albitar M, Letofsky J, Keating MJ, Huebner K, Croce CM. Loss of FHIT expression in acute lymphoblastic leukemia. Clin Cancer Res 5(9):2409-2414, 1999. e-Pub 1999. PMID: 10499611.
474. Thomas DA, Cortes J, O'Brien S, Pierce S, Faderl S, Albitar M, Hagemeister FB, Cabanillas FF, Murphy S, Keating MJ, Kantarjian H. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 17(8):2461-2470, 1999. e-Pub 1999. PMID: 10561310.
475. Wilhelm M, O'Brien S, Rios MB, Estey E, Keating MJ, Plunkett W, Sorenson M, Kantarjian HM. Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase. Leuk Lymphoma 34(5-6):511-518, 1999. e-Pub 1999. PMID: 10492074.
476. Kornblau SM, Thall PF, Estrov Z, Walterscheid M, Patel S, Theriault A, Keating MJ, Kantarjian H, Estey E, Andreeff M. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res 5(7):1758-1766, 1999. e-Pub 1999. PMID: 10430080.
477. Estey EH, Thall PF, Reed P, Kantarjian H, Beran M, Pierce S, Keating MJ. Treatment of newly diagnosed AML, RAEB-t or RAEB with lisofylline or placebo in addition to chemotherapy. Leukemia 13(6):850-854, 1999. e-Pub 1999. PMID: 10360371.
478. Estey EH, Thall PF, Pierce S, Cortes J, Beran M, Kantarjian H, Keating MJ, Andreeff M, Freireich E. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 93(8):2478-2484, 1999. e-Pub 1999. PMID: 10194425.
479. Kantarjian HM, O'Brien S, Smith TL, Rios MB, Cortes J, Beran M, Koller C, Giles FJ, Andreeff M, Kornblau S, Giralt S, Keating MJ, Talpaz M. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon-alpha and low dose cytosine arabinoside. J Clin Oncol 17(1):284-292, 1999. e-Pub 1999. PMID: 10458244.
480. Cortes J, Fayad L, O'Brien S, Keating M, Kantarjian H. Persistence of peripheral blood and bone marrow blasts during remission induction in adult acute lymphoblastic leukemia confers a poor prognosis depending on treatment intensity. Clinical Cancer Research 5(9):2491-2497, 1999. e-Pub 1999. PMID: 10499624.
481. Aguayo A, Cortes J, Thomas D, Pierce S, Keating M, Kantarjian H. Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia. Cancer 86(7):1203-1209, 1999. e-Pub 1999. PMID: 10506705.
482. Beran M, Estey E, O'Brien S, Cortes J, Koller CA, Giles FJ, Kornblau S, Andreeff M, Vey N, Pierce SR, Hayes K, Wong GC, Keating M, Kantarjian H. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. Journal of Clinical Oncology 17(9):2819-2830, 1999. e-Pub 1999. PMID: 10561358.
483. Albitar M, Manshouri T, Kantarjian H, Keating M, Estrov Z, Faber J, Freireich EJ, Pierce S, Estey E. Correlation between lower c-mpl protein expression and favorable cytogenetic groups in acute myeloid leukemia. Leukemia Research 23(1):63-69, 1999. e-Pub 1999. PMID: 9933137.
484. O'Brien S, Kantarjian H, Koller C, Feldman E, Beran M, Andreeff M, Giralt S, Cheson B, Keating M, Freireich E, Rios MB, Talpaz M. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood 93(12):4149-4153, 1999. e-Pub 1999. PMID: 10361112.
485. Starostik P, O'Brien S, Chung CY, Haidar M, Manshouri T, Kantarjian H, Freireich E, Keating M, Albitar M. The prognostic significance of 13q14 deletions in chronic lymphocytic leukemia. Leukemia Research 23(9):795-801, 1999. e-Pub 1999. PMID: 10475618.
486. Vey N, Keating M, Giles F, Cortes J, Beran M, Estey E. Effect of complete remission on survival in patients with acute myelogenous leukemia receiving first salvage therapy. Blood 93(9):3149-3150, 1999. e-Pub 1999. PMID: 10336269.
487. Koller CA, Kantarjian HM, Feldman EJ, O'Brien S, Rios MB, Estey E, Keating M. A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia. Cancer 86(11):2246-2251, 1999. e-Pub 1999. PMID: 10590364.
488. Weinkauff R, Estey EH, Starostik P, Hayes K, Huh YO, Hirsch-Ginsberg C, Andreeff M, Keating M, Kantarjian HM, Freireich EJ, Albitar M. Use of peripheral blood blasts versus bone marrow blasts for diagnosis of acute leukemia. American Journal of Clinical Pathology 111(6):753-758, 1999. e-Pub 1999. PMID: 10361507.
489. Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M, Giles F, Estrov Z, Barlogie B, Albitar M. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 94(11):3717-3721, 1999. e-Pub 1999. PMID: 10572084.
490. Dabaja BS, Faderl S, Thomas D, Cortes J, O'Brien S, Nasr F, Pierce S, Hayes K, Glassman A, Keating M, Kantarjian HM. Deletions and losses in chromosomes 5 or 7 in adult acute lymphocytic leukemia: incidence, associations and implications. Leukemia 13(6):869-872, 1999. e-Pub 1999. PMID: 10360374.
491. Cortes J, O'Brien S, Estey E, Giles F, Keating M, Kantarjian H. Phase I study of liposomal daunorubicin in patients with acute leukemia. Investigational New Drugs 17(1):81-87, 1999. e-Pub 1999. PMID: 10555126.
492. Estey EH, Giles FJ, Kantarjian H, O'Brien S, Cortes J, Freireich EJ, Lopez-Berestein G, Keating M. Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Blood 94(7):2230-2235, 1999. e-Pub 1999. PMID: 10498593.
493. Gandhi V, Plunkett W, Rodriguez CO, Nowak BJ, Du M, Ayres M, Kisor DF, Mitchell BS, Kurtzberg J, Keating MJ. Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. J Clin Oncol 16(11):3607-3615, 1998. e-Pub 1998. PMID: 9817282.
494. Anaissie EJ, Kontoyiannis DP, O'Brien S, Kantarjian H, Robertson L, Lerner S, Keating MJ. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 129(7):559-566, 1998. e-Pub 1998. PMID: 9758577.
495. Keating MJ, O'Brien S, Lerner S, Koller C, Beran M, Robertson LE, Freireich EJ, Estey E, Kantarjian H. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92(4):1165-1171, 1998. e-Pub 1998. PMID: 9694704.
496. Khouri IF, Keating M, Körbling M, Przepiorka D, Anderlini P, O'Brien S, Giralt S, Ippoliti C, von Wolff B, Gajewski J, Donato M, Claxton D, Ueno N, Andersson B, Gee A, Champlin R. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16(8):2817-2824, 1998. e-Pub 1998. PMID: 9704734.
497. Cortes J, Kantarjian H, O'Brien S, Kurzrock R, Keating M, Talpaz M. GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia. Leukemia 12(6):860-864, 1998. e-Pub 1998. PMID: 9639411.
498. Sacchi S, Kantarjian HM, Smith TL, O'Brien S, Pierce S, Kornblau S, Beran M, Keating MJ, Talpaz M. Early treatment decisions with interferon-alfa therapy in early chronic-phase chronic myelogenous leukemia. J Clin Oncol 16(3):882-889, 1998. e-Pub 1998. PMID: 9508169.
499. DeLima M, Albitar M, O'Brien S, Pierce S, Kantarjian H, Andreeff M, Fayad L, Keating M, Estey E. Comparison of referring and tertiary cancer center physician's diagnoses in patients with leukemia. Am J Med 104(3):246-251, 1998. e-Pub 1998. PMID: 9552087.
500. Khouri IF, Keating MJ. High-dose chemotherapy for chronic lymphocytic leukemia: eligibility, timing, and benefit?. Ann Oncol 9(2):131-132, 1998. e-Pub 1998. PMID: 9553656.
501. Wilhelm M, Bueso-Ramos C, O'Brien S, Pierce S, Keating M, Talpaz M, Kantarjian HM. Effect of interferon-alpha therapy on bone marrow fibrosis in chronic myelogenous leukemia. Leukemia 12(1):65-70, 1998. e-Pub 1998. PMID: 9436922.
502. Kornblau SM, Kantarjian H, O'Brien S, Andreeff M, Koller CA, Beran M, Keating M, Estey E. CECA-cyclophosphamide, etoposide, carboplatin and cytosine arabinoside - a new salvage regimen for relapsed or refractory acute myelogenous leukemia. Leuk Lymphoma 28(3-4):371-375, 1998. e-Pub 1998. PMID: 9517508.
503. Koller CA, Kantarjian HM, Thomas D, O'Brien S, Rios MB, Kornblau S, Murphy S, Keating M. The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Leukemia 12:65-70, 1998. e-Pub 1998.
504. Starostik P, Manshouri T, O'Brien S, Freireich E, Kantarjian H, Haidar M, Lerner S, Keating M, Albitar M. Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. Cancer Research 58(20):4552-4557, 1998. e-Pub 1998. PMID: 9788599.
505. Munker R, Kantarjian H, O'Brien S, Keating M, Andreeff M, Estey EH. Phase I study of taxol in refractory acute myelogenous leukemias using a weekly schedule. Acta Haematol 99(2):106-108, 1998. e-Pub 1998. PMID: 9554461.
506. Chandra J, Niemer I, Gilbreath J, Kliche KO, Andreeff M, Freireich EJ, Keating M, McConkey DJ. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood 92(11):4220-4229, 1998. e-Pub 1998. PMID: 9834227.
507. Beran M, Estey E, O'Brien SM, Giles FJ, Koller CA, Kornblau S, Keating M, Kantarjian HM. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leukemia and Lymphoma 31(5-6):521-531, 1998. e-Pub 1998. PMID: 9922042.
508. de Lima M, Strom SS, Keating M, Kantarjian H, Pierce S, O'Brien S, Freireich E, Estey E. Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work. Blood 90(12):4719-4724, 1997. e-Pub 1997. PMID: 9389687.
509. Estey E, deLima M, Strom S, Pierce S, Freireich EJ, Keating MJ. Long-term follow-up of patients with newly diagnosed acute myeloid leukemia treated at the University of Texas M.D. Anderson Cancer Center. Cancer 80(Suppl 11):2176-2180, 1997. e-Pub 1997. PMID: 9395030.
510. Freireich EJ, Keating MJ. Conclusions regarding leukemia long-term survival. Cancer 80(Suppl 11):2215-2217, 1997. e-Pub 1997. PMID: 9395037.
511. Beran M, Jeha S, O'Brien S, Estey E, Vitek L, Zurlo MG, Rios MB, Keating M, Kantarjian H. Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study. Clin Cancer Res 3(12 Pt 1):2377-2384, 1997. e-Pub 1997. PMID: 9815637.
512. Chandra J, Gilbreath J, Freireich EJ, Kliche KO, Andreeff M, Keating M, McConkey DJ. Protease activation is required for glucocorticoid-induced apoptosis in chronic lymphocytic leukemia lymphocytes. Blood 90(9):3673-3681, 1997. e-Pub 1997. PMID: 9345052.
513. Li L, Keating MJ, Plunkett W, Yang LY. Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance. Mol Pharmacol 52(5):798-806, 1997. e-Pub 1997. PMID: 9351970.
514. Rodriguez CO, Legha JK, Estey E, Keating MJ, Gandhi V. Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphate in primary human leukemia cells. Clin Cancer Res 3(11):2107-2113, 1997. e-Pub 1997. PMID: 9815603.
515. Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M. Effect of diagnosis refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML] on outcome of AML-type chemotherapy. Blood 90(8):2969-2977, 1997. e-Pub 1997. PMID: 9376577.
516. Estey E, Keating M, Pierce S, Beran M. Application of the International Scoring System for myelodysplasia to M.D. Anderson patients. Blood 90(7):2843-2846, 1997. e-Pub 1997. PMID: 9326255.
517. O'Brien S, Kantarjian H, Beran M, Koller C, Talpaz M, Lerner S, Keating MJ. Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. Leukemia 11(10):1631-1635, 1997. e-Pub 1997. PMID: 9324281.
518. Sacchi S, Kantarjian HM, O'Brien S, Beran M, Koller C, Pierce S, Kornblau S, Estey E, Keating MJ, Talpaz M. Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia. Leukemia 11(10):1610-1616, 1997. e-Pub 1997. PMID: 9324278.
519. Kantarjian HM, O'Brien SM, Keating M, Beran M, Estey E, Giralt S, Kornblau S, Rios MB, de Vos D, Talpaz M. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia 11(10):1617-1620, 1997. e-Pub 1997. PMID: 9324279.
520. Estey E, Thall P, Kantarjian H, Pierce S, Kornblau S, Keating M. Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Leukemia 11(10):1661-1664, 1997. e-Pub 1997. PMID: 9324286.
521. Gandhi V, Estey E, Du M, Keating MJ, Plunkett W. Minimum doses of fludarabine for the maximum modulation of arabinosylcytosine triphosphate in human leukemia blasts during therapy. Clin Cancer Res 3(9):1539-1545, 1997. e-Pub 1997. PMID: 9815841.
522. Cusack JC, Seymour JF, Lerner S, Keating MJ, Pollock RE. Role of splenectomy in chronic lymphocytic leukemia. J Am Coll Surg 185(3):237-243, 1997. e-Pub 1997. PMID: 9291400.
523. Bseiso AW, Kantarjian HM, Guo JQ, Cortes J, Talpaz M, Koller C, AlBitar M, Keating M, Arlinghaus R. Analysis of the BCR-ABL protein in Philadelphia chromosome-positive adult acute lymphocytic leukemia. Leukemia 11(9):1583-1587, 1997. e-Pub 1997. PMID: 9305617.
524. Iwasaki H, Huang P, Keating MJ, Plunkett W. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood 90(1):270-278, 1997. e-Pub 1997. PMID: 9207462.
525. Cortes J, Kantarjian H, O'Brien S, Beran M, Estey E, Keating M, Talpaz M. A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Leukemia 11(7):929-932, 1997. e-Pub 1997. PMID: 9204970.
526. Giralt S, Estey E, Albitar M, van Besien K, Rondón G, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Kørbling M, Keating M, Kantarjian H, Champlin R. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89(12):4531-4536, 1997. e-Pub 1997. PMID: 9192777.
527. Cortes J, Kantarjian H, Talpaz M, O'Brien S, Beran M, Koller C, Keating M. Treatment of chronic myelogenous leukemia with nucleoside analogs deoxycoformycin and fludarabine. Leukemia 11(6):788-791, 1997. e-Pub 1997. PMID: 9177428.
528. Khouri IF, Przepiorka D, van Besien K, O'Brien S, Palmer JL, Lerner S, Mehra RC, Vriesendorp HM, Andersson BS, Giralt S, Körbling M, Keating MJ, Champlin RE. Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol 97(2):466-473, 1997. e-Pub 1997. PMID: 9163617.
529. Kurzrock R, Strom SS, Estey E, O'Brien S, Keating MJ, Jiang H, Adams T, Talpaz M. Second cancer risk in hairy cell leukemia: analysis of 350 patients. J Clin Oncol 15(5):1803-1810, 1997. e-Pub 1997. PMID: 9164188.
530. Kornblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli U, Snell V, Sanchez-Williams G, Kantarjian H, Keating M, Newman RA, Andreeff M. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol 15(5):1796-1802, 1997. e-Pub 1997. PMID: 9164187.
531. Li L, Liu X, Glassman AB, Keating MJ, Stros M, Plunkett W, Yang LY. Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro. Cancer Res 57(8):1487-1494, 1997. e-Pub 1997. PMID: 9108450.
532. Manshouri T, Yang Y, Lin H, Stass SA, Glassman AB, Keating MJ, Albitar M. Downregulation of RAR alpha in mice by antisense transgene leads to a compensatory increase in RAR beta and RAR gamma and development of lymphoma. Blood 89(7):2507-2515, 1997. e-Pub 1997. PMID: 9116296.
533. Haidar MA, El-Hajj H, Bueso-Ramos CE, Manshouri T, Glassman A, Keating MJ, Maher A. Expression profile of MDM-2 proteins in chronic lymphocytic leukemia and their clinical relevance. Am J Hematol 54(3):189-195, 1997. e-Pub 1997. PMID: 9067496.
534. Kantarjian HM, O'Brien SM, Estey E, Giralt S, Beran M, Rios MB, Keating M, de Vos D, Talpaz M. Decitabine studies in chronic and acute myelogenous leukemia. Leukemia 11(Suppl 1):S35-36, 1997. e-Pub 1997. PMID: 9130691.
535. Estey E, Thall PF, Pierce S, Kantarjian H, Keating M. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 15(2):483-490, 1997. e-Pub 1997. PMID: 9053469.
536. Seymour JF, Cusack JD, Lerner SA, Pollock RE, Keating MJ. Case/control study of the role of splenectomy in chronic lymphocytic leukemia. J Clin Oncol 15(1):52-60, 1997. e-Pub 1997. PMID: 8996124.
537. Wilhelm M, Kantarjian HM, O'Brien S, Pierce S, Keating MJ, Freireich EJ, Estey EH. Pneumonia during remission induction chemotherapy in patients with AML or MDS. Leukemia 10(12):1870-1873, 1996. e-Pub 1996. PMID: 8946924.
538. Beran M, Kantarjian H, O'Brien S, Koller C, al-Bitar M, Arbuck S, Pierce S, Moore M, Abbruzzese JL, Andreeff M, Keating M, Estey E. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 88(7):2473-2479, 1996. e-Pub 1996. PMID: 8839838.
539. Fayad L, Robertson LE, O'Brien S, Manning JT, Wright S, Hagemeister F, Cabanillas F, Keating MJ. Hodgkin's disease variant of Richter's syndrome: experience at a single institution. Leuk Lymphoma 23(3-4):333-337, 1996. e-Pub 1996. PMID: 9031114.
540. Haidar MA, Loya F, Yang Y, Lin H, Glassman A, Keating MJ, Goldwasser E, Albitar M. Differential expression of lacZ in the liver and kidney of transgenic mice carrying chimeric lacZ-erythropoietin gene constructs with or without its 1.2 kb 3'-flanking sequence. Nucleic Acids Res 24(18):3621-3628, 1996. e-Pub 1996. PMID: 8836192.
541. Crane MM, Strom SS, Halabi S, Berman EL, Fueger JJ, Spitz MR, Keating MJ. Correlation between selected environmental exposures and karyotype in acute myelocytic leukemia. Cancer Epidemiol Biomarkers Prev 5(8):639-644, 1996. e-Pub 1996. PMID: 8824367.
542. Estey E, Kornblau S, Pierce S, Kantarjian H, Beran M, Keating M. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. Blood 88(2):756, 1996. e-Pub 1996. PMID: 8695828.
543. Marin MC, Fernandez A, Bick RJ, Brisbay S, Buja LM, Snuggs M, McConkey DJ, von Eschenbach AC, Keating MJ, McDonnell TJ. Apoptosis suppression by bcl-2 is correlated with the regulation of nuclear and cytosolic Ca2+. Oncogene 12(11):2259-2266, 1996. e-Pub 1996. PMID: 8649765.
544. Ghaddar HM, Pierce S, Kantarjian HM, Freireich EJ, Keating MJ, Estey EH. Amsacrine and continuous-infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemia. Leuk Lymphoma 22(1-2):71-76, 1996. e-Pub 1996. PMID: 8724530.
545. Anderlini P, Ghaddar HM, Smith TL, Pierce S, Kantarjian HM, O'Brien S, Keating MJ, Freireich EJ, Estey EH. Factors predicting complete remission and subsequent disease-free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first. Leukemia 10(6):964-969, 1996. e-Pub 1996. PMID: 8667653.
546. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87(12):4990-4997, 1996. e-Pub 1996. PMID: 8652811.
547. Anderlini P, Luna M, Kantarjian HM, O'Brien S, Pierce S, Keating MJ, Estey EH. Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes. Leukemia 10(4):600-608, 1996. e-Pub 1996. PMID: 8618434.
548. Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 10(3):456-459, 1996. e-Pub 1996. PMID: 8642861.
549. Kantarjian HM, Beran M, O'Brien S, Robertson L, Siddik Z, Yoshida M, Yang LY, Rios MB, Keating MJ, Meyer M. Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia. Leukemia 10(3):396-401, 1996. e-Pub 1996. PMID: 8642853.
550. Sarris A, Cortes J, Kantarjian H, Pierce S, Smith T, Keating M, Koller C, Kornblau S, O'Brien S, Andreeff M. Disseminated intravascular coagulation in adult acute lymphoblastic leukemia: frequent complications with fibrinogen levels less than 100 mg/dl. Leuk Lymphoma 21(1-2):85-92, 1996. e-Pub 1996. PMID: 8907274.
551. Pollicardo N, O'Brien S, Estey EH, al-Bitar M, Pierce S, Keating M, Kantarjian HM. Secondary acute promyelocytic leukemia. Characteristics and prognosis of 14 patients from a single institution. Leukemia 10(1):27-31, 1996. e-Pub 1996. PMID: 8558933.
552. Gandhi V, Estey E, Keating MJ, Chucrallah A, Plunkett W. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood 87(1):256-264, 1996. e-Pub 1996. PMID: 8547650.
553. Robertson LE, Denny AW, Huh YO, Plunkett W, Keating MJ, Nelson JA. Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine. Cancer Chemother Pharmacol 37(5):445-450, 1996. e-Pub 1996. PMID: 8599867.
554. Preti HA, Huh YO, O'Brien SM, Andreeff M, Pierce ST, Keating M, Kantarjian HM. Myeloid markers in adult acute lymphocytic leukemia. Correlations with patient and disease characteristics and with prognosis. Cancer 76(9):1564-1570, 1995. e-Pub 1995. PMID: 8635059.
555. O'Brien S, Kantarjian H, Keating M, Beran M, Koller C, Robertson LE, Hester J, Rios MB, Andreeff M, Talpaz M. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 86(9):3322-3326, 1995. e-Pub 1995. PMID: 7579434.
556. Cortes J, O'Brien SM, Pierce S, Keating MJ, Freireich EJ, Kantarjian HM. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood 86(6):2091-2097, 1995. e-Pub 1995. PMID: 7662956.
557. Robertson LE, O'Brien S, Kantarjian H, Koller C, Beran M, Andreeff M, Lerner S, Plunkett W, Keating MJ. A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia. Leukemia 9(9):1444-1449, 1995. e-Pub 1995. PMID: 7658710.
558. Verschraegen CF, Kantarjian HM, Hirsch-Ginsberg C, Lee MS, O'Brien S, Rios MB, Stass SA, Keating M, Talpaz M. The breakpoint cluster region site in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Clinical, laboratory, and prognostic correlations. Cancer 76(6):992-997, 1995. e-Pub 1995. PMID: 8625225.
559. Seymour JF, Robertson LE, O'Brien S, Lerner S, Keating MJ. Survival of young patients with chronic lymphocytic leukemia failing fludarabine therapy: a basis for the use of myeloablative therapies. Leuk Lymphoma 18(5-6):493-496, 1995. e-Pub 1995. PMID: 8528058.
560. O'Brien S, Kantarjian H, Beran M, Robertson LE, Koller C, Lerner S, Keating MJ. Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy. Blood 86(4):1298-1300, 1995. e-Pub 1995. PMID: 7632936.
561. Haidar MA, Cao XB, Manshouri T, Chan LL, Glassman A, Kantarjian HM, Keating MJ, Beran MS, Albitar M. p16INK4A and p15INK4B gene deletions in primary leukemias. Blood 86(1):311-315, 1995. e-Pub 1995. PMID: 7795238.
562. Estey E, Keating MJ, Pierce S, Stass S. Change in karyotype between diagnosis and first relapse in acute myelogenous leukemia. Leukemia 9(6):972-976, 1995. e-Pub 1995. PMID: 7596187.
563. Robertson LE, O'Brien S, Kantarjian H, Koller C, Beran M, Andreeff M, Lerner S, Keating MJ. Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia. Leukemia 9(6):943-945, 1995. e-Pub 1995. PMID: 7596181.
564. Marlton P, Keating M, Kantarjian H, Pierce S, O'Brien S, Freireich EJ, Estey E. Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16. Leukemia 9(6):965-971, 1995. e-Pub 1995. PMID: 7596186.
565. Yang LY, Li L, Keating MJ, Plunkett W. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair. Mol Pharmacol 47(5):1072-1079, 1995. e-Pub 1995. PMID: 7746274.
566. O'Brien S, Kantarjian H, Ellis A, Zwelling L, Estey E, Keating M. Topotecan in chronic lymphocytic leukemia. Cancer 75(5):1104-1108, 1995. e-Pub 1995. PMID: 7850708.
567. Estey EH, Kantarjian HM, O'Brien S, Kornblau S, Andreeff M, Beran M, Pierce S, Keating M. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF). Cytokines Mol Ther 1(1):21-28, 1995. e-Pub 1995. PMID: 9384660.
568. Seymour JF, Keating MJ. Parathyroid hormone related protein in hypercalcaemia in CLL. Br J Haematol 89(3):685-686, 1995. e-Pub 1995. PMID: 7734384.
569. Estey EH, Keating MJ. Post-remission chemotherapy for acute myeloid leukemia. N Engl J Med 332(5):334; author reply 334-335, 1995. e-Pub 1995. PMID: 7816077.
570. Gandhi V, Estey E, Du M, Nowak B, Keating MJ, Plunkett W. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia. Clin Cancer Res 1(2):169-178, 1995. e-Pub 1995. PMID: 9815970.
571. Dimopoulos MA, Weber D, Delasalle KB, Keating M, Alexanian R. Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors. Ann Oncol 6(1):49-52, 1995. e-Pub 1995. PMID: 7710983.
572. Cortes JE, Kantarjian H, O'Brien S, Keating M, Pierce S, Freireich EJ, Estey E. Clinical and prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes. Leukemia 9(1):115-117, 1995. e-Pub 1995. PMID: 7845005.
573. Cortes J, O'Brien S, Kantarjian H, Cork A, Stass S, Freireich EJ, Keating M, Pierce S, Estey E. Abnormalities in the long arm of chromosome 11 (11q) in patients with de novo and secondary acute myelogenous leukemias and myelodysplastic syndromes. Leukemia 8(12):2174-2178, 1994. e-Pub 1994. PMID: 7808007.
574. Dimopoulos MA, Kantarjian H, Weber D, O'Brien S, Estey E, Delasalle K, Rose E, Cabanillas F, Keating M, Alexanian R. Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 12(12):2694-2698, 1994. e-Pub 1994. PMID: 7989946.
575. Gale RP, Caligaris-Cappio F, Dighiero G, Keating M, Montserrat E, Rai K. Recent progress in chronic lymphocytic leukemia. International Workshop on chronic Lymphocytic Leukemia. Leukemia 8(9):1610-1614, 1994. e-Pub 1994. PMID: 7522296.
576. Kantarjian HM, O'Brien S, Smith T, Estey EH, Beran M, Preti A, Pierce S, Keating MJ. Acute lymphocytic leukaemia in the elderly: characteristics and outcome with the vincristine-adriamycin-dexamethasone (VAD) regimen. Br J Haematol 88(1):94-100, 1994. e-Pub 1994. PMID: 7803263.
577. Ghaddar HM, Plunkett W, Kantarjian HM, Pierce S, Freireich EJ, Keating MJ, Estey EH. Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside. Leukemia 8(8):1269-1274, 1994. e-Pub 1994. PMID: 8057660.
578. O'Brien S, Kurzrock R, Duvic M, Kantarjian H, Stass S, Robertson LE, Estey E, Pierce S, Keating MJ. 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood 84(3):733-738, 1994. e-Pub 1994. PMID: 7913841.
579. Cortes JE, Kantarjian H, O'Brien S, Robertson LE, Koller C, Hirsh-Ginsberg C, Stass S, Keating M, Estey E. All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. Cancer 73(12):2946-2952, 1994. e-Pub 1994. PMID: 8199992.
580. Seymour JF, Pierce SA, Kantarjian HM, Keating MJ, Estey EH. Investigation of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56). Leukemia 8(5):823-826, 1994. e-Pub 1994. PMID: 7514247.
581. Khouri IF, Keating MJ, Vriesendorp HM, Reading CL, Przepiorka D, Huh YO, Andersson BS, van Besien KW, Mehra RC, Giralt SA. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol 12(4):748-758, 1994. e-Pub 1994. PMID: 8151318.
582. Keating MJ. Leukemia, whither goest thou?. Mayo Clin Proc 69(4):397-398, 1994. e-Pub 1994. PMID: 8170187.
583. Dimopoulos MA, Weber DM, Kantarjian H, Keating M, Alexanian R. 2Chlorodeoxyadenosine therapy of patients with Waldenström macroglobulinemia previously treated with fludarabine. Ann Oncol 5(3):288-289, 1994. e-Pub 1994. PMID: 7514439.
584. McLaughlin P, Hagemeister FB, Swan F, Cabanillas F, Pate O, Romaguera JE, Rodriguez MA, Redman JR, Keating M. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol 12(3):575-579, 1994. e-Pub 1994. PMID: 8120556.
585. Mourad WA, Pugh WC, Huh YO, Keating MJ. Cell kinetic analysis of interleukin-2 receptor-tested chronic lymphocytic leukemia using the AgNOR silver stain. Am J Clin Pathol 101(3):300-304, 1994. e-Pub 1994. PMID: 8135185.
586. Huh YO, Pugh WC, Kantarjian HM, Stass SA, Cork A, Trujillo JM, Keating MJ. Detection of subgroups of chronic B-cell leukemias by FMC7 monoclonal antibody. Am J Clin Pathol 101(3):283-289, 1994. e-Pub 1994. PMID: 8135183.
587. O'Brien S, Kantarjian H, Estey E, Koller C, Robertson B, Beran M, Andreeff M, Pierce S, Keating M. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med 330(5):319-322, 1994. e-Pub 1994. PMID: 7904047.
588. Gandhi V, Robertson LE, Keating MJ, Plunkett W. Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology. Cancer Chemother Pharmacol 34(1):30-36, 1994. e-Pub 1994. PMID: 8174200.
589. Estey EH, Kantarjian H, Keating M. Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome. Semin Oncol 20(6 Suppl 8):1-5, 1993. e-Pub 1993. PMID: 8290966.
590. Kantarjian HM, Estey E, O'Brien S, Anaissie E, Beran M, Pierce S, Robertson L, Keating MJ. Granulocyte colony-stimulating factor supportive treatment following intensive chemotherapy in acute lymphocytic leukemia in first remission. Cancer 72(10):2950-2955, 1993. e-Pub 1993. PMID: 7693325.
591. Robertson LE, Pugh W, O'Brien S, Kantarjian H, Hirsch-Ginsberg C, Cork A, McLaughlin P, Cabanillas F, Keating MJ. Richter's syndrome: a report on 39 patients. J Clin Oncol 11(10):1985-1989, 1993. e-Pub 1993. PMID: 8410123.
592. Suki S, Kantarjian H, Gandhi V, Estey E, O'Brien S, Beran M, Rios MB, Plunkett W, Keating M. Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia. Cancer 72(7):2155-2160, 1993. e-Pub 1993. PMID: 8374873.
593. Di Raimondo F, Giustolisi R, Cacciola E, O'Brien S, Kantarjian H, Robertson LB, Keating MJ. Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine. Leuk Lymphoma 11(1-2):63-68, 1993. e-Pub 1993. PMID: 8220155.
594. O'Brien S, Kantarjian H, Beran M, Smith T, Koller C, Estey E, Robertson LE, Lerner S, Keating M. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 82(6):1695-1700, 1993. e-Pub 1993. PMID: 8400226.
595. Dimopoulos MA, O'Brien S, Kantarjian H, Pierce S, Delasalle K, Barlogie B, Alexanian R, Keating MJ. Fludarabine therapy in Waldenström's macroglobulinemia. Am J Med 95(1):49-52, 1993. e-Pub 1993. PMID: 8328496.
596. Keating M. Response. Science 260(5116):1962, 1993. e-Pub 1993. PMID: 17836725.
597. Keating MJ, O'Brien S, Kantarjian H, Plunkett W, Estey E, Koller C, Beran M, Freireich EJ. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 81(11):2878-2884, 1993. e-Pub 1993. PMID: 8499626.
598. Kemena A, O'Brien S, Kantarjian H, Robertson L, Koller C, Beran M, Estey E, Plunkett W, Lerner S, Keating MJ. Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule. Leuk Lymphoma 10(3):187-193, 1993. e-Pub 1993. PMID: 8220117.
599. Robertson LE, Hall R, Keating MJ, Estey E, Kantarjian HM, McLaughlin P, Hagemeister FB, Plunkett W. High-dose cytosine arabinoside in chronic lymphocytic leukemia: a clinical and pharmacologic analysis. Leuk Lymphoma 10(1-2):43-48, 1993. e-Pub 1993. PMID: 8374522.
600. Escudier SM, Pereira-Leahy JM, Drach JW, Weier HU, Goodacre AM, Cork MA, Trujillo JM, Keating MJ, Andreeff M. Fluorescent in situ hybridization and cytogenetic studies of trisomy 12 in chronic lymphocytic leukemia. Blood 81(10):2702-2707, 1993. e-Pub 1993. PMID: 7683927.
601. Gandhi V, Kemena A, Keating MJ, Plunkett W. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. Leuk Lymphoma 10(1-2):49-56, 1993. e-Pub 1993. PMID: 8374523.
602. Keating MJ. Immunosuppression with purine analogues--the flip side of the gold coin. Ann Oncol 4(5):347-348, 1993. e-Pub 1993. PMID: 8353067.
603. Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MJ. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma 9(4-5):343-350, 1993. e-Pub 1993. PMID: 8394169.
604. Dimopoulos MA, Kantarjian H, Estey E, O'Brien S, Delasalle K, Keating MJ, Freireich EJ, Alexanian R. Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med 118(3):195-198, 1993. e-Pub 1993. PMID: 8093333.
605. Derderian PM, Kantarjian HM, Talpaz M, O'Brien S, Cork A, Estey E, Pierce S, Keating M. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. Am J Med 94(1):69-74, 1993. e-Pub 1993. PMID: 8420302.
606. Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 11(1):116-124, 1993. e-Pub 1993. PMID: 8418222.
607. Dimopoulos MA, O'Brien S, Kantarjian H, Estey EE, Keating MJ, Alexanian R. Treatment of Waldenstrom's macroglobulinemia with nucleoside analogues. Leuk Lymphoma 11 Suppl 2:105-108, 1993. e-Pub 1993. PMID: 7907250.
608. Estey EH, Plunkett W, Kantarjian H, Rios MB, Keating MJ. Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C. Leuk Lymphoma 10 Suppl:115-121, 1993. e-Pub 1993. PMID: 8481661.
609. Keating MJ, O'Brien S, Robertson L, Huh Y, Kantarjian H, Plunkett W. Chronic lymphocytic leukemia--correlation of response and survival. Leuk Lymphoma 11 Suppl 2:167-175, 1993. e-Pub 1993. PMID: 8124227.
610. Kantarjian HM, Smith T, Estey E, Polyzos A, O'Brien S, Pierce S, Beran M, Feldman E, Keating MJ. Prognostic significance of elevated serum beta 2-microglobulin levels in adult acute lymphocytic leukemia. Am J Med 93(6):599-604, 1992. e-Pub 1992. PMID: 1466355.
611. Keating MJ, O'Brien S, Robertson L, Plunkett W, Kantarjian H, Koller C. New drugs in the treatment of chronic lymphocytic leukemia. Leukemia 6 Suppl 4:140-141, 1992. e-Pub 1992. PMID: 1359203.
612. Anaissie E, Kontoyiannis DP, Kantarjian H, Elting L, Robertson LE, Keating M. Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. Ann Intern Med 117(6):466-469, 1992. e-Pub 1992. PMID: 1354425.
613. Freireich EJ, Cork A, Stass SA, McCredie KB, Keating MJ, Estey EH, Kantarjian HM, Trujillo JM. Cytogenetics for detection of minimal residual disease in acute myeloblastic leukemia. Leukemia 6(6):500-506, 1992. e-Pub 1992. PMID: 1602788.
614. Redman JR, Cabanillas F, Velasquez WS, McLaughlin P, Hagemeister FB, Swan F, Rodriguez MA, Plunkett WK, Keating MJ. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol 10(5):790-794, 1992. e-Pub 1992. PMID: 1373760.
615. Kantarjian HM, Keating MJ, Estey EH, O'Brien S, Pierce S, Beran M, Koller C, Feldman E, Talpaz M. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine. J Clin Oncol 10(5):772-778, 1992. e-Pub 1992. PMID: 1569449.
616. del Giglio A, O'Brien S, Ford R, Saya H, Manning J, Keating M, Johnston D, Khetan R, el-Naggar A, Deisseroth A. Prognostic value of proliferating cell nuclear antigen expression in chronic lymphoid leukemia. Blood 79(10):2717-2720, 1992. e-Pub 1992. PMID: 1350226.
617. Estey E, Thall PF, Kantarjian H, O'Brien S, Koller CA, Beran M, Gutterman J, Deisseroth A, Keating M. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood 79(9):2246-2255, 1992. e-Pub 1992. PMID: 1571541.
618. Dreizen S, Keating MJ, Beran M. Orofacial fungal infections. Nine pathogens that may invade during chemotherapy. Postgrad Med 91(5):349-350, 353-354, 357-360 passim, 1992. e-Pub 1992. PMID: 1561171.
619. Kantarjian HM, Talpaz M, Kontoyiannis D, Gutterman J, Keating MJ, Estey EH, O'Brien S, Rios MB, Beran M, Deisseroth A. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor. J Clin Oncol 10(3):398-405, 1992. e-Pub 1992. PMID: 1740679.
620. Crane MM, Godwin JE, Annegers JF, Keating MJ. Is histological subtype a marker for environmental exposures in acute myelogenous leukemia?. Cancer Epidemiol Biomarkers Prev 1(3):183-188, 1992. e-Pub 1992. PMID: 1306103.
621. Gandhi V, Kemena A, Keating MJ, Plunkett W. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res 52(4):897-903, 1992. e-Pub 1992. PMID: 1737352.
622. Kantarjian HM, Estey EH, O'Brien S, Anaissie E, Beran M, Rios MB, Keating MJ, Gutterman J. Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia. Blood 79(4):876-881, 1992. e-Pub 1992. PMID: 1737098.
623. Rolston KV, Berkey P, Bodey GP, Anaissie EJ, Khardori NM, Joshi JH, Keating MJ, Holmes FA, Cabanillas FF, Elting L. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 152(2):283-291, 1992. e-Pub 1992. PMID: 1739355.
624. Estey EH, Kurzrock R, Kantarjian HM, O'Brien SM, McCredie KB, Beran M, Koller C, Keating MJ, Hirsch-Ginsberg C, Huh YO. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood 79(4):882-887, 1992. e-Pub 1992. PMID: 1346577.
625. Kantarjian HM, Talpaz M, Dhingra K, Estey E, Keating MJ, Ku S, Trujillo J, Huh Y, Stass S, Kurzrock R. Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. Blood 78(9):2411-2418, 1991. e-Pub 1991. PMID: 1932753.
626. Kantarjian HM, Talpaz M, Keating MJ, Estey EH, O'Brien S, Beran M, McCredie KB, Gutterman J, Freireich EJ. Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 68(6):1201-1207, 1991. e-Pub 1991. PMID: 1873771.
627. O'Brien S, Kantarjian H, Estey E, Koller C, Beran M, McCredie K, Keating M. Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia. Cancer 68(4):691-694, 1991. e-Pub 1991. PMID: 1855168.
628. Bodey G, Reuben A, Elting L, Kantarjian H, Keating M, Hagemeister F, Koller C, Velasquez W, Papadopoulos N. Comparison of two schedules of cefoperazone plus aztreonam in the treatment of neutropenic patients with fever. Eur J Clin Microbiol Infect Dis 10(7):551-558, 1991. e-Pub 1991. PMID: 1915397.
629. Crane MM, Keating MJ. Exposure histories in acute nonlymphocytic leukemia patients with a prior preleukemic condition. Cancer 67(8):2211-2214, 1991. e-Pub 1991. PMID: 2004342.
630. Estey EH, Kurzrock R, Talpaz M, McCredie KB, O'Brien S, Kantarjian HM, Keating MJ, Deisseroth AB, Gutterman JU. Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes. Br J Haematol 77(3):291-295, 1991. e-Pub 1991. PMID: 2012752.
631. Kantarjian HM, Schachner J, Keating MJ. Fludarabine therapy in hairy cell leukemia. Cancer 67(5):1291-1293, 1991. e-Pub 1991. PMID: 1991291.
632. Kantarjian HM, Childs C, O'Brien S, Huh Y, Beran M, Schachner J, Koller C, Keating MJ. Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia. Am J Med 90(2):223-228, 1991. e-Pub 1991. PMID: 1996592.
633. O'Brien S, Benvenuto JA, Estey E, Beran M, Felder TB, Keating M. Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia. Cancer Res 51(3):935-938, 1991. e-Pub 1991. PMID: 1988134.
634. Keating MJ, Kantarjian H, O'Brien S, Koller C, Talpaz M, Schachner J, Childs CC, Freireich EJ, McCredie KB. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 9(1):44-49, 1991. e-Pub 1991. PMID: 1702145.
635. Dreizen S, Menkin DJ, Keating MJ, McCredie KB, O'Neill PA. Effect of antileukemia chemotherapy on marrow, blood, and oral granulocyte counts. Oral Surg Oral Med Oral Pathol 71(1):45-49, 1991. e-Pub 1991. PMID: 1994322.
636. Kantarjian HM, Walters RS, Keating MJ, Smith TL, O'Brien S, Estey EH, Huh YO, Spinolo J, Dicke K, Barlogie B, et al.. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. J Clin Oncol 8(6):994-1004, 1990. e-Pub 1990. PMID: 2189958.
637. Plunkett W, Heinemann V, Estey E, Keating M. Pharmacologically directed design of leukemia therapy. Hamatologie und Bluttransfusion 33:610-613, 1990. e-Pub 1990.
638. Kantarjian HM, Walters RL, Keating MJ, Estey EH, O'Brien S, Schachner J, McCredie KB, Freireich EJ. Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia. Cancer 65(1):5-8, 1990. e-Pub 1990.
639. Dreizen S, McCredie KB, Keating MJ, Andersson BS. Nutritional deficiencies in patients receiving cancer chemotherapy. Postgraduate Medicine 87(1):163-170, 1990. e-Pub 1990.
640. Kantarjian HM, Walters RS, Keating MJ, Barlogie B, McCredie KB, Freireich EJ. Experience with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy in adults with refractory acute lymphocytic leukemia. Cancer 64(1):16-22, 1989. e-Pub 1989. PMID: 2659160.
641. Vadhan-Raj S, Hittelman WN, Broxmeyer HE, Keating M, Urdal D, Gutterman JU. In vivo biologic activities of recombinant human granulocyte-macrophage colony-stimulating factor. Annals of the New York Academy of Sciences 554:231-240, 1989. e-Pub 1989.
642. Maddox AM, Johnson DA, Keating MJ. 5-bromodeoxyuridine (BUdR) quenching of acridine orange fluorescence distinguishes cycling and non-cycling normal and malignant bone marrow cells in vitro. Leukemia Research 13(9):781-790, 1989. e-Pub 1989.
643. Gagnon GA, Childs CC, LeMaistre A, Keating M, Cork A, Trujillo JM, Nellis K, Freireich E, Stass SA. Molecular heterogeneity in acute leukemia lineage switch. Blood 74(6):2088-2095, 1989. e-Pub 1989.
644. Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Schiffer CA, Oken MM, Keating MJ, Boldt DH, Kempin SJ. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol 29(3):152-63, 1988. e-Pub 1988. PMID: 3189311.
645. Kantarjian HM, Walters RS, Smith TL, Keating MJ, Barlogie B, McCredie KB, Freireich EJ. Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia. Blood 72(5):1784-9, 1988. e-Pub 1988. PMID: 3052630.
646. Beran M, McCredie KB, Keating MJ, Gutterman JU. Antileukemic effect of recombinant tumor necrosis factor alpha in vitro and its modulation by alpha and gamma interferons. Blood 72(2):728-38, 1988. e-Pub 1988. PMID: 3135864.
647. Walters RS, Kantarjian HM, Keating MJ, Plunkett WK, Estey EH, Andersson B, Beran M, McCredie KB, Freireich EJ. Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia. Cancer 62(4):677-82, 1988. e-Pub 1988. PMID: 3165047.
648. Kantarjian HM, Walters RS, Keating MJ, Talpaz M, Andersson B, Beran M, McCredie KB, Freireich EJ. Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside. Cancer 62(4):672-6, 1988. e-Pub 1988. PMID: 3165046.
649. Dreizen S, McCredie KB, Bodey GP, Keating MJ. Mucocutaneous herpetic infections during cancer chemotherapy. Postgrad Med 84(2):181-4, 187-90, 1988. e-Pub 1988. PMID: 2840648.
650. Keating MJ, Smith TL, Kantarjian H, Cork A, Walters R, Trujillo JM, McCredie KB, Gehan EA, Freireich EJ. Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia 2(7):403-12, 1988. e-Pub 1988. PMID: 3164797.
651. Maddox AM, Freireich EJ, Keating MJ, Frasier-Scott KF, Haddox MK. Alterations in human circulating and bone marrow mononuclear cell polyamine levels in hematologic malignancies as a consequence of difluoromethylornithine administration. Invest New Drugs 6(2):125-34, 1988. e-Pub 1988. PMID: 3139580.
652. Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB, Freireich EJ. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 61(7):1441-6, 1988. e-Pub 1988. PMID: 3162181.
653. Keating MJ, Scouros M, Murphy S, Kantarjian H, Hester J, McCredie KB, Hersh EM, Freireich EJ. Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia. Leukemia 2(3):157-64, 1988. e-Pub 1988. PMID: 3347094.
654. Maddox AM, Freireich EJ, Keating MJ, Haddox MK. Alterations in bone marrow and blood mononuclear cell polyamine and methylglyoxal bis(guanylhydrazone) levels: phase I evaluation of alpha-difluoromethylornithine and methylglyoxal bis(guanylhydrazone) treatment of human hematological malignancies. Cancer Res 48(5):1367-73, 1988. e-Pub 1988. PMID: 3124958.
655. Kantarjian HM, Keating MJ, Walters RS, McCredie KB, Freireich EJ. The characteristics and outcome of patients with late relapse acute myelogenous leukemia. J Clin Oncol 6(2):232-8, 1988. e-Pub 1988. PMID: 3276823.
656. Ventura GJ, Hester JP, Smith TL, Keating MJ. Acute myeloblastic leukemia with hyperleukocytosis: risk factors for early mortality in induction. Am J Hematol 27(1):34-7, 1988. e-Pub 1988. PMID: 3162645.
657. Keating MJ, Kantarjian H, Talpaz M, Redman J, McCredie KB. Fludarabine therapy in chronic lymphocytic leukemia (CLL). Nouv Rev Fr Hematol 30(5-6):461-6, 1988. e-Pub 1988. PMID: 2464794.
658. Maddox AM, Keating MJ, Freireich EJ, Haddox MK. Polyamines increase in human peripheral blood and bone marrow mononuclear cells following administration of methylglyoxal bis(guanylhydrazone). Chemotherapy 34(5):419-29, 1988. e-Pub 1988. PMID: 3141118.
659. Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H, Keating MJ. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res 47(11):3005-11, 1987. e-Pub 1987. PMID: 3471322.
660. Dekmezian R, Kantarjian HM, Keating MJ, Talpaz M, McCredie KB, Freireich EJ. The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia. Cancer 59(10):1739-43, 1987. e-Pub 1987. PMID: 2435399.
661. Keating MJ, Gehan EA, Smith TL, Estey EH, Walters RS, Kantarjian HM, McCredie KB, Freireich EJ. A strategy for evaluation of new treatments in untreated patients: application to a clinical trial of AMSA for acute leukemia. J Clin Oncol 5(5):710-21, 1987. e-Pub 1987. PMID: 3553435.
662. Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 69(5):1280-8, 1987. e-Pub 1987. PMID: 3471281.
663. Plunkett W, Nowak B, Keating MJ. Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy. Cancer Treat Rep 71(5):479-83, 1987. e-Pub 1987. PMID: 3567973.
664. Kantarjian HM, Keating MJ, Walters RS, Smith TL, McCredie KB, Freireich EJ. Role of maintenance chemotherapy in acute promyelocytic leukemia. Cancer 59(7):1258-63, 1987. e-Pub 1987. PMID: 3469011.
665. Glass JP, Van Tassel P, Keating MJ, Cork A, Trujillo J, Holmes R. Central nervous system complications of a newly recognized subtype of leukemia: AMML with a pericentric inversion of chromosome 16. Neurology 37(4):639-44, 1987. e-Pub 1987. PMID: 3470629.
666. Maxwell SA, Kurzrock R, Parsons SJ, Talpaz M, Gallick GE, Kloetzer WS, Arlinghaus RB, Kouttab NM, Keating MJ, Gutterman JU. Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients. Cancer Res 47(6):1731-9, 1987. e-Pub 1987. PMID: 2434223.
667. Lee JS, Dixon DO, Kantarjian HM, Keating MJ, Talpaz M. Prognosis of chronic lymphocytic leukemia: a multivariate regression analysis of 325 untreated patients. Blood 69(3):929-36, 1987. e-Pub 1987. PMID: 3814821.
668. Dreizen S, McCredie KB, Bodey GP, Keating MJ. Necrotizing dermatitis in patients receiving cancer chemotherapy. Postgrad Med 81(4):263-71, 1987. e-Pub 1987. PMID: 3469638.
669. Dreizen S, McCredie KB, Keating MJ. Mucocutaneous granulocytic sarcomas of the head and neck. J Oral Pathol 16(2):57-60, 1987. e-Pub 1987. PMID: 3112348.
670. Keating MJ, Cork A, Broach Y, Smith T, Walters RS, McCredie KB, Trujillo J, Freireich EJ. Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia. Leuk Res 11(2):119-33, 1987. e-Pub 1987. PMID: 3469482.
671. Kantarjian HM, Talpaz M, Kurzrock R, Keating MJ, McCredie KB, Gutterman J, Freireich EJ. Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemia. Acta Haematol 78 Suppl 1:70-4, 1987. e-Pub 1987. PMID: 2449026.
672. Lee MS, Chang KS, Trujillo JM, McCredie KB, Keating MJ, Freireich EJ, Stass SA. T-cell receptor gamma chain gene rearrangement in acute myelogenous leukemia--evidence for lymphoid lineage prematurity. Hematol Pathol 1(2):93-8, 1987. e-Pub 1987. PMID: 2848796.
673. Keating MJ, Estey E, Kantarjian HM, Walters R, Smith T, McCredie KB, Freireich EJ. Comparison of results of salvage therapy in adult acute myelogenous leukemia. Acta Haematol 78 Suppl 1:120-6, 1987. e-Pub 1987. PMID: 3124434.
674. Lotzová E, Savary CA, Herberman RB, McCredie KB, Keating MJ, Freireich EJ. Augmentation of antileukemia lytic activity by OKT3 monoclonal antibody: synergism of OKT3 and interleukin-2. Nat Immun Cell Growth Regul 6(5):219-23, 1987. e-Pub 1987. PMID: 3502169.
675. Dalton WT, Ahearn MJ, Cork A, Trujillo JM, Keating MJ, McCredie KB, Freireich EJ, Stass SA. Acute myelomonocytic leukemia associated with abnormalities of chromosome 16: a light and electron microscopic study. Hematol Pathol 1(2):105-12, 1987. e-Pub 1987. PMID: 3504432.
676. Ventura GJ, Drewinko B, Keating MJ. Correlative patterns of neutrophil and platelet counts during very early remission of acute myeloblastic leukemia. Hematol Pathol 1(2):113-6, 1987. e-Pub 1987. PMID: 3504433.
677. Estey EH, Keating MJ, Dixon DO, Trujillo JM, McCredie KB, Freireich EJ. Karyotype is prognostically more important than the FAB system's distinction between myelodysplastic syndrome and acute myelogenous leukemia. Hematol Pathol 1(4):203-8, 1987. e-Pub 1987. PMID: 3504436.
678. Kantarjian HM, Keating MJ. The eosinophilic variant of acute myelomonocytic leukemia developing as a secondary leukemia in a patient with mycosis fungoides. Hematol Pathol 1(3):191-2, 1987. e-Pub 1987. PMID: 3509053.
679. Dreizen S, McCredie KB, Bodey GP, Keating MJ. Quantitative analysis of the oral complications of antileukemia chemotherapy. Oral Surg Oral Med Oral Pathol 62(6):650-3, 1986. e-Pub 1986. PMID: 3491969.
680. Kantarjian HM, Keating MJ, Walters RS, Smith TL, Cork A, McCredie KB, Freireich EJ. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol 4(12):1748-57, 1986. e-Pub 1986. PMID: 3783201.
681. Kantarjian HM, Keating MJ, Walters RS, McCredie KB, Smith TL, Talpaz M, Beran M, Cork A, Trujillo JM, Freireich EJ. Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia. Cancer 58(9):2023-30, 1986. e-Pub 1986. PMID: 3463397.
682. Kantarjian HM, Keating MJ, Walters RS, McCredie KB, Bodey GP, Freireich EJ. Early intensification and short-term maintenance chemotherapy does not prolong survival in acute myelogenous leukemia. Cancer 58(8):1603-8, 1986. e-Pub 1986. PMID: 3463390.
683. Talpaz M, McCredie K, Kantarjian H, Trujillo J, Keating M, Gutterman J. Chronic myelogenous leukaemia: haematological remissions with alpha interferon. Br J Haematol 64(1):87-95, 1986. e-Pub 1986. PMID: 3463363.
684. Kantarjian HM, Estey EH, Plunkett W, Keating MJ, Walters RS, Iacoboni S, McCredie KB, Freireich EJ. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am J Med 81(3):387-94, 1986. e-Pub 1986. PMID: 3463209.
685. Vellekoop L, Jagannath S, Spitzer G, Zander AR, Horwitz LJ, Keating M, McCredie KB, Dicke KA. High-dose cyclophosphamide, BCNU, and etoposide followed by autologous bone marrow rescue as treatment for adult acute leukemia in relapse. Am J Clin Oncol 9(4):307-10, 1986. e-Pub 1986. PMID: 3529919.
686. Kantarjian HM, Keating MJ, Walters RS, Beran M, McLaughlin P, McCredie KB, Freireich EJ. The association of specific "favorable" cytogenetic abnormalities with secondary leukemia. Cancer 58(4):924-7, 1986. e-Pub 1986. PMID: 3719557.
687. Quesada JR, Hersh EM, Manning J, Reuben J, Keating M, Schnipper E, Itri L, Gutterman JU. Treatment of hairy cell leukemia with recombinant alpha-interferon. Blood 68(2):493-7, 1986. e-Pub 1986. PMID: 3730612.
688. Iacoboni SJ, Plunkett W, Kantarjian HM, Estey E, Keating MJ, McCredie KB, Freireich EJ. High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis. J Clin Oncol 4(7):1079-88, 1986. e-Pub 1986. PMID: 3459811.
689. Dreizen S, McCredie KB, Bodey GP, Keating MJ. Microbial mucocutaneous infections in acute adult leukemia. Results of an 18-year inpatient study. Postgrad Med 79(8):107-18, 1986. e-Pub 1986. PMID: 3012497.
690. Ho DH, Brown NS, Yen A, Holmes R, Keating M, Abuchowski A, Newman RA, Krakoff IH. Clinical pharmacology of polyethylene glycol-L-asparaginase. Drug Metab Dispos 14(3):349-52, 1986. e-Pub 1986. PMID: 2872037.
691. Kantarjian HM, Keating MJ, Walters RS, Estey EH, McCredie KB, Smith TL, Dalton WT, Cork A, Trujillo JM, Freireich EJ. Acute promyelocytic leukemia. M.D. Anderson Hospital experience. Am J Med 80(5):789-97, 1986. e-Pub 1986. PMID: 3458366.
692. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 314(17):1065-9, 1986. e-Pub 1986. PMID: 3457264.
693. Dreizen S, McCredie KB, Bodey GP, Keating MJ. Unusual mucocutaneous infections in immunosuppressed patients with leukemia--expansion of an earlier study. Postgrad Med 79(4):287-94, 1986. e-Pub 1986. PMID: 3513146.
694. Plunkett W, Keating M. Effect of m-AMSA on the cellular pharmacology of ara-CTP in human leukemic cells during therapy with high-dose ara-C. Adv Exp Med Biol 195 Pt B:171-5, 1986. e-Pub 1986. PMID: 3766228.
695. Danhauser L, Plunkett W, Keating M, Cabanillas F. 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. Cancer Chemother Pharmacol 18(2):145-52, 1986. e-Pub 1986. PMID: 2431803.
696. Maddox AM, Keating MJ, Smith TL, Speer J, Cork MA, Trujillo JM, McCredie KB, Freireich EJ. Prognostic factors for survival of 194 patients with low infiltrate leukemia. Leuk Res 10(8):995-1006, 1986. e-Pub 1986. PMID: 3747589.
697. Plunkett W, Iacoboni S, Keating MJ. Cellular pharmacology and optimal therapeutic concentrations of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in leukemic blasts during treatment of refractory leukemia with high-dose 1-beta-D-arabinofuranosylcytosine. Scand J Haematol Suppl 44:51-9, 1986. e-Pub 1986. PMID: 3457439.
698. Kantarjian HM, Smith TL, McCredie KB, Keating MJ, Walters RS, Talpaz M, Hester JP, Bligham G, Gehan E, Freireich EJ. Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. Blood 66(6):1326-35, 1985. e-Pub 1985. PMID: 3864497.
699. Andersson BS, Cogan BM, Keating MJ, Estey EH, McCredie KB, Freireich EJ. Subacute pulmonary failure complicating therapy with high-dose Ara-C in acute leukemia. Cancer 56(9):2181-4, 1985. e-Pub 1985. PMID: 4052964.
700. Zander AR, Dicke KA, Keating M, Vellekoop L, Culbert S, Spitzer G, Kanojia M, Jagannath S, Schell S, Hester J. Allogeneic bone marrow transplantation for acute leukemia refractory to induction chemotherapy. Cancer 56(6):1374-9, 1985. e-Pub 1985. PMID: 3896457.
701. Stewart DJ, Smith TL, Keating MJ, Maor M, Leavens M, Hurtubise M, McCredie KB, Bodey GP, Freireich EJ. Remission from central nervous system involvement in adults with acute leukemia. Effect of intensive therapy and prognostic factors. Cancer 56(3):632-41, 1985. e-Pub 1985. PMID: 3891072.
702. Kantarjian HM, Barlogie B, Keating MJ, Hall RR, Smith TL, McCredie KB, Freireich EJ. Pretreatment of cytokinetics in acute myelogenous leukemia. Age-related prognostic implications. J Clin Invest 76(1):319-24, 1985. e-Pub 1985. PMID: 3860508.
703. Kantarjian HM, Barlogie B, Pershouse M, Swartzendruber D, Keating MJ, McCredie KB, Freireich EJ. Preferential expression of double-stranded ribonucleic acid in tumor versus normal cells: biological and clinical implications. Blood 66(1):39-46, 1985. e-Pub 1985. PMID: 4005432.
704. Holmes RI, Keating MJ, Cork A, Trujillo JM, McCredie KB, Freireich EJ. Loss of the Y chromosome in acute myelogenous leukemia: a report of 13 patients. Cancer Genet Cytogenet 17(3):269-78, 1985. e-Pub 1985. PMID: 3859363.
705. Plunkett W, Iacoboni S, Estey E, Danhauser L, Liliemark JO, Keating MJ. Pharmacologically directed ara-C therapy for refractory leukemia. Semin Oncol 12(2 Suppl 3):20-30, 1985. e-Pub 1985. PMID: 4012338.
706. Kantarjian HM, Keating MJ, McCredie KB, Beran M, Walters R, Dalton WT, Hittleman W, Freireich EJ. A characteristic pattern of leukemic cell differentiation without cytoreduction during remission induction in acute promyelocytic leukemia. J Clin Oncol 3(6):793-8, 1985. e-Pub 1985. PMID: 3859586.
707. Maddox AM, Johnston DA, Barlogie B, Youness E, Keating M, Freireich EJ. DNA-RNA measurements in patients with acute leukemia undergoing remission induction therapy. J Clin Oncol 3(6):799-808, 1985. e-Pub 1985. PMID: 4009216.
708. Keating MJ, Estey E, Plunkett W, Iacoboni S, Walters R, Kantarjian H, Andersson B, Beran M, McCredie KB, Freireich EJ. Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital. Semin Oncol 12(2 Suppl 3):98-104, 1985. e-Pub 1985. PMID: 3859935.
709. Dreizen S, Bodey GP, McCredie KB, Keating MJ. Orofacial aspergillosis in acute leukemia. Oral Surg Oral Med Oral Pathol 59(5):499-504, 1985. e-Pub 1985. PMID: 3859809.
710. Holmes R, Keating MJ, Cork A, Broach Y, Trujillo J, Dalton WT, McCredie KB, Freireich EJ. A unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16)(p13q22). Blood 65(5):1071-8, 1985. e-Pub 1985. PMID: 3857943.
711. Bodey GP, Keating MJ, McCredie KB, Elting L, Rosenbaum B, Freireich EJ. Prospective randomized trial of antibiotic prophylaxis in acute leukemia. Am J Med 78(3):407-16, 1985. e-Pub 1985. PMID: 3919579.
712. Kantarjian HM, Vellekoop L, McCredie KB, Keating MJ, Hester J, Smith T, Barlogie B, Trujillo J, Freireich EJ. Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia. J Clin Oncol 3(2):192-200, 1985. e-Pub 1985. PMID: 3855444.
713. McCredie KB, Kantarjian H, Keating MJ, Hester JP, Freireich EJ. New approaches to the treatment of chronic myelogenous leukemia. Haematol Blood Transfus 29:51-2, 1985. e-Pub 1985. PMID: 3896975.
714. Maddox AM, Keating MJ, McCredie KE, Estey E, Freireich EJ. Phase I evaluation of intravenous difluoromethylornithine--a polyamine inhibitor. Invest New Drugs 3(3):287-92, 1985. e-Pub 1985. PMID: 3934106.
715. Blick M, Westin E, Gutterman J, Wong-Staal F, Gallo R, McCredie K, Keating M, Murphy E. Oncogene expression in human leukemia. Blood 64(6):1234-9, 1984. e-Pub 1984. PMID: 6208953.
716. Hittelman WN, Menegaz SD, McCredie KB, Keating MJ. Premature chromosome condensation studies in human leukemia: 5. Prediction of early relapse. Blood 64(5):1067-73, 1984. e-Pub 1984. PMID: 6386072.
717. Legha SS, Keating M, Picket S, Ajani JA, Ewer M, Bodey GP. Phase I clinical investigation of homoharringtonine. Cancer Treat Rep 68(9):1085-91, 1984. e-Pub 1984. PMID: 6478448.
718. Jadeja L, Bolivar R, Fainstein V, Keating M, McCredie K, Hay M, Bodey GP. Piperacillin plus vancomycin in the therapy of febrile episodes in cancer patients. Antimicrob Agents Chemother 26(3):295-9, 1984. e-Pub 1984. PMID: 6508260.
719. Fainstein V, Bodey GP, Bolivar R, Elting L, McCredie KB, Keating MJ. Moxalactam plus ticarcillin or tobramycin for treatment of febrile episodes in neutropenic cancer patients. Arch Intern Med 144(9):1766-70, 1984. e-Pub 1984. PMID: 6383246.
720. Estey E, Maksymiuk A, Smith T, Fainstein V, Keating M, McCredie KB, Freireich EJ, Bodey GP. Infection prophylaxis in acute leukemia. Comparative effectiveness of sulfamethoxazole and trimethoprim, ketoconazole, and a combination of the two. Arch Intern Med 144(8):1562-8, 1984. e-Pub 1984. PMID: 6087753.
721. Vellekoop L, Dicke KA, Zander AR, Spitzer G, Verma DS, Keating MJ, McCredie KB. Repeated high-dose cyclophosphamide, BCNU and VP-16-213 and autologous bone marrow transplantation in adult acute lymphocytic leukemia in first remission. Eur J Cancer Clin Oncol 20(5):593-9, 1984. e-Pub 1984. PMID: 6376130.
722. Dreizen S, McCredie KB, Keating MJ. Chemotherapy-associated oral hemorrhages in adults with acute leukemia. Oral Surg Oral Med Oral Pathol 57(5):494-8, 1984. e-Pub 1984. PMID: 6610154.
723. Barlogie B, Johnston DA, Keating M, Spitzer G, Hittelman WN, Nishioki K, Freireich EJ. Evolution of oligoleukemia. Cancer 53(10):2115-24, 1984. e-Pub 1984. PMID: 6704901.
724. Maddox AM, Johnston DA, Barlogie B, Haq M, Keating MJ, Freireich EJ. In vitro suppression of DNA synthesis by a remission induction agent and its correlation with response in adult acute leukemia. Eur J Cancer Clin Oncol 20(4):507-14, 1984. e-Pub 1984. PMID: 6586421.
725. Valdivieso M, Cabanillas F, Keating M, Barkley HT, Murphy WK, Burgess MA, Frazier H, Chen T, Bodey GP. Effects of intensive induction chemotherapy for extensive-disease small cell bronchogenic carcinoma in protected environment-prophylactic antibiotic units. Am J Med 76(3):405-12, 1984. e-Pub 1984. PMID: 6322584.
726. Davis FM, Hittelman WN, McCredie KB, Keating MJ, Vellekoop L, Rao PN. Human malignancy-associated nucleolar antigen as a marker for tumor cells in patients with acute leukemia. Blood 63(3):676-83, 1984. e-Pub 1984. PMID: 6365205.
727. Stewart DJ, Smith TL, Keating MJ, McCredie KB, Hersh EM, Quesada J, Freireich EJ. Prognostic factors in hairy cell leukemia (leukemic reticuloendotheliosis). Cancer 53(5):1198-1201, 1984. e-Pub 1984. PMID: 6692307.
728. Estey EH, Keating MJ, Smith TL, McCredie KB, Legha SS, Walters RS, Bodey GP, Freireich EJ. Prediction of complete remission in patients with refractory acute leukemia treated with AMSA. J Clin Oncol 2(2):102-6, 1984. e-Pub 1984. PMID: 6583328.
729. Lawson RD, Gentry LO, Bodey GP, Keating MJ, Smith TL. A randomized study of tobramycin plus ticarcillin, tobramycin plus cephalothin and ticarcillin, or tobramycin plus mezlocillin in the treatment of infection in neutropenic patients with malignancies. Am J Med Sci 287(1):16-23, 1984. e-Pub 1984. PMID: 6367466.
730. Stewart DJ, Zhengang G, Lu K, Savaraj N, Feun LG, Luna M, Benjamin RS, Keating MJ, Loo TL. Human tissue distribution of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (NSC 141549, AMSA). Cancer Chemother Pharmacol 12(2):116-9, 1984. e-Pub 1984. PMID: 6583026.
731. Plunkett W, Nowak B, Feun LG, Benjamin RS, Keating M, Freirich EJ. Modulation of arabinosyladenine metabolism by 2'-deoxycoformycin in the therapy of human acute leukemia. Adv Exp Med Biol 165 Pt B:345-50, 1984. e-Pub 1984. PMID: 6372382.
732. Talpaz M, Mavligit G, Keating M, Walters RS, Gutterman JU. Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia. Ann Intern Med 99(6):789-92, 1983. e-Pub 1983. PMID: 6580836.
733. Fainstein V, Bodey GP, McCredie KB, Keating MJ, Estey EH, Bolivar R, Elting L. Coagulation abnormalities induced by beta-lactam antibiotics in cancer patients. J Infect Dis 148(4):745-50, 1983. e-Pub 1983. PMID: 6631064.
734. Hug V, Keating M, McCredie K, Hester J, Bodey GP, Freireich EJ. Clinical course and response to treatment of patients with acute myelogenous leukemia presenting with a high leukocyte count. Cancer 52(5):773-9, 1983. e-Pub 1983. PMID: 6575857.
735. Fainstein V, Bodey GP, Elting L, Bolivar R, Keating MJ, McCredie KB, Valdivieso M. A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients. J Antimicrob Chemother 12 Suppl A:101-10, 1983. e-Pub 1983. PMID: 6352612.
736. Dreizen S, McCredie KB, Keating MJ, Luna MA. Malignant gingival and skin "infiltrates" in adult leukemia. Oral Surg Oral Med Oral Pathol 55(6):572-9, 1983. e-Pub 1983. PMID: 6576290.
737. Estey EH, Keating MJ, McCredie KB, Bodey GP, Freireich EJ. Phase II trial of mitoxantrone in refractory acute leukemia. Cancer Treat Rep 67(4):389-90, 1983. e-Pub 1983. PMID: 6850655.
738. Maddox AM, Keating MJ, Trujillo J, Cork A, Youness E, Ahearn MJ, McCredie KB, Freireich EJ. Philadelphia chromosome-positive adult acute leukemia with monosomy of chromosome number seven: a subgroup with poor response to therapy. Leuk Res 7(4):509-22, 1983. e-Pub 1983. PMID: 6578392.
739. Zander AR, Vellekoop L, Dicke KA, Keating MJ, McCredie KB, Legha SS, Spitzer G, Verma D, Bodey GP. High-dose AMSA and autologous bone marrow transplantation in relapsed acute leukemia. Cancer Treat Rep 66(11):1991-2, 1982. e-Pub 1982. PMID: 6754077.
740. Keating MJ, McCredie KB, Bodey GP, Smith TL, Gehan E, Freireich EJ. Improved prospects for long-term survival in adults with acute myelogenous leukemia. JAMA 248(19):2481-6, 1982. e-Pub 1982. PMID: 6957624.
741. Legha SS, Keating MJ, McCredie KB, Bodey GP, Freireich EJ. Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults. Blood 60(2):484-90, 1982. e-Pub 1982. PMID: 6953987.
742. Estey EH, Keating MJ, McCredie KB, Bodey GP, Freireich EJ. Causes of initial remission induction failure in acute myelogenous leukemia. Blood 60(2):309-15, 1982. e-Pub 1982. PMID: 6953982.
743. Smith TL, Gehan EA, Keating MJ, Freireich EJ. Prediction of remission in adult acute leukemia: development and testing of predictive models. Cancer 50(3):466-72, 1982. e-Pub 1982. PMID: 7093888.
744. Keating MJ, Smith TL, Gehan EA, McCredie KB, Bodey GP, Freireich EJ. A prognostic factor analysis for use in development of predictive models for response in adult acute leukemia. Cancer 50(3):457-65, 1982. e-Pub 1982. PMID: 7093887.
745. Januszewicz E, Firkin FC, Chesterman CN, Garson OM, Beswick W, Keating MJ, Penington DG. Retrospective analysis of 158 cases of adult acute leukaemia: factors influencing prognosis and treatment response. Aust N Z J Med 12(3):238-45, 1982. e-Pub 1982. PMID: 6956290.
746. Dreizen S, McCredie KB, Keating MJ, Bodey GP. Oral infections associated with chemotherapy in adults with acute leukemia. Postgrad Med 71(6):133-8, 143-6, 1982. e-Pub 1982. PMID: 6952176.
747. Bodey GP, Grose WE, Keating MJ. Use of trimethoprim-sulfamethoxazole for treatment of infections in patients with cancer. Rev Infect Dis 4(2):579-85, 1982. e-Pub 1982. PMID: 6981174.
748. Hersh EM, Quesada J, Keating MJ, Rasmussen S, Murphy SG, Gschwind C, Morgan J. Host defence factors and prognosis in hairy cell leukemia. Leuk Res 6(5):625-37, 1982. e-Pub 1982. PMID: 7154705.
749. Keating MJ, McCredie KB, Benjamin RS, Bodey GP, Zander A, Smith TL, Freireich EJ. Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidazone and cytosine arabinoside, vincristine, and prednisone (ROAP). Blood 58(3):584-91, 1981. e-Pub 1981. PMID: 6942848.
750. Keating MJ, Smith TL, McCredie KB, Bodey GP, Hersh EM, Gutterman JU, Gehan E, Freireich EJ. A four-year experience with anthracycline, cytosine arabinoside, vincristine and prednisone combination chemotherapy in 325 adults with acute leukemia. Cancer 47(12):2779-88, 1981. e-Pub 1981. PMID: 6942906.
751. Keating MJ, Lawson R, Grose W, Bodey GP. Combination therapy with ticarcillin and sulfamethoxazole-trimethoprim for infections in patients with cancer. Arch Intern Med 141(7):926-30, 1981. e-Pub 1981. PMID: 7235813.
752. Zander AR, Vellekoop L, Spitzer G, Verma DS, Litam J, McCredie KB, Keating M, Hester JP, Dicke KA. Combination of high-dose cyclophosphamide, BCNU, and VP-16-213 followed by autologous marrow rescue in the treatment of relapsed leukemia. Cancer Treat Rep 65(5-6):377-81, 1981. e-Pub 1981. PMID: 7016323.
753. Rosenblum MG, Keating MJ, Yap BS, Loo TL. Pharmacokinetics of [14C]methylglyoxal-bis-guanylhydrazone) in patients with leukemia. Cancer Res 41(5):1748-50, 1981. e-Pub 1981. PMID: 7214342.
754. Yap BS, McCredie KB, Keating MJ, Bodey GP, Freireich EJ. Phase I--II study of 3-deazauridine in adults with acute leukemia. Cancer Treat Rep 65(5-6):521-4, 1981. e-Pub 1981. PMID: 7237473.
755. Barlogie B, Plunkett W, Raber M, Latreille J, Keating M, McCredie K. In vivo cellular kinetic and pharmacological studies of 1-beta-D-arabinofuranosylcytosine and 3-deazauridine chemotherapy for relapsing acute leukemia. Cancer Res 41(3):1227-35, 1981. e-Pub 1981. PMID: 7459863.
756. McCredie KB, Bodey GP, Freireich EJ, Hester JP, Rodriguez V, Keating MJ. Chemoimmunotherapy of adult acute leukemia. Cancer 47(6):1256-61, 1981. e-Pub 1981. PMID: 6939477.
757. Dreizen S, McCredie KB, Keating MJ. Chemotherapy-induced oral mucositis in adult leukemia. Postgrad Med 69(2):103-8, 111-2, 1981. e-Pub 1981. PMID: 7454641.
758. Granatek CH, Ezaki K, Hersh EM, Keating MJ, Rasmussen S. Antibody responses of remission leukemia patients receiving active specific and nonspecific immunotherapy. Cancer 47(2):272-9, 1981. e-Pub 1981. PMID: 7006793.
759. Stewart DJ, Keating MJ, McCredie KB, Smith TL, Youness E, Murphy SG, Bodey GP, Freireich EJ. Natural history of central nervous system acute leukemia in adults. Cancer 47(1):184-96, 1981. e-Pub 1981. PMID: 7459807.
760. Quesada JR, Hersh EM, Keating M, Zander A, Hester J. Hairy cell leukemia: clinical effects of the methanol extraction residue (MER) of BCG, lithium carbonate and mononuclear cell-enriched leukocyte transfusions. Leuk Res 5(6):463-76, 1981. e-Pub 1981. PMID: 6799699.
761. McCredie KB, Keating MJ, Bodey GP, Gehan EA, Smith T, Freireich EJ. Prognostic factors in response to anthracyclines. Cancer Treat Rep 65 Suppl 4:83-6, 1981. e-Pub 1981. PMID: 6955014.
762. Yap BS, McCredie KB, Keating MJ, Bodey GP, Freireich EJ. Asparaginase and methotrexate combination chemotherapy in relapsed acute lymphoblastic leukemia in adults. Cancer Treat Rep 65 Suppl 1:83-7, 1981. e-Pub 1981. PMID: 6948610.
763. Mavlight GM, Stuckey SE, Cabanillas FF, Keating MJ, Tourtellotte WW, Schold SC, Freireich EJ. Diagnosis of leukemia or lymphoma in the central nervous system by beta 2-microglobulin determination. N Engl J Med 303(13):718-22, 1980. e-Pub 1980. PMID: 6157089.
764. Legha SS, Keating MJ, Zander AR, McCredie KB, Bodey GP, Freireich EJ. 4'-(9-Acridinylamino) methanesulfon-m-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemia. Ann Intern Med 93(1):17-21, 1980. e-Pub 1980. PMID: 6930826.
765. Dreizen S, McCredie KB, Bodey GP, Keating MJ, Patt YZ. Superficial head and neck metastases in adults with widespread cancer. Postgrad Med 67(5):171-6, 179-80, 183-4 passim, 1980. e-Pub 1980. PMID: 7375404.
766. Keating MJ, Smith TL, Gehan EA, McCredie KB, Bodey GP, Spitzer G, Hersh E, Gutterman J, Freireich EJ. Factors related to length of complete remission in adult acute leukemia. Cancer 45(8):2017-29, 1980. e-Pub 1980. PMID: 6989483.
767. Dosik GM, Barlogie B, Smith TL, Gehan EA, Keating MJ, McCredie KB, Freireich EJ. Pretreatment flow cytometry of DNA content in adult acute leukemia. Blood 55(3):474-82, 1980. e-Pub 1980. PMID: 6928378.
768. Plunkett W, Hug V, Keating MJ, Chubb S. Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res 40(3):588-91, 1980. e-Pub 1980. PMID: 6937239.
769. Yap HY, Blumenschein GR, Keating MJ, Hortobagyi GN, Tashima CK, Loo TL. Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer. Cancer Treat Rep 64(2-3):279-83, 1980. e-Pub 1980. PMID: 7407762.
770. Gehan EA, Smith TL, Buzdar AU, Keating MJ, Freireich EJ. Knowledge acquisition from historical data: application to breast cancer patients. Bull Cancer 67(4):437-45, 1980. e-Pub 1980. PMID: 7013864.
771. Bodey GP, McCredie KB, Keating MJ, Freireich EJ. Treatment of acute leukemia in protected environment units. Cancer 44(2):431-6, 1979. e-Pub 1979. PMID: 113075.
772. Benjamin RS, Keating MJ, Valdivieso M, McCredie KB, Livingston RA, Burgess MA, Rodriguez V, Bodey GP, Gottlieb JA. Phase I-II study of piperazinedione in adults with solid tumors and acute leukemia. Cancer Treat Rep 63(6):939-43, 1979. e-Pub 1979. PMID: 380802.
773. Benjamin RS, Keating MJ, Swenerton KD, Legha S, McCredie KB. Clinical studies with rubidazone. Cancer Treat Rep 63(5):925-9, 1979. e-Pub 1979. PMID: 287557.
774. Issell BF, Keating MJ, Valdivieso M, Bodey GP. Continuous infusion tobramycin combined with carbenicillin for infections in cancer patients. Am J Med Sci 277(3):311-8, 1979. e-Pub 1979. PMID: 256433.
775. Keating MJ, Bodey GP, Valdivieso M, Rodriguez V. A randomized comparative trial of three aminoglycosides--comparison of continuous infusions of gentamicin, amikacin and sisomicin combined with carbenicillin in the treatment of infections in neutropenic patients with malignancies. Medicine (Baltimore) 58(2):159-70, 1979. e-Pub 1979. PMID: 431401.
776. McCredie KB, Keating MJ, Dicke KA, Bodey GP, Smith T, Freireich EJ. Treatment of adult acute myeloblastic leukemia. Haematol Blood Transfus 23:89-92, 1979. e-Pub 1979. PMID: 296117.
777. Freireich EJ, Keating MJ, Gehan EA, McCredie KB, Bodey GP, Smith T. Therapy of acute myelogeneous leukemia. Cancer 42(2 Suppl):874-82, 1978. e-Pub 1978. PMID: 278638.
778. Rodriguez V, Bodey GP, Freireich EJ, McCredie KB, Gutterman JU, Keating MJ, Smith TL, Gehan EA. Randomized trial of protected environment--prophylactic antibiotics in 145 adults with acute leukemia. Medicine (Baltimore) 57(3):253-66, 1978. e-Pub 1978. PMID: 642793.
779. Rodriguez V, McCredie KB, Keating MJ, Valdivieso M, Bodey GP, Freireich EJ. Isophosphamide therapy for hematologic malignancies in patients refractory to prior treatment. Cancer Treat Rep 62(4):493-7, 1978. e-Pub 1978. PMID: 350386.
780. Ezaki K, Hersh EM, Keating M, Dyre S, Hollinshead A, McCredie KB, Mavlight GM, Gutterman JU. Active specific immunization with allogeneic leukemia associated antigens or irradiated allogeneic leukemia cells in acute leukemia. Cancer 41(1):70-83, 1978. e-Pub 1978. PMID: 75055.
781. Benjamin RS, Keating MJ, McCredie KB, Bodey GP, Freireich EJ. A phase 1 and 2 trial of rubidazone in patients with acute leukemia. Cancer Res 37(12):4623-8, 1977. e-Pub 1977. PMID: 270389.
782. Bodey GP, Rodriguez V, Valdivieso M, Keating M. Gram-negative bacillary infections in cancer patients. S Afr Med J 52(26):1049-55, 1977. e-Pub 1977. PMID: 609979.
783. Keating MJ, Rodriguez V, Bodey GP. Protected environments and microbial suppression in cancer therapy. Am J Clin Nutr 30(11):1904-10, 1977. e-Pub 1977. PMID: 920650.
784. Keating MJ, Sethi MR, Bodey GP, Samaan NA. Hypocalcemia with hypoparathyroidism and renal tubular dysfunction associated with aminoglycoside therapy. Cancer 39(4):1410-4, 1977. e-Pub 1977. PMID: 856439.
785. Keating MJ, Freireich EJ, McCredie KB, Bodey GP, Hersh E, Hester JP, Rodriguez V, Hart J. Acute leukemia in adults, 1977. CA Cancer J Clin 27(1):2-25, 1977. e-Pub 1977. PMID: 401669.
786. Penington DG, Keating MJ. Prognosis of acute leukaemia in adults. Med J Aust 1(26):1031-5, 1974. e-Pub 1974. PMID: 4527947.
787. Keating MJ, Penington DG. Prophylaxis against septicaemia in acute leukaemia: the use of oral framycetin. Med J Aust 2(5):213-7, 1973. e-Pub 1973. PMID: 4200661.

Invited Articles

1. Ma D, Chen Z, Patel KP, Mishra BM, Yao H, Abruzzo LV, Medeiros LJ, Wierda W, Keating M, Sargent R, Luthra R. Array comparative genomic hybridization analysis identifies recurrent gain of chromosome 2p25.3 involving the ACP1 and MYCN genes in chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 11(Supplement 1):S17-S24, 2011. e-Pub 2011. PMID: 22035742.
2. Tsimberidou AM, Keating MJ. Richter’s transformation in chronic lymphocytic leukemia. Seminars in Oncology 33(2):250-256, 2006. e-Pub 2006.
3. Ferrajoli A, Faderl S, Keating MJ. Monoclonal antibodies in chronic lymphocytic leukemia. Expert Review of Anticancer Therapy 6(8):1231-1238, 2006. e-Pub 2006.
4. Tam CS, Ferrajoli A, Keating MJ. Practical considerations for frontline therapy of chronic lymphocytic leukemia. CLL: The Cutting Edge 11:3-6, 2006. e-Pub 2006.
5. Tsimberidou AM, Khouri I, Keating MJ. Richter’s syndrome: A report on response, survival, failure-free survival, and prognostic factors. The American Journal of Hematology/Oncology 5(11):662-665, 2006. e-Pub 2006.
6. Kipps TJ, Dohner H, Croce CM, Keating MJ. Advances in the biology and management of chronic lymphocytic leukemia. The American Society of Clinical Oncology 42nd Annual Meeting Educational Book:398-408, 2006. e-Pub 2006.
7. Keating MJ, Rai KR, Wierda WG. Evolution of treatment strategies in chronic lymphocytic leukemia. Part 2 of a 3-part series: Advances in the treatment of hematologic malignancies. Clin Adv Hematol Oncol 3(8):1-10; quiz 11-12, 2005. e-Pub 2005. PMID: 16201050.
8. Tsimberidou AM, Keating MJ. Richter syndrome: biology, incidence, and therapeutic strategies. Cancer 103(2):216-228, 2005. e-Pub 2005. PMID: 15578683.
9. Tsimberidou AM, Keating MJ. Richter's syndrome. Cancer 103(2):216-228, 2005. e-Pub 2005.
10. Keating M. Mayo clinic office visit. Germs and you. An interview with Michael Keating, M.D. Mayo Clinic Womens Healthsource 9(9):7-8, 2005. e-Pub 2005.
11. Wang J, Coombes KR, Highsmith WE, Keating MJ, Abruzzo LV. Differences in gene expression between B-cell chronic lymphocytic leukemia and normal B cells: a meta-analysis of three microarray studies. Bioinformatics 20(17):3166-3178, 2004. e-Pub 2004. PMID: 15231529.
12. Ferrajoli A, Keating MJ. Current guidelines in defining therapeutic strategies. Hematol Oncol Clin North Am 18(4):881-893, ix, 2004. e-Pub 2004. PMID: 15325704.
13. Wierda WG, Keating MJ, O'Brien S. Refractory chronic lymphocytic leukemia - prognosis and treatment options. American Journal of Cancer 3(3):163-178, 2004. e-Pub 2004.
14. Keating MJ. New therapeutic strategies in chronic lymphocytic leukemia (CLL). Leukemia Insights 8(1):1-2, 2003. e-Pub 2003.
15. Keating MJ. Therapeutic role of Alemtuzumab (CamPathÒ) in fludarabine-refractory patients with chronic lymphocytic leukemia. The American Journal of Oncology Review 2(6):328-336, 2003. e-Pub 2003.
16. Keating MJ. Management of chronic lymphocytic leukemia: A changing field. Rev Clin Exp Hematol 6(4):350-365, 2002. e-Pub 2002. PMID: 12823777.
17. Osterborg A, Mellstedt H, Keating M. Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia. Medical Oncology 19:S21-S26, 2002. e-Pub 2002. PMID: 12180488.
18. Keating MJ, Hallek M. Guest editorial. Medical Oncology 19:S1-S2, 2002. e-Pub 2002.
19. Keating MJ. Campath-1H (alemtuzumab). A major new drug in chronic lymphocytic leukemia. Haematologica 86(1):40-42, 2001. e-Pub 2001.
20. Keating MJ. Long-term results of initial treatment with fludarabine for chronic lymphocytic leukemia. CLL: The Cutting Edge 5:5-7, 2000. e-Pub 2000.
21. Keating MJ, O’Brien S. Conventional management of chronic lymphocytic leukemia. Reviews in Clinical and Experimental Hematology 4(2):118-133, 2000. e-Pub 2000.
22. Keating MJ. Chronic lymphocytic leukemia. Semin Oncol 26(5 Suppl 14):107-114, 1999. e-Pub 1999. PMID: 10561025.
23. Keating MJ. Leukemia: A model for drug development. Clin Cancer Res 3(12 Pt 2):2598-2604, 1997. e-Pub 1997. PMID: 9815664.
24. Kantarjian HM, Talpaz M, O'Brien S, Kurzrock R, Gutterman J, Keating MJ, McCredie KB, Freireich EJ. Chronic myelogenous leukemia - progress at the M. D. Anderson Cancer Center over the past two decades and future directions: first Emil J Freireich Award Lecture. Clin Cancer Res 3(12 Pt 2):2723-2733, 1997. e-Pub 1997. PMID: 10068280.

Manuals, Teaching Aids, Other Teaching Publications

1. Rozovski U, Hazan-Halevy I, Calin G, Harris D, Li P, Liu Z, Keating MJ, Estrov Z. Describing a transcription factor dependent regulation of the MicroRNA transcriptome. Journal of Visualized Experiments (JoVE), 2016.

Other Articles

1. Kantarjian HM, Keating MJ, Freireich EJ Toward the potential cure of leukemias in the next decade. Cancer 124(22):4301-4313, 2018. PMID: 30291792.
2. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O'Brien S, Robak T, Seymour JF, Kipps TJ iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131(25):2745-2760, 2018. PMID: 29540348.
3. Rozovski U, Keating MJ, Estrov Z Why Is the Immunoglobulin Heavy Chain Gene Mutation Status a Prognostic Indicator in Chronic Lymphocytic Leukemia?. Acta Haematol 140(1):51-54, 2018. PMID: 30114695.
4. Sanford DS, Wierda WG, Burger JA, Keating MJ, O'Brien SM Three Newly Approved Drugs for Chronic Lymphocytic Leukemia: Incorporating Ibrutinib, Idelalisib, and Obinutuzumab into Clinical Practice. Clin Lymphoma Myeloma Leuk 15(7):385-91, 2015. PMID: 25817936.
5. Al-Kali A, Gandhi V, Ayoubi M, Keating M, Ravandi F Forodesine: review of preclinical and clinical data. Future Oncol 6(8):1211-1217, 2010. PMID: 20799866.
6. Koehrer S, Keating MJ, Wierda WG Eltrombopag, a second-generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia-associated ITP. Leukemia 24(5):1096-1098, 2010. PMID: 20339441.
7. Thomas DA, Ravandi F, Keating M, Kantarjian HM Importance of minimal residual disease in hairy cell leukemia: monoclonal antibodies as a therapeutic strategy. Leuk Lymphoma 50 Suppl 1:27-31, 2009. PMID: 19814695.
8. Tsimberidou AM, Keating MJ Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer 115(13):2824-2836, 2009. PMID: 19402170.
9. Awais A, Tam CS, Kontoyiannis D, Ferrajoli A, Duvic M, Cortes J, Keating MJ Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia. Clin Infect Dis 46(7):e69-71, 2008. PMID: 18444808.
10. Ault P, Lynn A, Tam CS, Medeiros LJ, Keating MJ Systemic mastocytosis in association with chronic lymphocytic leukemia: a rare diagnosis. Leuk Res 31(12):1755-8, 2007. PMID: 17521719.
11. Tam CS, Keating MJ Chemoimmunotherapy of chronic lymphocytic leukemia. Best Pract Res Clin Haematol 20(3):479-98, 2007. PMID: 17707835.
12. Tsimberidou AM, Kantarjian H, Keating MJ, Estey E Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide?. Leuk Lymphoma 47(11):2282-2288, 2006. PMID: 17107899.
13. Ferrajoli A, Faderl S, Keating MJ Monoclonal antibodies in chronic lymphocytic leukemia. Expert Rev Anticancer Ther 6(9):1231-1238, 2006. PMID: 17020457.
14. O'Brien SM, Keating MJ, Mocarski ES Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma 7(2):125-130, 2006. PMID: 17026823.
15. Tsimberidou AM, Estey E, Kantarjian H, Keating MJ, Pierce S, Garcia-Manero G Granulocyte colony stimulating factor administration associated with cerebral hemorrhage in acute promyelocytic leukemia. Leukemia 20(8):1452-1453, 2006. PMID: 16728980.
16. Tsimberidou AM, Giles FJ, Estey E, O'Brien S, Keating MJ, Kantarjian HM The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br J Haematol 132(4):398-409, 2006. PMID: 16412015.
17. Faderl S, O'Brien S, Keating MJ Monoclonal antibody combinations in CLL: evolving strategies. Best Pract Res Clin Haematol 19(4):781-793, 2006. PMID: 16997183.
18. Wierda WG, Kipps TJ, Keating MJ Novel immune-based treatment strategies for chronic lymphocytic leukemia. J Clin Oncol 23(26):6325-6332, 2005. PMID: 16155015.
19. Faderl S, Gandhi V, Keating MJ, Jeha S, Plunkett W, Kantarjian HM The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog. Cancer 103(10):1985-1995, 2005. PMID: 15803490.
20. Faderl SJ, Keating MJ Treatment of chronic lymphocytic leukemia. Curr Hematol Rep 4(1):31-38, 2005. PMID: 15610657.
21. Sun X, Amin HM, Freireich EJ, Keating MJ, Kantarjian HM, Koller CA, O'Brien SM, Giles F, Albitar M Hairy cell leukemia with large cells: long disease course with adequate response to therapy. Leukemia 18(11):1912-1914, 2004. PMID: 15385931.
22. Jabbour E, Keating MJ, Champlin RE, Khouri IF Stem cell transplantation for chronic lymphocytic leukemia: should not more patients get a transplant?. Bone Marrow Transplant 34(4):289-297, 2004. PMID: 15220957.
23. Lenihan DJ, Alencar AJ, Yang D, Kurzrock R, Keating MJ, Duvic M Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood 104(3):655-658, 2004. PMID: 15073032.
24. D'Arena G, Di Renzo N, Brugiatelli M, Vigliotti ML, Keating MJ Biological and clinical heterogeneity of B-cell chronic lymphocytic leukemia. Leuk Lymphoma 44(2):223-228, 2003. PMID: 12688337.
25. Keating MJ, Chiorazzi N, Messmer B, Damle RN, Allen SL, Rai KR, Ferrarini M, Kipps TJ Biology and treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program:153-75, 2003. PMID: 14633781.
26. Keating MJ, O'Brien S, Albitar M Emerging information on the use of rituximab in chronic lymphocytic leukemia. Semin Oncol 29(1 Suppl 2):70-74, 2002. PMID: 11842391.
27. Lai R, McDonnell TJ, O'Connor SL, Medeiros LJ, Oudat R, Keating M, Morgan MB, Curiel TJ, Ford RJ Establishment and characterization of a new mantle cell lymphoma cell line, Mino. Leukemia Research 26(9):849-855, 2002. PMID: 12127561.
28. Ferrajoli A, O'Brien S, Keating MJ Alemtuzumab: a novel monoclonal antibody. Expert Opin Biol Ther 1(6):1059-1065, 2001. PMID: 11728236.
29. Aboul-Nasr R, O'Brien S, Freireich EJ, Ginsberg CF, Kantarjian HM, Koller CA, Keating MJ, Albitar M "T-cell-rich B-cell lymphoproliferative disorder" of the bone marrow. Leuk Lymphoma 42(5):1023-1031, 2001. PMID: 11697619.
30. Rai KR, Döhner H, Keating MJ, Montserrat E Chronic lymphocytic leukemia: case-based session. Hematology Am Soc Hematol Educ Program:140-156, 2001. PMID: 11722982.
31. Byrd JC, Waselenko JK, Keating M, Rai K, Grever MR Novel therapies for chronic lymphocytic leukemia in the 21st century. Semin Oncol 27(5):587-597, 2000. PMID: 11049025.
32. Tsiodras S, Samonis G, Keating MJ, Kontoyiannis DP Infection and immunity in chronic lymphocytic leukemia. Mayo Clin Proc 75(10):1039-1054, 2000. PMID: 11040852.
33. Keating MJ Chronic lymphocytic leukemia. Clinical oral poster session. Hematol Cell Ther 42(1):35-39, 2000. PMID: 11036949.
34. Saad ED, Thomas DA, O'Brien S, Fuller GN, Medeiros LJ, Forman A, Albitar M, Schomer D, Kantarjian HM, Keating MJ Progressive multifocal leukoencephalopathy with concurrent Richter's syndrome. Leuk Lymphoma 38(1-2):183-190, 2000. PMID: 10811461.
35. D'Arena G, Keating MJ, Carotenuto M Chronic lymphoproliferative disorders: an integrated point of view for the differential diagnosis. Leuk Lymphoma 36(3-4):225-237, 2000. PMID: 10674895.
36. Faber J, Kantarjian H, Roberts MW, Keating M, Freireich E, Albitar M Terminal deoxynucleotidyl transferase-negative acute lymphoblastic leukemia. Arch Pathol Lab Med 124(1):92-97, 2000. PMID: 10629138.
37. O’Brien, SM, Kantarjian H, Cortes J, Beran M, Koller CA, Giles FJ, Lerner S, Keating M Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. Journal of Clinical Oncology, 2000.
38. Seymour, JF, Estey EH, Keating MJ, Kurzrock R Response to interferon-a in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine. Leukemia, 2000.
39. Rodriguez, Jr CO, Plunkett W, Paff MT, Du M, Nowak B, Ramakrishna P, Keating MJ, Gandhi V A high-pressure liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells. Journal of Chromatography, 2000.
40. Giles, F, O’Brien S, Cortes J, Verstovsek S, Bueso-Ramos C, Shan J, Pierce S, Garcia-Manero G, Keating M, Kantarjian H Outcome of patients with acute myelogenous leukemia following second salvage therapy. Cancer, 2000.
41. Kantarjian, HM, Estey E, O'Brien S, Anaissie E, Beran M, Pierce S, Robertson L, Keating MJ Granulocyte colony-stimulating factor supportive care following intensive chemotherapy consolidation in acute lymphocytic leukemia in first remission. Cancer, 2000.
42. Lin, CW, O’Brien S, Faber J, Manshouri T, Romaguera J, Huh YO, Kantarjian H, Keating M, Albitar M De novo CD5-positive Burkitt’s lymphoma/leukemia. American Journal of Clinical Pathology, 2000.
43. Montillo, M, Alessandra T, O’Brien S, DiRaimondo F, Lerner S, Morra E, Keating MJ Clinical features, management and outcome of cytopenic episodes of immune and non-immune origin observed in previously untreated chronic lymphocytic leukemia receiving fludarabine. Blood, 2000.
44. O’Brien, S, Kantarjian H, Koller C, Andreeff M, Feldman E, Keating M, Beran M, Freireich E, Rios MB, Talpaz B Sequential Homoharringtonine and Alpha Interferon in CML. Blood, 2000.
45. Suki, S, Kantarjian H, Estey E, O'Brien S, Beran M, Rios MB, Plunkett W, Keating MJ Fludarabine and high-dose cytosine arabinoside in the treatment of refractory acute lymphocytic leukemia. Cancer, 2000.
46. Pahler, JC, Nutt LK, Thomas DA, Calvert LR, Krupnik Y, Andreeff M, Keating M, McConkey DJ Arsenic trioxide induces cell death in CLL cells by increasing mitochondrial calcium and modulating bcl-2 family members. Blood, 2000.
47. Rodriguez, CO, Legha JK, Estey E, Keating MJ, Gandhi V Pharmacological and Biochemical Strategies to Increase the Accumulation of Arabinofuranosylguanine Triphosphate in Primary Human Leukemia Cells. . Clinical Cancer Research, 2000.
48. Rashad, A, O’Brien S, Freireich E, Ginsberg C, Kantarjian H, Koller C, Keating M, Albitar M T-Cell Rich B-Cell Chronic Lympoproliferative Disorder of the bone marrow. American Journal of Clinical Pathology, 2000.
49. Aguayo, A, Kantarjian HM, Estey E, Giles FJ, Verstovsek S, Manshouri T, Gidel C, O’Brien S, Keating MJ, Albitar A Plasma vascular endothelial growth factor levels are prognostically significant in acute myeloid leukemia but not in myelodysplastic syndromes; plasma basic fibroblast growth factor levels are not related to prognosis in either. . Journal of Clinical Oncology, 2000.
50. Buffler, PA, Downs TD, Christensen BL, Burau KD, Garza-Ibarra A, Rosenthal J, Keating MJ Leukemias and myelodysplasia in adult males residing in the upper Texas Gulf Coast, 1982-1986: The incidence study. Annals of Epidemiology, 2000.
51. Chandra, J, Gilbreath J, Freireich EJ, Keating M, McConkey DJ Activation of the Ca2+ - dependent lamin protease is required for chemotherapy-induced apoptosis in chronic lymphocytic leukemia lymphocytes. Journal of Experimental Medicine, 2000.
52. Dabaja, BS, Faderl S, Thomas D, Cortes J, O’Brien S, Nasr F, Pierce S, Keating M, Kantarjian HM Deletions and losses in chromosomes 5 or 7 in adult acute lymphocytic leukemia: incidence, associations and implications. Leukemia, 2000.
53. Faber, J, Kantarjian H, Roberts M, Keating M, Freireich E, Albitar M Terminal Deoxynucleotidyl Transferase-Negative Acute Lymphoblastic Leukemia. American Journal of Clinical Pathology, 2000.
54. Gandhi, V, Keating MJ, Estey E, Plunkett W Modulation of ara-C metabolism by fludarabine: Therapy of AML, 2000.
55. Gandhi, V, Estey E, Keating MJ, Plunkett W Combination of fludarabine and arabinosylcytosine for therapy of acute myelogenous leukemia: Potentiation of ara-CTP metabolism, 2000.
56. Cortes JE, Kantarjian HM, O'Brien S, Giles F, Keating MJ, Freireich EJ, Estey EH A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission. Cancer 85(7):1506-1513, 1999. PMID: 10193940.
57. Aguayo A, Cortes JE, Kantarjian HM, Beran M, Gandhi V, Plunkett W, Kurtzberg J, Keating MJ Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature. Cancer 85(1):58-64, 1999. PMID: 9921974.
58. Lin CW, O'Brien S, Faber J, Manshouri T, Romaguera J, Huh YO, Kantarjian H, Keating M, Albitar M De novo CD5+ Burkitt"s lymphoma/leukemia. American Journal of Clinical Pathology 112(6):828-835, 1999. PMID: 10587706.
59. Giles FJ, O'Brien SM, Keating MJ Chronic lymphocytic leukemia in (Richter's) transformation. Semin Oncol 25(1):117-125, 1998. PMID: 9482533.
60. de Lima M, O'Brien S, Lerner S, Keating MJ Chronic lymphocytic leukemia in the young patient. Semin Oncol 25(1):107-116, 1998. PMID: 9482532.
61. Keating MJ, McLaughlin P, Cabanillas F Low-grade non-Hodgkin's lymphoma - development of a new effective combination regimen (fludarabine, mitoxantrone and dexamethasone; FND). Eur J Cancer Care (Engl) 6(Suppl 4):21-26, 1997. PMID: 9460339.
62. Fayad L, Kantarjian H, O'Brien S, Seong D, Albitar M, Keating M, Talpaz M Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases. Leukemia 11(5):767-771, 1997. PMID: 9180306.
63. Keating MJ, O'Brien S, McLaughlin P, Dimopoulos M, Gandhi V, Plunkett W, Lerner S, Kantarjian H, Estey E Clinical experience with fludarabine in hemato-oncology. Hematol Cell Ther 38 Suppl 2:S83-91, 1996. PMID: 9137961.
64. Keating M, Cheson B, Gribben JG, Robertson B, Nadler L Innovative strategies for the treatment of CLL. Leuk Lymphoma 22 Suppl 2:53-64, 1996. PMID: 9021709.
65. O'Brien S, Jeha S, Kantarjian H, Pisa P, Jin G, Keating M, Beran M Engraftment of chronic prolymphocytic and T cell leukemia in SCID mice. Leukemia 10(2):338-344, 1996. PMID: 8637244.
66. O'Brien S, Kantarjian H, Keating MJ Purine analogs in chronic lymphocytic leukemia and Waldenström's macroglobulinemia. Ann Oncol 7 Suppl 6:S27-33, 1996. PMID: 9010576.
67. Wright SJ, Keating MJ Cyclosporine A in chronic lymphocytic leukemia: dual anti-leukemic and immunosuppressive role?. Leuk Lymphoma 20(1-2):131-136, 1995. PMID: 8750634.
68. Seymour JF, Estey EH, Keating MJ, Kurzrock R Response to interferon-alpha in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine. Leukemia 9(5):929-932, 1995. PMID: 7769859.
69. Bueso-Ramos CE, Manshouri T, Haidar MA, Huh YO, Keating MJ, Albitar M Multiple patterns of MDM-2 deregulation in human leukemias: implications in leukemogenesis and prognosis. Leuk Lymphoma 17(1-2):13-18, 1995. PMID: 7773150.
70. O'Brien S, del Giglio A, Keating M Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood 85(2):307-318, 1995. PMID: 7811987.
71. Robertson LE, Estey E, Kantarjian H, Koller C, O'Brien S, Brown B, Keating MJ Therapy-related leukemia and myelodysplastic syndrome in chronic lymphocytic leukemia. Leukemia 8(12):2047-2051, 1994. PMID: 7807993.
72. Wright SJ, Robertson LE, O'Brien S, Plunkett W, Keating MJ The role of fludarabine in hematological malignancies. Blood Rev 8(3):125-134, 1994. PMID: 7819814.
73. Seymour JF, Khouri IF, Champlin RE, Keating MJ Refractory chronic lymphocytic leukemia complicated by hypercalcemia treated with allogeneic bone marrow transplantation. Case report and review. Am J Clin Oncol 17(4):360-368, 1994. PMID: 8048400.
74. Montserrat E, Binet JL, Dighiero G, Gale RP, Juliusson G, Keating M, Rai KR Chronic lymphoproliferative disorders. Rev Invest Clin Suppl:52-58, 1994. PMID: 7886310.
75. Keating MJ, O'Brien S, Plunkett W, Robertson LE, Gandhi V, Estey E, Dimopoulos M, Cabanillas F, Kemena A, Kantarjian H Fludarabine phosphate: a new active agent in hematologic malignancies. Semin Hematol 31(1):28-39, 1994. PMID: 7510070.
76. Keating MJ, McLaughlin P, Plunkett W, Robertson LE, O'Brien S, Gandhi V, Gregoire V, Yang L, Cabanillas F Fludarabine--present status and future developments in chronic lymphocytic leukemia and lymphoma. Ann Oncol 5 Suppl 2:79-83, 1994. PMID: 8204523.
77. Preti A, Kantarjian HM, Estey E, Huh Y, Keating M, Pierce S, Hirsch-Ginsberg C, Yee G, Stass SA Characteristics and outcome of patients with acute lymphocytic leukemia and myeloperoxidase-positive blasts by electron microscopy. Hematol Pathol 8(4):155-167, 1994. PMID: 7860434.
78. Keating MJ, Estey E, O'Brien S, Kantarjian H, Robertson LE, Plunkett W Clinical experience with fludarabine in leukaemia. Drugs 47 Suppl 6:39-49, 1994. PMID: 7525188.
79. Keating MJ, O'Brien S, Robertson LE, Kantarjian H, Dimopoulos M, McLaughlin P, Cabanillas F, Gregoire V, Li YY, Gandhi V The expanding role of fludarabine in hematologic malignancies. Leuk Lymphoma 14 Suppl 2:11-16, 1994. PMID: 7533576.
80. Keating MJ, O'Brien S, Robertson LE, Kantarjian H, Dimopoulos M, McLaughlin P, Cabanillas F, Gregoire V, Yang LY, Gandhi V New initiatives with fludarabine monophosphate in hematologic malignancies. Semin Oncol 20(5 Suppl 7):13-20, 1993. PMID: 7694371.
81. Plunkett W, Gandhi V, Huang P, Robertson LE, Yang LY, Gregoire V, Estey E, Keating MJ Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol 20(5 Suppl 7):2-12, 1993. PMID: 8235690.
82. Del Giglio A, O'Brien S, Ford RJ, Manning J, Saya H, Keating M, Johnston D, Chamone DF, Deisseroth AB Proliferating cell nuclear antigen (PCNA) expression in chronic lymphocytic leukemia (CLL). Leuk Lymphoma 10(4-5):265-271, 1993. PMID: 8106065.
83. Kantarjian HM, Beran M, Ellis A, Zwelling L, O'Brien S, Cazenave L, Koller C, Rios MB, Plunkett W, Keating MJ Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood 81(5):1146-1151, 1993. PMID: 8382970.
84. Kantarjian HM, Estey EH, Keating MJ Treatment of therapy-related leukemia and myelodysplastic syndrome. Hematol Oncol Clin North Am 7(1):81-107, 1993. PMID: 7680643.
85. Keating MJ Chronic lymphoproliferative disorders: chronic lymphocytic leukemia and hairy-cell leukemia. Curr Opin Oncol 5(1):35-41, 1993. PMID: 8427892.
86. Keating MJ, O'Brien S, Kantarjian H, Robertson LB, Koller C, Beran M, Estey E Nucleoside analogs in treatment of chronic lymphocytic leukemia. Leuk Lymphoma 10 Suppl:139-145, 1993. PMID: 8097653.
87. Feldman EJ, Keating MJ Fludarabine in the treatment of lymphoproliferative malignancies. Cancer Invest 11(3):314-318, 1993. PMID: 8485654.
88. Keating MJ, Holmes R, Lerner S, Ho DH L-asparaginase and PEG asparaginase--past, present, and future. Leuk Lymphoma 10 Suppl:153-157, 1993. PMID: 8481665.
89. Gandhi V, Estey E, Keating MJ, Plunkett W Biochemical modulation of arabinosylcytosine for therapy of leukemias. Leuk Lymphoma 10 Suppl:109-114, 1993. PMID: 8481660.
90. Robertson LE, Keating MJ Fludarabine phosphate in the treatment of chronic lymphocytic leukemia: biology, clinical impact, and future directions. Cancer Treat Res 64:105-119, 1993. PMID: 7680874.
91. Robertson LE, Huh YO, Butler JJ, Pugh WC, Hirsch-Ginsberg C, Stass S, Kantarjian H, Keating MJ Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: Clinical, pathologic, immunophenotypic, and molecular analysis. Blood 80(1):29-36, 1992. PMID: 1377051.
92. Estey E, Trujillo JM, Cork A, O'Brien S, Beran M, Kantarjian H, Keating M, Freireich EJ, Stass S AML-associated cytogenetic abnormalities (inv (16), del (16), t(8;21)) in patients with myelodysplastic syndromes. Hematol Pathol 6(1):43-48, 1992. PMID: 1601822.
93. Keating MJ, Estey E, Kantarjian H, Plunkett W, O'Brien S, Koller C, Beran M, Freireich EJ Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991. Leukemia 6 Suppl 2:78-80, 1992. PMID: 1578950.
94. Kemena A, Gandhi V, Shewach DS, Keating M, Plunkett W Inhibition of fludarabine metabolism by arabinosylcytosine during therapy. Cancer Chemother Pharmacol 31(3):193-199, 1992. PMID: 1464155.
95. Robertson LE, Keating MJ Therapeutic approaches to chronic lymphocytic leukemia. Tex Med 87(11):68-74, 1991. PMID: 1759245.
96. Kemena A, Fernandez M, Bauman J, Keating M, Plunkett W A sensitive fluorescence assay for quantitation of fludarabine and metabolites in biological fluids. Clin Chim Acta 200(2-3):95-106, 1991. PMID: 1723357.
97. Ventura GJ, Keating MJ, Castellanos AM, Glass JP Reversible bilateral lateral rectus muscle palsy associated with high-dose cytosine arabinoside and mitoxantrone therapy. Cancer 58(8):1633-5, 1986. PMID: 3463392.
98. Talpaz M, Trujillo JM, Hittelman WN, Keating MJ, Gutterman JU Suppression of clonal evolution in two chronic myelogenous leukaemia patients treated with leucocyte interferon. Br J Haematol 60(4):619-24, 1985. PMID: 3861194.
99. Lopez-Berestein G, Fainstein V, Hopfer R, Mehta K, Sullivan MP, Keating M, Rosenblum MG, Mehta R, Luna M, Hersh EM Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis 151(4):704-10, 1985. PMID: 3973417.
100. Freireich EJ, Keating M, Cabanillas F, Barlogie B The hematologic malignancies. Leukemia, lymphoma, and myeloma. Cancer 54(11 Suppl):2741-50, 1984. PMID: 6208991.
101. Quesada JR, Keating MJ, Libshitz HI, Llamas L Bone involvement in hairy cell leukemia. Am J Med 74(2):228-31, 1983. PMID: 6824003.
102. Barlogie B, Maddox AM, Johnston DA, Raber MN, Drewinko B, Keating MJ, Freireich EJ Quantitative cytology in leukemia research. Blood Cells 9(1):35-55, 1983. PMID: 6344934.
103. Stewart DJ, Keating MJ Second malignancies in hairy cell leukemia (leukemic reticuloendotheliosis). Am J Hematol 13(2):167-9, 1982. PMID: 6291381.
104. Plunkett W, Benjamin RS, Keating MJ, Freireich EJ Modulation of 9-beta-D-arabinofuranosyladenine 5'-triphosphate and deoxyadenosine triphosphate in leukemic cells by 2'-deoxycoformycin during therapy with 9-beta-D-arabinofuranosyladenine. Cancer Res 42(5):2092-6, 1982. PMID: 6175407.
105. Stewart DJ, Keating MJ, Youness E, Burgess MA Long-term chemotherapy-induced remission in a probable case of hairy cell leukemia. Cancer Treat Rep 65(3-4):313-5, 1981. PMID: 6940658.
106. Stewart DJ, Keating MJ Radiation exposure as a possible etiologic factor in hairy cell leukemia (leukemic reticuloendotheliosis). Cancer 46(7):1577-80, 1980. PMID: 7417955.
107. Stewart DJ, Benjamin RS, McCredie KB, Murphy S, Keating M The effectiveness of rubidazone in hairy cell leukemia (leukemic reticuloendotheliosis). Blood 54(2):298-304, 1979. PMID: 454838.
108. Dicke KA, McCredie KB, Spitzer G, Zander A, Peters L, Verma DS, Stewart D, Keating M, Stevens EE Autologous bone marrow transplantation in patients with adult acute leukemia in relapse. Transplantation 26(3):169-73, 1978. PMID: 360515.

Abstracts

1. Thompson PA, Wierda WG, Ferrajoli A, Smith SC, O'Brien S, Burger JA, Estrov Z, Jain N, Kantarjian HM, Keating MJ. Complex karyotype, rather than del(17p), is associated with inferior outcomes in relapsed or refractory CLL patients treated with Ibrutinib-based regimens. Blood 124(21):(#22), 2014. e-Pub 2014.
2. Kebriaei P, Huls H, Singh H, Olivares S, Figliola M, Maiti S, Shihuang S, Kumar PR, Jena B, Forget MA, Ang S, Rineka J, Liu T, McNiece IK, Rondon G, Hackett P, Wierda WG, O'Brien S, Keating MJ, Kantarjian HM, Hosing CM, Shpall EJ, Champlin RE, Cooper LJN. Adoptive therapy using Sleeping Beauty gene transfer system and artificial antigen presenting cells to manufacture T cells expressing CD19-specific chimeric antigen receptor. Blood 124(21):(#311), 2014. e-Pub 2014.
3. Burger JA, Li K, Keating M, Sivina M, Ferrajoli A, Jalayer A, Huang X, Kantarjian HM, Wierda WG, O'Brien S, Hellerstein M, Turner S, Emson C, S-S C, X-J Y, Chiorazzi N. Functional evidence from deuterated water labeling that the Bruton tyrosine kinase inhibitor Ibrutinib blocks leukemia cell proliferation and trafficking and promotes leukemia cell death in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. Blood 124(21):(#326), 2014. e-Pub 2014.
4. O'Brien S, Jones JA, Coutre S, Mato AR, Hillmen P, Tam C, Osterborg A, Siddiqi T, Thirman TJ, Furman RR, Ilhan O, Keating M, Call TG, Brown JR, Stevens-Brogan M, Li Y, Fardis M, Clow F, James DF, Chu AD, Hallek M, Stilgenbauer S. Efficacy and safety of Ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia with 17p deletion: results from the phase II RESONATE-17 trial. Blood 124(21):(#327), 2014. e-Pub 2014.
5. Thompson PA, Keating MJ, Hinojosa C, Smith SC, Daver NG, Jain N, Burger JA, Estrov E, O'Brien S, Wierda WG, Kantarjian HM, Ferrajoli A. Lenalidomide and rituximab in combination as initial treatment of chronic lymphocytic leukemia: initial results of a phase II study. Blood 124(21):(#1988), 2014. e-Pub 2014.
6. Kim E, Werner L, Keating MJ, Wierda WG, Ferrajoli A, Estrov Z, Zacharian G, Kipps TJ, Kantarjian HM, Neuberg D, O'Brien S, Burger JA. Addition of rituximab abrogates ibrutinib-induced lymphocytosis and promotes more rapid decrease in absolute lymphocyte counts in patients with relapsed chronic lymphocytic leukemia. Blood 124(21):(#1998), 2014. e-Pub 2014.
7. George B, Jabbour E, Cabrero M, Jain N, Daver N, Ravandi F, Borthakur G, Bohannan Z, Cortes J, Keating MJ, O'Brien S, Kantarjian HM, Garcia-Manero G. Retrospective analysis of survival in patients with acute erythroid leukemia (AML-6) treated with conventional chemotherapy versus hypomethylating agents. Blood 124(21):(#2278), 2014. e-Pub 2014.
8. Rozovski U, Grgurevic S, Bueso-Ramos CE, Harris DM, Li P, Liu Z, Wu JY, Wierda W, Burger JA, O'Brien S, Jain N, Ferrajoli A, Keating M, Estrov Z. STAT3-driven, aberrantly expressed lipoprotein lipase mediates free fatty acid metabolism in chronic lymphocytic leukemia cells. Blood 124(21):(#3304), 2014. e-Pub 2014.
9. ten Hacken E, Scielzo C, O'Brien S, Wierda WG, Keating M, Ghia P, Caligaris-Cappio F, Burger JA. Nurse-like cells engage sigm and sigd on chronic lymphocytic leukemia (CLL) cells: implications for BCR signaling activation and functional outcome. Blood 124(21):(#3312), 2014. e-Pub 2014.
10. Falchi L, Keating M, Lerner S, Wang X, Gbito KYE, Strom SS, Wierda WG, Ferrajoli A. Other cancers in long-term survivors of chronic lymphocytic leukemia: incidence and prognostic relevance. Blood 124(21):(#3323), 2014. e-Pub 2014.
11. Coutre S, O'Brien S, Byrd JC, Hillmen P, Brown JR, Dyer MJS, Mato AR, Miklos DB, Keating M, Zhou C, Fardis M, Styles L, Jaglowski S. Safety and efficacy of Ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma who have undergone prior allogeneic stem cell transplant. Blood 124(21):(#4697), 2014. e-Pub 2014.
12. Chen R, Chen Y, Ghia EM, Rassenti L, Kipps T, Keating MJ, Wierda WG, Plunkett W. Targeting SF3B1 mediated splicing control of Mcl-1 in chronic lymphocytic leukemia. Cancer Research 74(19):(#343), 2014. e-Pub 2014.
13. Vangapandu HV, Balakrishnan K, Wierda WG, Keating MJ, Stellrecht CM, Gandhi V. Marrow stromal cells promote mitochondrial energy metabolism in primary CLL cells without impacting cellular proliferation. Cancer Research 74(19):(#4328), 2014. e-Pub 2014.
14. Cervantes-Gomez F, Balakrishnan K, Wierda WG, Keating MJ, Gandhi V. Ex-vivo and in-vitro combination strategies with ibrutinib in chronic lymphocytic leukemia. Cancer Research 74(19):(#4769), 2014. e-Pub 2014.
15. Liu P, Liu J, Ogasawara MA, Pelicano H, Xu R, Keating MJ, Huang P. A novel therapeutic strategy to effectively kill CLL cells in stromal microenvironment by targeting lipid metabolism. Cancer Research 74(19):(#2697), 2014. e-Pub 2014.
16. Jiang Y, Liu X, Wen S, K-A D, Su X, Keating MJ, Wierda W, Plunkett W. Quantitation of ATM function in primary CLL cells. Cancer Research 73(8):(#3528), 2013. e-Pub 2013.
17. Strati P, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Faderl S, Jain N, Wierda WG. Outcomes of first-line treatment for chronic lymphocytic leukemia (CLL) with 17p deletion (del17p). Journal of Clinical Oncology 31:(#7102), 2013. e-Pub 2013.
18. Balakrishnan K, Fu M, Onida F, Wierda WG, Keating M, Gandhi V. Role of smac-mimetic in restoring apoptosis in chronic lymphocytic leukemia. Cancer Research 73(8):(#3325), 2013. e-Pub 2013.
19. Falchi L, Keating MJ, Wang X, Schlette EJ, Sargent RL, Marom EM, Truong M, Wierda WG, Ferrajoli A. Predictors of survival in patients with transformed chronic lymphocytic leukemia (TC). Journal of Clinical Oncology 31:(#7098), 2013. e-Pub 2013.
20. Pozadzides JV, Keating MJ, Wierda WG, O'Brien S, Burger JA, Jorgensen JL, Calin S, Wang SA, Lerner S, Ferrajoli A. Initial experience with lenalidomide as consolidation treatment in patients with chronic lymphocytic leukemia and residual disease after chemotherapy. Blood 118(21):(#3907), 2011. e-Pub 2011.
21. Hsu Y, Saliba RM, G-J O, O'Brien S, Ferrajoli A, Abruzzo LV, Champlin R, Keating MJ, Khouri IF. Feasibility analysis of nonmyeloablative allogeneic stem cell transplantation (NST) in patients with chronic lymphocytic leukemia (CLL) and 17p- deletion. Blood 118(21):(#4123), 2011. e-Pub 2011.
22. Ramos CA, Savoldo B, Liu E, Bollard CM, Mims MP, Keating MJ, Gee AP, Mei Z, Rooney CM, Heslop HE, Brenner MK, Dotti G. Effect of a costimulatory endodomain on the performance of T cells expressing CD19-directed chimeric antigen receptors (CARs) in subjects with relapsed/refractory B-cell malignancies. Journal of Clinical Oncology 29(15S):175s(#2541), 2011. e-Pub 2011.
23. Kadia T, Delioukina ML, Kantarjian HM, Keating MJ, Wierda WG, Burger JA, Wieland S, Levitt D. A pilot phase II study of the lyn kinase inhibitor bafetinib in patients with relapsed or refractory B cell chronic lymphocytic leukemia. Blood 118(21):(#2858), 2011. e-Pub 2011.
24. Badoux XC, Keating MJ, O'Brien S, Wierda WG, Faderl S, Estrov Z, Pasia M, Lerner S, Sargent RL, Kantarjian HM, Ferrajoli A. Final analysis of a phase 2 study of lenalidomide and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood 118(21):(#980), 2011. e-Pub 2011.
25. Tambaro FP, Garcia-Manero G, Faderl S, O'Brien S, Ferrajoli A, Burger JA, Trinh LX, Lerner S, Kantarjian HM, Keating MJ, Wierda WG. Acute leukemia and myelodysplastic syndrome: outcomes in patients with chronic lymphocytic leukemia (CLL) at MD Anderson Cancer Center (MDACC). Blood 118(21):(#981), 2011. e-Pub 2011.
26. Fiorcari S, Brown WS, McIntyre BW, O'Brien S, Sivina M, Hoellenriegel J, Wierda WG, Keating MJ, Marasca R, Lannutti BJ, Estrov Z, Burger JA. The PI3 kinase delta inhibitor, CAL-101 (GS-1101) inhibits chronic lymphocytic leukemia (CLL) cell survival in endothelial and marrow stromal cell co-cultures. Blood 118(21):(#1769), 2011. e-Pub 2011.
27. Ferrajoli A, O'Brien S, Wierda WG, Faderl S, Badoux X, Estrov Z, Schlette E, Smith SC, Ayala AB, Falchi L, Calin S, Kantarjian HM, Keating MJ. Combination therapy with ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL): results of a phase II trial. Blood 118(21):(#1788), 2011. e-Pub 2011.
28. Pashos CL, Flowers CR, Weiss M, Lamanna N, Farber CM, Kipps TJ, Lerner S, Kay N, Sharman JP, Grinblatt DL, Flinn IW, Kozloff M, Swern AS, Kahn ZM, Street TK, Sullivan KA, Harding G, Keating MJ. Variation in health-related quality of life by age among patients with chronic lymphocytic leukemia. Blood 118(21):(#2085), 2011. e-Pub 2011.
29. Quintas-Cardama A, Kantarjian H, Ravandi F, Garcia-Manero G, Faderl S, Pierce S, Brandt M, Borthakur G, Keating MJ, Freireich E, Cortes JE. Outcomes of patients with newly-diagnosed acute myeloid leukemia over the last 5 decades at M.D. Anderson Cancer Center. Blood 118(21):(#2606), 2011. e-Pub 2011.
30. Schuster SJ, Hosing CM, Shpall EJ, Levine BL, Aqui NA, Chong EA, Svoboda J, Gordon A, McMannis JD, Bosque D, Cotte J, Brennan AL, Zheng Z, Leinbach L, Xu YY, Veloso E, Decker W, Bollard CM, Keating MJ, June CH. Adoptive immunotherapy with autologous CD3/CD28-costimulated T-cells after fludarabine-based chemotherapy in patients with chronic lymphocytic leukemia. Blood 118(21):(#2855), 2011. e-Pub 2011.
31. Schuster SJ, Hosing C, Shpall EJ, Levine B, Aqui N, Chong EA, Svoboda J, Gordon A, McMannis JD, Bosque D, Cotte J, Brennan A, Zheng Z, Leinbach L, Xu Y, Veloso EA, Decker W, Bollard CM, Keating MJ, June CH. Adoptive immunotherapy with autologous CD3/CD28-costimulated T cells after fludarabine-based chemotherapy in patients with chronic lymphocytic leukemia. Journal of Clinical Oncology 29(15S):179s(#2557), 2011. e-Pub 2011.
32. Ponader S, Balasubramanian S, Pham LV, Chen J, Tamayo AT, Wang M, O'Brien S, Wierda WG, Keating MJ, Ford RJ, Burger JA. Activity of Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in mantle cell lymphoma (MCL) identifies Btk as a novel therapeutic target. Blood 18(21):(#3688), 2011. e-Pub 2011.
33. Hoellenriegel J, Zboralski D, Estrov Z, Wierda WG, Keating M, Kruschinski A, Burger JA. The spiegelmer Nox-A12, a novel SDF-1 (CXCL12) inhibitor, and its effects on chronic lymphocytic leukemia (CLL) cell migration. Blood 118(21):(#3878), 2011. e-Pub 2011.
34. Li P, Liu Z, Harris D, Ferrajoli A, Wang Y, Hazan-Halevy I, Grgurevic S, Wierda WG, Burger JA, O'Brien S, Faderl S, Keating MJ, Estrov Z. Signal transducer and activator of transcription (STAT)-3 induces granulocyte/macrophage colony-stimulating factor (GM-CSF) receptor-alpha expression in chronic lymphocytic leukemia (CLL) cells. Blood 118(21):(#3879), 2011. e-Pub 2011.
35. Wierda WG, Balakrishnan K, Ferrajoli A, Kadia T, Cortes JE, O'Brien S, Burger JA, Tambaro FP, Jalayer A, Lerner S, Keating MJ, Gandhi V. A phase I/II trial of fludarabine, bendamustine, and rituximab (FBR) chemoimmunotherapy for previously treated patients with CLL. Blood 118(21):(#3901), 2011. e-Pub 2011.
36. Wierda WG, O'Brien S, Ferrajoli A, Koller CA, Burger JA, Faderl S, Garcia- Manero G, Kadia T, Lerner S, Keating MJ. Pretreatment patient characteristics associated with achieving bone marrow minimal residual disease-free status with frontline fludarabine, cyclophosphamide, rituximab (FCR) chemoimmunotherapy for CLL. Blood 118(21):(#3902), 2011. e-Pub 2011.
37. Tsimberidou AM, Wierda WG, Badoux X, Wen S, Plunkett W, O'Brien SM, Kipps TJ, Jones JA, Kantarjian H, Keating MJ. Evaluation of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) combination therapy in aggressive chronic lymphocytic leukemia (CLL) and Richter's syndrome (RS). Journal of Clinical Oncology 28(15S):492s(#6521), 2010. e-Pub 2010.
38. Savoldo B, Ramos CA, Bollard CM, Liu E, Mims M, Keating M, Gee AP, Mei Z, Rooney CM, Heslop HE, Brenner MK, Dotti G. The effects of co-stimulatory endodomains on the fate of T cells expressing a tumor directed chimeric antigen receptor (CAR) in human subjects with B cell malignancies. Blood 116(21):1610(#3949), 2010. e-Pub 2010.
39. Hoellenriegel J, Coffey G, Sinha U, Pandey A, Wierda WG, Keating MJ, Burger JA. Spleen tyrosine kinase (Syk) inhibitors block B cell receptor signaling and survival in chronic lymphocytic leukemia. Blood 116(21):1483(#3604), 2010. e-Pub 2010.
40. Badoux X, O'Brien S, Wierda WG, Faderl S, Estrov Z, Yerrow K, Kantarjian HM, Keating MJ, Ferrajoli A. Combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia: Initial results of a Phase II trial. Blood 116(21):1023(#2464), 2010. e-Pub 2010.
41. Ravandi F, Jorgenson J, O'Brien S, Thomas DA, Faderl S, York S, Burger JA, Ferrajoli A, Pierce S, Keating M, Kantarjian H. Phase II study of sequential therapy with cladribine followed by an extended course rituximab in patients with hairy cell leukemia. Blood 116(21):1020(#2458), 2010. e-Pub 2010.
42. Ferrajoli A, Badoux X, O'Brien S, Wierda WG, Faderl S, Estrov Z, Pasia M, Lerner S, Kantarjian H, Keating MJ. The combination of lenalidomide and rituximab induces complete and partial responses in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 116(21):600(#1395), 2010. e-Pub 2010.
43. Tsimberidou AM, Wierda WG, Wen S, Plunkett W, O'Brien S, Kipps TJ, Jones JA, Kantarjian HM, Keating MJ. Results of a phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) combination therapy in patients with aggressive, relapsed/refractory chronic lymphocytic leukemia (CLL) and Richter syndrome (RS). Blood 116(21):408(#923), 2010. e-Pub 2010.
44. Liu Z, Hazan-Halevy I, Harris D, Li P, Ferrajoli A, Faderl S, Keating M, Estrov Z. Signal transducer and activator of transcription (STAT)-3 activates nuclear factor (NF)-kappaB in chronic lymphocytic leukemia (CLL) cells. Blood 116(21):170(#376), 2010. e-Pub 2010.
45. Sivina M, Hartmann E, Boucas J, Keating MJ, Wierda WG, Herling M, Rosenwald A, Burger JA. Stroma-induced TCL1 expression in chronic lymphocytic leukemia cells is associated with down regulation of TCL1A-targeting miRNAs. Blood 116(21):29(#52), 2010. e-Pub 2010.
46. Hoellenriegel J, Meadows SA, Wierda WG, Keating MJ, Lannutti B, Burger JA. Phosphoinositide 3'-kinase (PI3K) delta inhibition with CAL-101 blocks B-cell receptor (BCR) signaling and the prosurvival actions of nurslike cells (NLC) in chronic lymphocytic leukemia. Blood 116(21):27(#48), 2010. e-Pub 2010.
47. Ponader S, Buggy J, O'Brien S, Wierda WG, Keating M, Burger JA. Bruton's tyrosine kinase inhibitor PCI-32765 abrogates BCR- and nurselike cell-derived activation of CLL cells in vitro and in vivo. Blood 116(21):26(#45), 2010. e-Pub 2010.
48. Hornberger JC, Reyes CM, Shewade A, Friedmann M, Chan L, Gutierrez H, Satram-Hoang S, Lerner S, Keating MJ. Cost-effectiveness of rituximab, fludarabine, and cyclophosphamide (R-FC) in patients with previously untreated chronic lymphocytic leukemia (CLL). Journal of Clinical Oncology 28:e16500, 2010. e-Pub 2010.
49. Parikh SA, Wierda WG, Badoux X, O'Brien SM, Ferrajoli A, Faderl S, Burger JA, Lerner S, Kantarjian H, Keating MJ. Comparison of fludarabine (F) plus cyclophosphamide (C) versus FC plus rituximab (R) in previously untreated Rai stage III/IV chronic lymphocytic leukemia (CLL). Journal of Clinical Oncology 28(15S):491s(#6519), 2010. e-Pub 2010.
50. Badoux X, Wierda WG, O'Brien SM, Faderl S, Estrov Z, Yerrow KA, Keating MJ, Ferrajoli A. A phase II study of lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia. Journal of Clinical Oncology 28(15S):489s(#6508), 2010. e-Pub 2010.
51. Sivina M, Hartmann E, Keating M, Wierda WG, Rosenwald A, Burger JA. Marrow stromal cells induce TCL1 expression in chronic lymphocytic leukemia B cells. Blood 114(22):927(2347), 2009. e-Pub 2009.
52. Li P, Harris D, Liu Z, Keating M, Estrov Z. Signal transducer and activator of transcription (Stat)-3 activates the receptor tyrosine kinase-like orphan (ROR)-1 gene in chronic lymphocytic leukemia (CLL). Blood 114(22):29(#57), 2009. e-Pub 2009.
53. Zhang K, Kantarjian HM, Ma W, Zhang XI, Wang X, Estrov Z, C-H Y, Sferruzza A, O'Brien S, Keating M, Albitar M. Use of ubiquitin-proteasome system profiling for differentiating between various leukemic processes. Blood 114(22):(#4712), 2009. e-Pub 2009.
54. J-M B, Estrov Z, Kantarjian H, O'Brien S, Keating M, Wierda W, Albitar M. Plasma circulating caspase-3 index as a biomarker in patients with chronic lymphocytic leukemia. Blood 114(22):(4381), 2009. e-Pub 2009.
55. Batty N, Badoux XC, Keating M, Lin E, Lerner S, O'Brien S, Ferrajoli A, Kadia T, Burger JA, Faderl S, Wierda WG. Pretreatment factors associated with second malignancies occurring after frontline fludarabine, cyclophosphamide, and rituximab (FCR) in patients with chronic lymphocytic leukemia (CLL). Blood 114(22):1339(3448), 2009. e-Pub 2009.
56. A-M T, Wierda W, Plunkett W, O'Brien S, Kipps TJ, Jones JA, Smith S, Jalayer A, Kantarjian HM, Keating M. Oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy induces high response rates in aggressive chronic lymphocytic leukemia (CLL) and Richter's syndrome (RS). Blood 114(22):1337(3443), 2009. e-Pub 2009.
57. Janssens A, Foa R, Keating M, Ouwens M, Tatt I, Carr ESC. Comparative efficacy of first line therapies for chronic lymphocytic leukemia: a systematic review and meta-analyses. Blood 114(22):1333(3432), 2009. e-Pub 2009.
58. Badoux XC, Keating M, O'Brien S, Kadia T, Ferrajoli A, Faderl S, Koller C, Garcia-Manero G, Burger JA, Wierda WG. Chemoimmunotherapy with cyclophosphamide, fludarabine, alemtuzumab and rituximab (CFAR) is effective in relapsed patients with chronic lymphocytic leukemia. Blood 114(22):1332(3431), 2009. e-Pub 2009.
59. Keating MJ, Wierda WG, Tam CS, Lynn A, O'Brien S, Lerner S, Kantarjian HM. Long term outcome following treatment failure of FCR chemoimmunotherapy as initial therapy for chronic lymphocytic leukemia. Blood 114(22):940(2381), 2009. e-Pub 2009.
60. Verma D, Balakrishnan K, O'Brien S, Thomas DA, Ferrajoli A, Wierda WG, Verma A, Faderl S, Bickel SM, Bantia S, Kantarjian HM, Keating MJ, Gandhi V, Ravandi F. Phase II, single center study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia (CLL). Blood 114(22):935(2369), 2009. e-Pub 2009.
61. Hu Y, Chen G, Jia Y, Zhang H, Huang P, Bhalla KN, Keating M, Garcia-Manero G. The combination of PEITC (phenehyl isothiocyanate) with a histone deacetylase inhibitor (HDACi) has synergistic antileukemia activity by overcoming a redox-mediated resistance pathway. Blood 114(22):691(#1739), 2009. e-Pub 2009.
62. Wang XS, Mendoza TR, Broadway JB, Mobley GM, Keating M, Cleeland CS, Ferrajoli A. Symptom profiles in patients with chronic lymphocytic leukemia: validation and application of the M. D. Anderson symptom inventory. Blood 114(22):567(#1393), 2009. e-Pub 2009.
63. J-M B, Estrov Z, Kantarjian HM, Ma W, C-H Y, Wierda W, Donahue A, O'Brien S, Keating M, Albitar M. Plasma circulating Ki-67 index as a biomarker and prognostic indicator in patients with chronic lymphocytic leukemia. Blood 114(22):519(1261), 2009. e-Pub 2009.
64. Badoux XC, Keating M, O'Brien S, Ferrajoli A, Burger JA, Faderl S, Garcia-Manero G, Kadia T, Abruzzo LV, Wierda WG. Patients with relapsed CLL and 17p deletion by FISH have very poor survival outcomes. Blood 114(22):513(1248), 2009. e-Pub 2009.
65. Badoux XC, Bueso Ramos C, Harris D, Li P, Liu Z, Burger J, O'Brien S, Ferrajoli A, Keating M, Estrov Z. Cross-talk between CLL cells and endothelial cells in the bone marrow microenvironment: role of signal transducer and activator of transcription (Stat)-3. Blood 114(22):511(1242), 2009. e-Pub 2009.
66. Ma W, Kantarjian HM, Wang X, O'Brien S, C-H Y, Zhang XI, Estrov Z, Sferruzza A, Wierda W, Keating M, Albitar M. Clinical relevance of circulating poly-ubiquitin as a prognostic indicator in chronic lymphocytic leukemia. Blood 114(22):510(1240), 2009. e-Pub 2009.
67. Thomas DA, Kantarjian HM, Faderl S, Wierda WG, Cortes J, Burger JA, Ferrajoli A, Estrov Z, Koller C, Konopleva M, Borthakur G, Jabbour E, Ravandi F, Kadia T, Garcia-Manero G, Kornblau SM, Andreeff M, Garris R, Keating MJ, O'Brien S. Chemoimmunotherapy with a modified Hyper-CVAD and rituximab regimen improves outcome for patients with de novo Philadelphia negative precursor B-cell acute lymphoblastic leukemia (ALL). Blood 114(22):344(836), 2009. e-Pub 2009.
68. Sivina M, Hartmann E, Krupnik D, LaPushin R, Keating M, Kipps TJ, Rosenwald A, Wierda WG, Burger JA. CCL3 and CCL4 plasma levels correlate with established prognostic markers in chronic lymphocytic leukemia: towards a simple, ELISA-based assay for risk assessment. Blood 114(22):151(358), 2009. e-Pub 2009.
69. Kurtova A, Sivina M, Quiroga MP, Wierda WG, Keating MJ, Burger JA. The immunophenotype signature CD49d+ CD38+ identifies chronic lymphocytic leukemia cases with a higher potential for migration beneath marrow stromal cells. Blood 114(22):150(#356), 2009. e-Pub 2009.
70. Parikh SA, Keating M, O'Brien S, Ferrajoli A, Faderl S, Koller C, Estrov Z, Lerner S, Wierda WG. Frontline combined chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab and rituximab (CFAR) in high-risk chronic lymphocytic leukemia. Blood 114(22):91(208), 2009. e-Pub 2009.
71. Ferrajoli A, Badoux XC, O'Brien S, Wierda WG, Faderl S, Estrov Z, Pasia M, B-N L, Reuben JM, Kantarjian H, Keating M. Combination therapy with lenalidomide and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL). Blood 114(22):89(206), 2009. e-Pub 2009.
72. Hazan-Halevy I, Harris D, Liu Z, Ferrajoli A, Keating MJ, Estrov Z. Importin-B1 and nucleus transporter chromosome region maintenance 1 (CRM1) constitute the nucleocytoplasmic transport system of STAT3 in blood-derived CLL cells. Blood 112(11):388(1059), 2008. e-Pub 2008.
73. Hazan-Halevy I, Harris D, Liu Z, Ferrajoli A, Keating MJ, Estrov Z. STAT3 is constitutively phosphorylated on serine 727 residues, activates transcription and plays a major role in the pathogenesis of B-cell chronic lymphocytic leukemia. Blood 112(11):387(1058), 2008. e-Pub 2008.
74. Tam CS, Shanafelt TD, Wierda WG, Abruzzo LV, Van Dyke DL, Lerner S, Lynn A, Kay NE, Keating MJ. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson/Mayo Clinic experience. Blood 112(11):387(1056), 2008. e-Pub 2008.
75. Verma D, Faderl S, O'Brien S, Pierce S, Cortes J, Vu K, Freireich E, Keating MJ, Kantarjian HM, Ravandi F. Late relapses in acute myelogenous leukemia: analysis of characteristics and outcome. Blood 112(11):350(951), 2008. e-Pub 2008.
76. Santos FPS, Faderl S, Garcia-Manero G, Koller CA, Beran M, Borthakur G, Bueso-Ramos C, Keating M, Cortes J, Kantarjian HM, Ravandi F. Acute erythroleukemia: an analysis of 108 patients treated with cytarabine-containing regimens at the M. D. Anderson Cancer Center. Blood 112(11):342(925), 2008. e-Pub 2008.
77. Ferrajoli A, O'Brien S, Wierda W, Faderl S, Kornblau S, Yerrow K, Estrov Z, Kantarjian H, Keating M. Lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia (CLL). Blood 112(11):23(45), 2008. e-Pub 2008.
78. McClain WD, Gunn SR, Bolla AR, Barron LL, Gorre ME, Bahler DW, Mellink CHM, van Oers MHJ, Keating MJ, Ferrajoli A, Coombes KR, Abruzzo LV, Robetorye RS. Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11. Blood 112(11):384(1050), 2008. e-Pub 2008.
79. Wierda WG, Castro J, Aguillon RA, Sampath D, Jalayer A, Prussak C, Keating MJ, Kipps TJ. Active immune gene therapy using ISF35: responses associated with priming for death receptor-induced apoptosis and sensitivity to fludarabine in patients with CLL and del 17p. Blood 112(11):1210(3530), 2008. e-Pub 2008.
80. Ferrajoli A, Faderl S, O'Brien S, Wierda W, Ayala A, Smith S, Brown TC, Kantarjian H, Keating M. Experience with fludarabine, cyclophosphamide, rituximab (FCR) plus GM-CSF in frontline therapy for chronic lymphocytic leukemia (CLL). Blood 112(11):1088(3173), 2008. e-Pub 2008.
81. Tam CS, Wierda W, O'Brien SM, Lerner S, Abruzzo LV, Ferrajoli A, Kantarjian HM, Keating MJ. The clinical significance of chromosome 17p deletion in chronic lymphocytic leukemia: A study of 180 consecutive patients. Journal of Clinical Oncology 26(15S):380s(#7035), 2008. e-Pub 2008.
82. Kurtova A, Quiroga MP, Wierda WG, Keating M, Burger JA. Standardizing co-culture conditions between chronic lymphocytic leukemia cells and marrow stromal cells: towards a reliable and reproducible system to assess cell adhesion-mediated drug resistance. Blood 112(11):1080(3149), 2008. e-Pub 2008.
83. Brown JR, Rassenti L, Neuberg D, Greaves A, Byrd JC, Grever MR, Gribben JG, Kay NE, Keating M, Rai KR, Wierda WG, Kipps TJ. Characteristics of familial CLL evaluated in the CLL Research Consortium cohort. Blood 112(11):1071(3125), 2008. e-Pub 2008.
84. Carr E, Lerner S, Aultman R, Weisgerber-Kriegl U, Keating M. Treatment effect of first line rituximab, fludarabine and cyclophosphamide in a chronic lymphocytic leukemia patient cohort: an evaluation of prognostic factors, estimated life expectancy and economic outcomes. Blood 112(11):835(2396), 2008. e-Pub 2008.
85. Tong W, S-Q K, Wierda W, Keating MJ, Garcia-Manero G. Identification of multiple promoter associated CpG islands commonly methylated in both acute lymphocytic leukemia (ALL) and chronic lymphocytic leukemia (CLL) using novel genome-wide microarray technique: implications for common primordial molecular pathways in lymphoid leukemias. Blood 112(11):789(2263), 2008. e-Pub 2008.
86. Wierda WG, Kipps TJ, Keating MJ, Brown JR, Gribben JG, Rassenti LZ, Greaves AW, Neuberg D, O'Brien SM. Plasma alemtuzumab levels at end of treatment correlate with response and response duration in patients with CLL receiving treatment for residual disease. Blood 112(11):734(2109), 2008. e-Pub 2008.
87. Gao H, Ferrajoli A, Cohen EN, B-N L, Tin S, O'Brien S, Wierda WG, Estrov Z, Faderl S, Keating MJ, Reuben JM. Treatment with lenalidomide has a positive immunomodulatory effect in patients with chronic lymphocytic leukemia. Blood 112(11):733(2107), 2008. e-Pub 2008.
88. Wierda WG, O'Brien SM, Faderl SH, Ferrajoli A, Koller C, Estrov Z, Burger JA, Lerner S, Kantarjian HM, Keating MJ. CFAR, an active frontline regimen for high-risk patients with CLL, including those with del 17p. Blood 112(11):729(2095), 2008. e-Pub 2008.
89. Wierda WG, O'Brien SM, Wang X, Faderl SH, Ferrajoli A, Garcia-Manero G, Cortes J, Tam CS, Burger JA, Abruzzo LV, Schlette E, Lerner S, Keating MJ. Integrating newer with traditional prognostic factors in evaluating patients with CLL receiving frontline chemoimmunotherapy. Blood 112(11):729(2094), 2008. e-Pub 2008.
90. Keating MJ, Lerner S, Wang X, Rassenti LZ, O'Brien S, Kipps TJ, Wierda WG. Predicting time to initial treatment in early stage CLL - integration of classical and novel prognostic factors. Blood 112(11):728(2093), 2008. e-Pub 2008.
91. Tam CS, Wierda WG, O'Brien S, Lerner S, Khouri IF, Kantarjian HM, Keating MJ. Life after fludarabine, cyclophosphamide, & rituximab (FCR) - the clinical outcome of patients with chronic lymphocytic leukemia who receive salvage treatment after frontline FCR. Blood 112(11):727(2090), 2008. e-Pub 2008.
92. Schlette E, Tam CS, Herling M, Bueso-Ramos C, Wierda W, Ferrajoli A, O'Brien S, Keating M, Jones D. High T-cell lymphoma breakpoint 1 (TCL1) levels are associated with lack of response and inferior outcome following fludarabine, cyclophosphamide, rituximab (FCR) frontline therapy in patients with chronic lymphocytic leukemia (CLL). Blood 112(11):726(2086), 2008. e-Pub 2008.
93. Henderson JD, O'Brien SM, Wang X, Faderl SH, Ferrajoli A, Garcia-Manero G, Tam CS, Burger JA, Abruzzo LV, Schlette E, Lerner S, Keating MJ, Wierda WG. Integrating newer prognostic factors in evaluation of previously treated patients with CLL receiving salvage treatment. Blood 112(11):723(2078), 2008. e-Pub 2008.
94. Quiroga MP, Kurtova A, Wierda W, Keating M, Burger JA. Inhibition of BCR signaling using the SYK inhibitor R406 antagonizes migratory and pro-survival responses in CLL cells. Blood 112(11):719(2064), 2008. e-Pub 2008.
95. Borthakur G, Tam C, Kantarjian H, Lin E, Cortes J, O'Brien S, Koller C, Pierce S, Keating M. Chromosome 17 abnormalities are associated with worse overall and relapse free survival in patients with acute myelogenous leukemia and poor-risk cytogenetics. Blood 112(11):534(1501), 2008. e-Pub 2008.
96. Khouri I, Bassett RL, Hsu Y, Dickason T, Acholonu S, Harrell R, G-J O, de Padua Silva L, Korbling MJ, Alousi AM, Hosing C, Popat U, Giralt SA, Kebriaei P, Qazilbash MH, Ledesma C, Keating MJ, Champlin RE, Bueso-Ramos C. Prognostic factors after nonmyeloablative allogeneic stem transplantation (NST) in chronic lymphocytic leukemia (CLL): expression of p53 may not predict survival. Blood 112(11):412(1128), 2008. e-Pub 2008.
97. Ma W, Jilani I, Bekele B, Kantarjian H, Donahue A, Zhang X, Zhang Z, O’Brien S, Estey E, Estrov Z, Cortes J, Keating M, Giles F, Albitar M. Proteasome chymotrypsin-like activity in plasma is a major predictor of outcome in acute myeloid leukemia and myelodysplastic syndrome patients with normal karyotype. Blood 110(11):835a(#2837), 2007. e-Pub 2007.
98. Tam CS, O’Brien S, Wierda W, Lerner S, Kantarjian H, Keating MJ. Seventy percent of complete responders remain in continuous remission: Five-year follow-up of 300 patients treated with fludarabine, cyclophosphamide, and rituximab (FCR) as initial therapy of CLL. Journal of Clinical Oncology 25(18S):359s(#7008), 2007. e-Pub 2007.
99. Keating MJ, Wierda W, O’Brien S, Tam C, Lerner S, Kantarjian H. Salvage therapy following failure or relapse after FCR chemo-immunotherapy as initial treatment for chronic lymphocytic leukemia. Journal of Clinical Oncology 25(18S):359s(#7009), 2007. e-Pub 2007.
100. Tsimberidou AM, Wierda WG, Plunkett WW, O’Brien S, Kipps TJ, Brown JR, Lerner S, Kantarjian HM, Keating MJ. Clinical efficacy of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richters syndrome or fludarabine-refractory chronic lymphocytic leukemia: results of a phase I-II clinical trial. Haematologica/The Hematology Journal 92(s1):130(0364), 2007. e-Pub 2007.
101. Burger JA, Niedermeier M, Burkle A, Hartmann E, Wierda WG, Keating MJ, Rosenwald A. High-level expression of the T cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell co-cultures and in response to BCR stimulation. Blood 110(11):107a(#342), 2007. e-Pub 2007.
102. W-G T, Wierda WG, Bekele N, S-Q K, Keating MJ, Garcia-Manero G. Genome-wide DNA methylation profile of CLL with 17p del allowed identification of multiple epigenetically inactivated molecular pathways with prognostic value in human leukemia. Blood 110(11):152a(#492), 2007. e-Pub 2007.
103. Faderl S, Wierda W, Ferrajoli A, O’Brien S, Ravandi F, Kantarjian HM, Showalter BL, Lerner S, Keating MJ. Update of experience with fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline therapy for chronic lymphocytic leukemia (CLL). Blood 110(11):193a(627), 2007. e-Pub 2007.
104. Ghia EM, Rassenti LZ, Widhopf GF, Silverman GJ, Neuberg DS, Keating MJ, Wierda WG, Gribben JG, Brown JR, Rai KR, Byrd JC, Kay NE, Greaves AW, Kipps TJ. Stereotypic IGHV3-21/IGLV3-21 antibodies expressed in high-risk chronic lymphocytic leukemia bind peptostreptococcus magnus protein L. Blood 110(11):227a(740), 2007. e-Pub 2007.
105. Lin KI, Tam CS, Abruzzo LV, Wierda W, Barron L, O’Brien S, Kipps T, Rassenti L, Lerner S, Kantarjian H, Keating MJ. IgVH mutational status does not affect complete remission rate but is associated with reduced remission duration in CLL patients treated with fludarabine, cyclophosphamide and rituximab (FCR)-based therapy. Blood 110(11):232a(#753), 2007. e-Pub 2007.
106. Ferrajoli A, Keating MJ, Wierda WG, O’Brien SM, Padmanabhan S, Czuczman MS, Chanan-Khan AA. Lenalidomide is active in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) carrying unfavorable chromosomal abnormalities. Blood 110(11):232a(#754), 2007. e-Pub 2007.
107. Neidermeier MTW, Rawluk J, Knight Z, Shokat K, Wierda WG, Keating MJ, Burger JA. Importance of P13 kinase family for crosstalk between chronic lymphocytic leukemia B cells and the stromal microenvironment: Therapeutic implications. Blood 110(11):341a(#1125), 2007. e-Pub 2007.
108. Hazan-Halevy I, Ferrajoli A, Harris D, Mandal PK, McMurray JS, Keating M, Estrov Z. Constitutively serine phosphorylated STAT3 provides chronic lymphocytic leukemia (CLL) cells with survival advantage and promotes their proliferation. Blood 110(11):344a(#1132), 2007. e-Pub 2007.
109. Tam CS, Abruzzo LV, Lin KI, Cortes J, Lynn A, Keating MJ, Thomas DA, Kantarjian H, Verstovsek S. Cytogenetics findings and pattern of clonal evolution determine survival in patients with primary or secondary myelofibrosis. Blood 110(11):461a(#1543), 2007. e-Pub 2007.
110. Tam CS, Keating MJ, O’Brien S, Ferrajoli A, Abruzzo L, Lerner S, Faderl S, Kantarjian H, Wierda W. The natural history and treatment outcome of de-novo chromosome 17p deletion CLL: A single institution experience with 48 patients. Blood 110(11):608a(2041), 2007. e-Pub 2007.
111. A-M T, Tam C, Wierda WG, O’Brien S, Lerner S, Kantarjian HM, Keating MJ. The prognostic significance of 11q deletion detected by fluorescence in situ hybridization (FISH) in untreated chronic lymphocytic leukemia (CLL): The MDACC experience. Blood 110(11):619a(2078), 2007. e-Pub 2007.
112. Tam CS, Cortes J, Lynn A, Abruzzo L, Thomas DA, Pierce S, Zhou L, Keating MJ, Kantarjian H, Verstovsek S. High blast percentage, chromosome 17 abnormalities and severe pancytopenia predict death within twelve months in patients with myelofibrosis. Blood 110(11):749a(#2542), 2007. e-Pub 2007.
113. Ferrajoli A, Wang Y, O’Brien SM, Faderl SH, Harris DM, Van Q, Hallevi I, Liu Z, Koch PE, Sensintaffar J, Burrows F, Kantarjian HM, Keating MJ, Estrov Z. The synthetic heat shock protein (Hsp) 90 inhibitor EC141 induces degradation of the Bcr-Abl p190 protein and apoptosis of Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) cells. Blood 110(11):819a(2784), 2007. e-Pub 2007.
114. Ma W, Zhang X, Jilani I, Ravandi F, Estey E, Kantarjian H, Giles F, Sheikholeslami M, Keating M, Albitar M. Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: Clinical significance and implications. Blood 110(11):840a(#2855), 2007. e-Pub 2007.
115. Tseng R, C-H Y, Jilani I, Zhang Z, Kantarjian H, Cortes J, O’Brien S, Giles F, Hannah A, Estrov Z, Keating M, Albitar M. High levels of circulating HSP70 levels in patients with chronic myeloid leukemia and correlation with resistance to therapy with imatinib. Blood 110(11):859a(#2922), 2007. e-Pub 2007.
116. Tam CS, Keating MJ, Tsimberidou AM, O’Brien S, Ferrajoli A, Lerner S, Abruzzo L, Schlette E, Kantarjian H, Wierda W. The clinical usefulness of novel prognostic factors in CLL: A study of 477 patients with low-risk (non-11q, non-17p) FISH and known IGVH mutation status. Blood 110(11):905a(3079), 2007. e-Pub 2007.
117. Schlette EJ, Tam C, Admirand J, Wierda W, O’Brien S, Lerner S, Keating MJ. ZAP70 expression by immunohistochemistry correlates with IgVH mutation status in chronic lymphocytic leukemia and predicts time to progression, but survival is decreased in p53-positive CLL, regardless of ZAP70 expression. Blood 110(11):907a(3083), 2007. e-Pub 2007.
118. Chen R, Wierda WG, Benaissa S, Hoch U, Hawtin RE, Fox JA, Keating MJ, Gandhi V, Plunkett W. Mechanism of action of SNS-032, a novel cyclin dependent kinase inhibitor, in chronic lymphocytic leukemia: Comparison with flavopiridol. Blood 110(11):915a(#3112), 2007. e-Pub 2007.
119. O’Brien S, Kipps TJ, Faderl S, Crump M, Keating MJ, Anderson B, Soho C, Bole J, Turner R, Viallet J, Cheson BJ. A phase I trial of the small molecule pan-bcl-2 family inhibitor GX15-070 administered intravenously (IV) every 3 weeks to patients with previously treated chronic lymphocytic leukemia (CLL) 106:135a(446), 2005. e-Pub 2005.
120. Oldham EA, Feng L, Liu J, Keating MJ, Plunkett W, Huang P. Increased free radical production in cancer cells: A biochemical basis for the selective anticancer activity of 2-methoxyestradiol. Cancer Research 42:190(1021), 2001. e-Pub 2001.
121. Rai K, Coutre S, Rizzieri D, Gribben J, Flinn I, Rabinowe S, Keating MJ. Efficacy and safety of alemtuzumab (Campath-1H) in refractory B-CLL patients treated on a compassionate basis. Blood 98:365a(1538), 2001. e-Pub 2001.
122. Yazji S, Cortes J, Albitar M, Keating M, O’Brien S, Kantarjian H. Clinical characteristics and outcome of patients diagnosed with large granular lymphocytic leukemia (LGL). Blood 98:288b(4897), 2001. e-Pub 2001.
123. Wierda W, O’Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Kantarjian H, Keating M. Combined fludarabine, cyclophosphamide, and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia. Blood 98:771a(3210), 2001. e-Pub 2001.
124. Tsimberidou AM, Thomas DA, Faderl S, Cortes J, Garcia-Manero G, O’Brien SM, Albitar M, Kantarjian HM, Keating M, Giles FJ. Alternating cyclophosphamide, vincristine, liposomal daunorubicin (DaunoXome), and dexamethasone (hCVXD) with methotrexate (MTX), and ara-C (A) regimen plus rituximab and GM-CSF in patients with refractory chronic lymphocytic leukemia (CLL) or Richter’s syndrome (RS). Blood 98:294b(4921), 2001. e-Pub 2001.
125. Sen F, Jilani I, Kantarjian H, Giles F, Keating MJ, Freireich E, Talpaz M, Albitar M. High expression of CXCR1, CXCR2 and CXCR4 in marrow CD34+ cells but not in mature myeloid cells from CML patients compared to acute leukemias and MDS. Blood 98:267b(4801), 2001. e-Pub 2001.
126. Scappini B, Gatto S, Kantarjian H, Onida F, Keating MJ, Beran M. Characterization of Bcr-Abl-positive cell lines with inherent and acquired resistance to STI571. Blood 98:182b(4420), 2001. e-Pub 2001.
127. Beran M, Onida F, Cortes J, O’Brien S, Giles F, Estey E, Keating MJ, Koller C, Kantarjian H. Chemotherapy of increasing intensity in the treatment of chronic myelomonocytic leukemia (CMML). Blood 98:624a(2614), 2001. e-Pub 2001.
128. Coutre S, Rai K, Keating MJ, Gribben JG, Flinn I, Rabinowe S, Rizzieri D. Efficacy and safety of alemtuzumab (Campath-1H) used on a compassionate basis in refractory T-PLL. Blood 98:366a(1542), 2001. e-Pub 2001.
129. Faderl S, Thomas D, O’Brien S, Giles F, Koller C, Beran M, Williams M, Garcia-Manero G, Kantarjian H, Keating MJ. An exploratory study of the combination of monoclonal antibodies CAMPATH-1H and rituximab in the treatment of CD52- and CD20- positive chronic lymphoid disorders. Blood 98:365a(1537), 2001. e-Pub 2001.
130. Ferrajoli A, O’Brien S, Williams M, Faderl S, Kantarjian H, Keating MJ. Campath-1H in refractory hematological malignancies expressing CD-52. A phase II clinical trial of 68 patients. Blood 98:366a(1541), 2001. e-Pub 2001.
131. Gatto, SR, Scappini B, Verstovsek S, Milella M, Onida F, Ball G, Kantarjian H, Keating MJ, Cortes J, Beran M. In vitro effects of PS-341 alone and in combination with STI571 in bcr-abl positive cell lines both sensitive and resistant to STI571. Blood 98:101a(424), 2001. e-Pub 2001.
132. Giles F, Vose J, Manshouri T, Dey A, Bociek G, Bierman P, Keating M. Clinical relevance of angiogenesis-modulating factors in patients with Hodgkin’s disease (HD) and non-Hodgkin’s lymphoma (NHL). Blood 98:805a(3346), 2001. e-Pub 2001.
133. Jilani I, Estey E, Manshouri T, Caligiuri M, Keating MJ, Giles F, Thomas D, Kantarjian H, Albitar M. Detection of FLT-3 internal tandem duplication in peripheral blood plasma DNA: the hemizygous genotype predicts poor outcome in acute myeloid leukemia (AML). Blood 98:459a(1920), 2001. e-Pub 2001.
134. Kantarjian H, Cortes J, O’Brien S, Giles F, Thomas D, Garcia-Manero G, Faderl S, Rios MB, Shan J, Hayes K, Keating MJ. Imatinib mesylate (STI571) therapy of Philadelphia chromosome-positive chronic myeloid leukemia in early chronic phase (Ph + CML early CP). Blood 98:137a(577), 2001. e-Pub 2001.
135. Keating MJ, Reddy B, Bodey Sr G, Lerner S, O’Brien S, Kontoyiannis D. Infectious complications in fludarabine refractory CLL patients. Blood 98:633a(2651), 2001. e-Pub 2001.
136. O’Brien S, Giles F, Rai K, Andreeff M, Cunningham C, Frankel S, Keating M. Bcl-2 antisense (Genasense) as monotherapy for refractory chronic lymphocytic leukemia. Blood 98:722a(3213), 2001. e-Pub 2001.
137. Khouri, IF, Giralt S, Saliba R, Korbling M, Gajewski J, Younes A, Romaguera J, Anderlini P, Rodriguez MA, Donato ML, Ippoliti C, Keating M. “Mini” –allogeneic stem cell transplantation for relapsed/refractory lymphomas with aggressive histologies. . Journal of Clinical Oncology 19:47a, 2000. e-Pub 2000.
138. Cortes, J, O’Brien S, Giles F, Thomas D, Lenaz L, Beer M, Keating M, Kantarjian HM. 9-Nitro-20-(S)-Camptothecin (9-NC, RFS2000) in chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML) and myelodysplastic syndromes (MDS). . Journal of Clinical Oncology 19:7a, 2000. e-Pub 2000.
139. Ferrajoli A, O’Brien S, Kurzrock R, Giles F, Williams M, Thomas D, Kantarjian H, Beran M, Keating M. Phase II clinical trial of campath-1H in refractory hematological malignancies expressing the surface antigen CD52. . Journal of Clinical Oncology 19:8a, 2000. e-Pub 2000.
140. Keating, MJ, O’Brien S, Cortes J, Giles F, Kantarjian H. Fludarabine and cyclophosphamide combined with rituxan (FCR) is a potent cytoreductive regimen as initial therapy of chronic lymphocytic leukemia. . Journal of Clinical Oncology 19:8a, 2000. e-Pub 2000.
141. Thomas, DA, Aguayo A, Estey E, Albitar M, O’Brien S, Giles FJ, Beran M, Cortes J, Zeldis J, Keating MJ, Barlogie B, Kantarjian HM. Thalidomide as anti-angiogenesis therapy (Rx) in refractory or relapsed leukemias. Blood 94:507a, 1999. e-Pub 1999.
142. Cortes J, Plunkett W, O’Brien S, Giles F, Habboubi N, Du M, Ayres M, Keating M, Kantarjian H. Phase I trial of trimetrexate (TMTX) in acute leukemias. Journal of Clinical Oncology 18:22a, 1999. e-Pub 1999.
143. Fayad L, Keating MJ, O’Brien S, Talpaz M, Kurzrock R. High serum interleukin-6 (sIL-6) and serum interleukin-10 (sIL-10) levels correlates with poor survival in chronic lymphocytic leukemia (CLL) patients (pts). . Blood 92:24a, 1999. e-Pub 1999.
144. Chung-Wu L, Manshouri T, Neuberg D, Patel K, Gidel C, Kantarjian H, Andreeff M, Estrov Z, Beran M, Keating M, Estey E, Albitar M. Proliferation and apoptosis in leukemias and myelodysplasia as measured by PCNA level and caspase-3 activity. . Blood 94:69a, 1999. e-Pub 1999.
145. Ferrajoli, A, Estrov Z, Keating M, Lerner S, Manshouri T, Beran M, Kantarjian H, Albitar M. The level of vascular endothelial growth factor receptor-2 in peripheral blood chronic lymphocytic leukemia (CLL) cells correlates with patient survival. Blood 94:536a, 1999. e-Pub 1999.
146. Aguayo A, Manshouri T, O’Brien S, Lerner S, Kantarjian H, Rogers A, Beran M, Freireich E, Keating M, Albitar M. Expression and clinical relevance of Tie-1 and Flt-1 in chronic lymphocytic leukemia (CLL). . Blood 94:294b, 1999. e-Pub 1999.
147. Choudhury A, Vasquez ZM, Arena CA, Claxton DF, Thomas EK, Keating MJ, Champlin RE. B-CLL cells treated with CD40 ligand, upregulate their T-cell stimulatory capacity and serve as accessory cells for the ex vivo generation of autologous antileukemic cytotoxicity. . Blood 94:126a, 1999. e-Pub 1999.
148. Chandra J, Pahler J, Niemer I, Andreeff M, Keating M, McConkey DJ. Inhibition of NFxB induces apoptosis in CLL lymphocytes. Blood 94:279a, 1999. e-Pub 1999.
149. Beran M, Giles FJ, Cortes JE, Thomas DA, Koller C, O’Brien SM, Keating MJ, Freireich E, Kantarjian HM, Estey E. Comparison of the cyclophsophamide (C), ara-C (A), topotecan (T), (CAT) regimen to ara-C plus topotecan or idarubicin (I) as initial therapy for patients with adverse abnormal karyotype acute myeloid leukemia (AML). . Blood 94:238b, 1999. e-Pub 1999.
150. Montillo M, Tedeschi A, DiRaimondo F, O’Brien S, Lerner S, Morra E, Keating M. Phase II study of 2-chlorodeoxyadenosine (2-CDA) and cyclophosphamide (CP) in patients with chronic lymphocytic leukemia. Blood 94:127a, 1999. e-Pub 1999.
151. O’Brien, SM, Thomas DA, Freireich EJ, Andreeff M, Giles FJ, Keating MJ. Rituxan has significant activity in patients with CLL. . Blood 94:603a, 1999. e-Pub 1999.
152. Kantarjian H, O’Brien S, Cortes J, Faderl S, Giles F, Koller C, Pierce S, Keating MJ. Outcome with the hyper-CVAD regimen in lymphoblastic lymphoma (LL). . Journal of Clinical Oncology 18:22a, 1999. e-Pub 1999.
153. Kantarjian HM, Talpaz M, Cortes J, Rios MB, Giles FJ, Mallard S, Bramble D, Murgo A, Cheson B, Kornblau S, Keating M, O’Brien S. Homoharringtonine and low-dose cytosine (LDara-C) in late chronic phase chronic myelogenous leukemia (CML). . Blood 94:276b, 1999. e-Pub 1999.
154. Kantarjian, HM, Talpaz M, Cortes J, Rios MB, Giles FJ, Thomas D, Andreeff M, Mallard S, Lim J, Murgo A, Cheson B, Keating M, O’Brien S. Triple combination therapy with interferon-alpha (IFN-a), low-dose cytarabine (LDara-C) and homoharringtonine (HHT) in Philadelphia chromosome (PH)-positive chronic myelogenous leukemia (CML) in early chronic phase. Blood 94:275b, 1999. e-Pub 1999.
155. Onida F, Smith T, S-Y L, Kantarjian H, Keating MJ, Estey E, Albitar M, Giles FJ, Pierce S, Beran M. Prognostic factors in chronic myelomonocytic leukemia: A retrospective single institution analysis of 228 patients. Blood 94:308a, 1999. e-Pub 1999.
156. Keating AR, O’Brien SM, Cortes JE, Thomas D, Koller C, Beran M, Kantarjian HM, Keating MJ, Giles FJ. Pilot study of fludarabine (F), cyclophosphamide ©, and amifostine (A) (FCA) in patients with chronic lymphocytic leukemia. Blood 94:313a, 1999. e-Pub 1999.
157. Keating MJ, Byrd J, Rai K, Flinn I, Jain V, Binet JL, Bolin R, Hillmen P, Hutchinson M, Campath. 1H collaborative study group: Multicenter study of Campath-1H in patients with chronic lymphocytic leukemia (B-CLL) refractory to fludarabine. . Blood 94:705, 1999. e-Pub 1999.
158. Pahler JC, Niemer I, Andreeff M, Keating MJ, McConkey DJ. PKC- and AKT- dependent cell survival pathways in CLL. . Blood 94:703a, 1999. e-Pub 1999.
159. Aguayo A, Kantarjian H, Estey E, Cortes J, Beran M, O’Brien S, Keating M, Freireich E, Thomas D, Rogers A, Albitar M. Plasma levels of VEGF and bFGF in various leukemias and their correlation with angiogenesis. Blood 94:503a, 1999. e-Pub 1999.
160. Thomas, DA, Aguayo A, Giles FJ, Albitar M, O’Brien S, Cortes J, Faderl S, Bivins C, Zeldis J, Keating MJ, Barlogie B, Kantarjian H. Thalidomide anti-angiogenesis therapy (Rx) in Philadelphia (Ph)-negative myeloproliferative disorders (MPD) and myelofibrosis (MF). . Blood 94:702a, 1999. e-Pub 1999.
161. Thomas DA, O’Brien S, Cortes J, Giles FJ, Koller C, Estey E, Kurzrock R, Faderl S, Pierce S, Keating MJ, Kantarjian H. Pilot study of Rituximab in refractory or relapsed hairy cell leukemia (HCL). . Blood 94:705a, 1999. e-Pub 1999.
162. Thomas DA, Sarris A, O’Brien S, Cortes J, Giles FJ, Faderl S, Keating MJ, Burge C, Cabanillas F, Kantarjian H. Phase II study of liposomal vincristine (LIPOV) in relapsed or refractory adult acute lymphoblastic leukemia (ALL). . Blood 94:238b, 1999. e-Pub 1999.
163. Aguayo A, Estey E, Kantarjian H, Cortes J, Beran M, O’Brien S, Keating M, Freireich E, Thomas D, Rogers A, Albitar M. High plasma levels of VEGF correlate with chroter survival in patients with acute myelogenous leukemia (AML). . Blood 94:503a, 1999. e-Pub 1999.
164. Kozuch P, Ibrahim N, Khuri F, Hoff P, Estey E, Gandhi V, Du M, Rios MB, Plunkett W, Keating MJ, Kantarjian H. Phase I clinical and pharmacological study of clofarabine. Blood 94:127a, 1999. e-Pub 1999.
165. Kurtzberg J, Ernst TJ, Keating MJ, Gandhi V, Hodge JP, Kisor DF, Therriault R, Stephens C, Levin J, Krenitsky T, Elion GB, Mitchell BS. A phase I study of 2-amino-9-B-D-arabinosyl-6-methoxy-9H-purine (506U78) administered on a consecutive five day schedule in children and adults with refractory hematologic malignancies. Blood 94:629a, 1999. e-Pub 1999.
166. Dabaja BS, Kantarjian HM, Cortes JE, Thomas DA, Sarris A, O’Brien SM, Keating MJ, Giles FJ. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), dexamethasone (hyperCVXD) regimen in Richter’s syndrome. Blood 94:260b, 1999. e-Pub 1999.
167. Dabaja BS, Estallila O, Giles FJ, O’Brien SM, Keating MJ, Sarris AH, Medeiros LJ, Cabanillas F. A distinct subtype of blastoid NK cell non-Hodgkin’s lymphoma (NHL) expressing TdT: Clinicopathologic analysis of 4 cases. . Blood 94:244b, 1999. e-Pub 1999.
168. Aguayo, A, Kantarjian H, Talpaz M, Estey E, Koller C, Estrov Z, O’Brien S, Keating M, Barlogie B, Albitar M. Increased angiogenesis in chronic myeloid leukemia and myelodysplastic syndromes. Blood 92:607a, 1998. e-Pub 1998.
169. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Barlogie B, Koller C, O’Brien S, Albitar M, Keating M. Low levels of vascular endothelial growth factor (VEGF) in cells of patients with chronic lymphocytic leukemia (CLL) correlate with survival, particularly in patients with low b-2 microglobulin (b2M) levels. . Blood 92:226a, 1998. e-Pub 1998.
170. Vey, N, Keating MJ, Rios MB, Estey E. Effect of CR on survival in patients with AML receiving first salvage therapy. . Blood 92:235a, 1998. e-Pub 1998.
171. Thomas D, Kantarjian H, Cortes J, O’Brien S, Pierce S, Faderl S, Murphy S, Albitar M, Keating MJ. The Hyper-CVAD program in Burkitt’s type adult acute lymphoblastic leukemia (B-ALL). Blood 92:402a, 1998. e-Pub 1998.
172. Thomas D, O’Brien S, Kantarjian H, Giles FJ, Lerner S, Keating MJ. outcome in 203 patients (pts) with relapsed or refractory B-cell chronic lymphocytic leukemia (CLL) with salvage therapy (Rx): retreatment with fludarabine (FLU). . Blood 92:102a, 1998. e-Pub 1998.
173. Talpaz M, Cortes J, O’Brien S, Keating M, Giles F, Rose E, Rybak ME, Kantarjian H. Phase I study of polyethlene glycol (PEG) interferon alpha-2B (INTRON-A) in CML patients. . Blood 92:251a, 1998. e-Pub 1998.
174. Seymour JF, O’Brien S, Kantarjian HM, Lerner S, Pollock R, Keating M. The incidence and impact of persistent cytopenias despite significant leukemic cytoreduction with fludarabine (FAMP) in patients with CLL. Journal of Clinical Oncology 17:6a, 1998. e-Pub 1998.
175. Sandoval, A, Huang P, Van Den Neste E, Keating M, Plunkett W. Inhibition of RNA synthesis: A biochemical mechanism of fludarabine-induced apoptosis in chronic lymphocytic leukemia cells. . Cancer Research 39:405, 1998. e-Pub 1998.
176. Sacchi, S, Kantarjian HM, O’Brien S, Cortes J, Kornblau S, Keating MJ, Freireich EJ, Talpaz M. Excessive toxicity with the combination of alpha interferon (IFN-a), low-dose cytosine arabinoside (LD-Ara-C) and all trans-retinoic acid (ATRA) in patients with chronic myellogenous leukemia (CML). . Blood 92:249b, 1998. e-Pub 1998.
177. Rodriguez, J, O’Brien S, Lerner S, Cortes J, Kantarjian H, Keating M. Activity of fludarabine in patietns (PTS) with de novo B-cell prolymphocytic leukemia (PLL) and the prolymphocytoid variant of chronic lymphocytic leukemia (CLL-Pro). Blood 92:104a, 1998. e-Pub 1998.
178. Przepiorka, D, Cortes J, Folloder J, Ueno NT, Mehra R, Khouri I, Giralt S, Gajewski J, Donato M, Claxton D, K-W C, Braunschweig I, Van Besein K, Andersson B, Anderlini P, Keating M, Champlin R. Allogeneic transplantation for adult acute lymphoblastic leukemia. Blood 92:354b, 1998. e-Pub 1998.
179. O’Brien S, Kantarjian H, Koller C, Andreeff M, Feldman E, Keating M, Beran M, Freireich E. Sequential homoharringtonine (HHT) and interferon (IFN-A0 produce high hematologic and cytogenetic response rates in Philadelphia chromosome positive (Ph) chronic myelogenous leukemia (CML). . Blood 92:656a, 1998. e-Pub 1998.
180. O’Brien S, Cortes J, Giles FJ, Faderl S, Rios M, Keating M, Talpaz M. “Sudden” blastic phase (SBP) transformation in the first 2 years (YRS) of interferon-a (IFN) therapy (Rx) for chronic phase (CP) chronic myelogenous leukemia (CML). Blood 92:251a, 1998. e-Pub 1998.
181. O’Brien, S, Freireich E, Andreef M, Lerner S, Keating M. Phase I/II study of rituxan in chronic lymphocytic leukemia (CLL). . Blood 92:105a, 1998. e-Pub 1998.
182. O’Brien S, Boyer K, Keating M, Kurzock R. Relapse of hairy cell leukemia (HCL) after 2-chlorodeoxyadenosine (2-CDA) therapy (Rx): long-term follow-up (FU) of 99 patients (PTS). . Blood 92:103a, 1998. e-Pub 1998.
183. Lee, B-N, Estrov Z, Huh Y, O’Brien S, Lerner S, Kurzrock R, Keating M, Reuben J. Peripheral blood normal polyclonal B cells from patients with B-chronic lymphocytic leukemia (B-CLL) produce B-cell stimulatory cytokines. . Cancer Research 39:405, 1998. e-Pub 1998.
184. Koller C, Cortes J, O’Brien S, Giles F, Keating M, Kantarjian H. A pilot study of dose-intensive anthracyclines for acute lymphoblastic leukemia (ALL) using liposomal daunorubicin (LD) with hyperfractionated cyclophosphamide (CTX), vincristine (VCR), and prednisone (PDN). . Journal of Clinical Oncology 17:28a, 1998. e-Pub 1998.
185. Khouri I, Keating M, Lerner S, O’Brien S, Champlin R. Improved survial with allogeneic and autologous stem cell transplantation for chronic lymphocytic leukemia (CLL): a case-matched analysis with conventional chemotherapy. . Blood 92:287a, 1998. e-Pub 1998.
186. Kantarjian HM, O’Brien S, M-B R, Cortes J, Giles FJ, Andreeff M, Keating MJ, Talpaz M. Treatment of Philadelphia chromosome (Ph)-positive early chronic phase (CP) chronic myelogenous leukemia (CML) with daily doses of interferon alpha (IFN-a) and low dose cytosine arabinoside (ara-C). . Blood 92:246b, 1998. e-Pub 1998.
187. Kantarjian H, O’Brien S, M-B R, Cortes J, Giles FJ, Gajewski M, Beran M, Kornblau S, Mallard S, Keating M, Cheson B, Murgo A, Talpaz M. Homoharringtonine (HHT) and low-dose cytosine arabinoside )LD-ara-C) is effective and safe for the treatment of Philadelphia chromosome (Ph)-positive late chronic phase (CP) chronic myelogenous leukemia (CML). Blood 92:246b, 1998. e-Pub 1998.
188. Kantarjian H, O’Brien S, Keating MJ, Cortes J, Giles FJ, Beran M, Koller C, Andreeff M, Kornblau S, Pierce S, Murphy S, Freireich EJ. Update of the hyper-CVAD dose-intensive regimen in adult acute lymphocytic leukemia (ALL). . Blood 92:312a, 1998. e-Pub 1998.
189. Huh, Y, Kantarjian H, Pierce S, Bueso-Ramos C, Hirsch-Ginsberg C, Albitar M, O’Brien S, Alexanian R, Weber D, Keating M. Expression of CD52 in human hematopoietic malignancies. . Blood 92:278b, 1998. e-Pub 1998.
190. Haidar, M, Kantarjian H, Manshouri T, C-Y C, O’Brien S, Freireich E, Keating M, Albitar M. ATM gene deletion and prognosis in adult acute lymphoblastic leukemia (ALL). . Blood 92:225a, 1998. e-Pub 1998.
191. Giles, FJ, Wong GC, O’Brien SM, Kantatjian HM, Keating MJ. Fractionated cyclophosphamide, vincristine, liposomal daunomycin and dexamethasone regimen (CVXD) is active in transformed chronic lymphocytic leukemia (CLL). . Blood 92:276b, 1998. e-Pub 1998.
192. Giles, FJ, Wong GC, O’Brien SM, Cortes J, Freireich E, Estey E, Talpaz M, Kantarjian HM, Keating MJ. A pilot study of daily oral idarubicin in patients with chronic myeloid leukemia (CML). . Blood 92:224b, 1998. e-Pub 1998.
193. Giles, FJ, Kantarjian H, O’Brien SM, Freireich E, Keating MJ, Estey E. Leukapheresis reduces early risk of mortality in acute myeloid leukemia (AML) patients with high white cell counts receiving first induction therapy. Blood 92:237a, 1998. e-Pub 1998.
194. Gandhi, V, Keating MJ, Rodriguez CO, Du M, Nowak B, Ayres M, Ramakrishna P, Hodge J, Weller S, Plunkett W. 506U78 in indolent leukemias: pharmacokinetics of arabinosylguanine triphosphate during therapy. Blood 92:102a, 1998. e-Pub 1998.
195. Estey E, Giles F, O’Brien S, Kantarjian H, Kornblau S, Keating M, Freireich E. Liposomal (Lipo) atra monotherapy of newly –diagnosed APL. Blood 92:402a, 1998. e-Pub 1998.
196. Cortes, J, Kantarjian H, Talpaz M, O’Brien S, Beran M, Giles FJ, Koller C, Keating M, Estey E, Freireich EJ. Cyclophosphamide (CTX), Ara-C, and topotecan (TOP) (CAT) for patients (PTS) with chronic myelogenous leukemia (CML) in transformation. . Blood 92:627a, 1998. e-Pub 1998.
197. Cortes J, Koller C, Thomas D, O’Brien S, Giles FJ, Rios A, Keating M, Kantarjian H. Treatment of AIDS-related burkitt’s leukemia (ALL-L3) or lymphoma with the hyper-CVAD regimen. Blood 92:402a, 1998. e-Pub 1998.
198. Cortes, J, Kantarjian H, O’Brien S, Giles FJ, Koller C, Beran M, Keating M, Estey E. High-dose liposomal daunorubicin (DNX) and ara-C (HDAC) for refractory or relapsed acute leukemias: a dose searching study. . Blood 92:234a, 1998. e-Pub 1998.
199. Cortes J, O’Brien, Kantarjian H, Giles FJ, Keating M. Treatment of anemia and/or thrombocytopenia associated with chronic lymphocytic leukemia (CLL) with cyclosporin A (CsA). . Blood 92:104a, 1998. e-Pub 1998.
200. Cortes J, Kantarjian H, O’Brien S, Beran M, Giles F, Keating M, Estey E. Phase I study of liposomal daunorubicin (LD) in refractory or relapsed acute myeloid leukemia (AML) or blast phase chronic myelogenous leukemia (CML-BP). Journal of Clinical Oncology 17:5a, 1998. e-Pub 1998.
201. Chandra, J, Niemer I, Gilbreath J, Kliche KO, Andreeff M, Keating M, McConkey DJ. Inhibition of the proteasome induces apoptosis in resistant chronic lymphocytic leukemia lymphocytes. Cancer Research 39:405, 1998. e-Pub 1998.
202. Berman RS, Bouvet M, Lerner SA, Keating MJ, Pollock RE. Splenectomy provides durable restoration of platelets in thromobocytopenic chronic lymphocytic leukemia. Journal of Clinical Oncology 17:6a, 1998. e-Pub 1998.
203. Albitar, M, O’Brien S, Manshouri T, Gidel C, Kantarjian H, Freireich E, Keating M. Deletions of p16INKa/p19ARF and p15INK4b in chronic lymphocytic leuekmia (CLL) and their clinical significance. Blood 92:258b, 1998. e-Pub 1998.
204. Albitar M, O’Brien S, Manshouri T, Gidel C, Kantarjian H, Lerner S, Freireich EJ, Keating M. The clinical significance of multidrug resistance proteins MDR1, MRP, and LRP in chronic lymphocytic leukemia. Blood 92:258b, 1998. e-Pub 1998.
205. Albitar, M, O’Brien S, Manshouri T, Gidel C, Lerner S, Kantarjian H, Freireich EJ, Keating MJ. Discrepancy between cellular b2-Microglobulin (sb2M in predicting prognosis in chronic lymphocytic leukemia (CLL). . Blood 92:258b, 1998. e-Pub 1998.
206. Albitar M, O’Brien S, Lerner S, Manshouri T, Sim S, Dodd K, Kantarjian H, Freireich EJ, Keating M. Variations in the low levels of CD1/BCL1 have prognostic value in chronic lymphocytic leukemia (CLL). . Blood 92:430a, 1998. e-Pub 1998.
207. Albitar, M, C-Y C, Haidar M, Manshouri T, Gidel C, Freireich E, Keating M, Kantarjian H. Deletions in the 13q14 locus in adult acute lymphoblastic leukemia (ALL) and their impact on prognosis. Blood 92:225a, 1998. e-Pub 1998.
208. Aguayo, A, Kantarjian H, Manshouri T, Gidel C, Keating M, Giles F, Estrov Z, Barlogie B, Estey E, Albitar M. Intracellular levels of vascular endothelial growth factor (VEGF) in leukemic cells are an independent predictor of complete remission rate and survival in acute myeloid leukemia (AML). . Blood 92:678a, 1998. e-Pub 1998.
209. Albitar, M, Manshouri T, Kantarjian H, Keating M, Estrov Z, Faber J, Freireich E, Pierce S, Estey E. Favorable cytogenetic groups in acute myeloid leukemia (AML) do not overexpress c-MPL protein. Blood 90:63a, 1997. e-Pub 1997.
210. Albitar, M, Kantarjian H, Manshouri T, O’Brien S, Andreeff M, Kornblau S, Beran M, Keating M, Talpaz M. Expression of BCL-2 and FAS in chronic myelogenous leukemia (CML). . Blood 90:275b, 1997. e-Pub 1997.
211. Beran M, Kantarjian H, Keating M, O’Brien S, Pierce S, Koller C, Cortes J, Andreeff M, Kornblau S, Estey E. Results of combination chemotherapy with topotecan and high-dose cytosine arabinoside (ara-C) in previously untreated patients with high-risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). . Blood 90:583a, 1997. e-Pub 1997.
212. Chandra J, Neimer I, Gilbreath J, Kliche KO, Andreeff M, Keating M, McConkey DJ. Inhibition of the proteasome and subsequent downregulation of NFkB induces apoptosis in glucocorticoid resistant chronic lymphocytic leukemia lymphocytes in vitro. . Blood 90:306b, 1997. e-Pub 1997.
213. Cortes, J, Kantarjian H, Keating M, O’Brien S, Rodriguez J, Pierce S, Estey E. b-2-microglobulin (B2M) is a significant prognostic factor for outcome of patients (pts) with newly diagnosed acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). . Blood 90:66a, 1997. e-Pub 1997.
214. Cortes, J, Kantarjian H, Beran M, O’Brien S, Koller C, Kornblau S, Andreeff M, Keating M, Freireich EJ, Estey E. Cyclophosphamide (CTX), ara-C and topotecan (TOP) (CAT) in patients (pts) with refractory or relapsed acute leukemias and transformed chronic myelogenous leukemia (CML). . Blood 90:505a, 1997. e-Pub 1997.
215. Cortes J, Kantarjian H, O’Brien S, Keating M, Estey E. Interleukin 2 (IL2) therapy for adult patients (pts) with acute myelogenous leukemia (AML) in first complete remission (CR). . Blood 90:505a, 1997. e-Pub 1997.
216. Cortes J, Kantarjian H, O’Brien S, Andreeff M, Estey E, Keating M. Methotrexate, vincristine, PEG-asparaginase and prednisone (MOAP) for patients (pts) with refractory or relapsed acute lymphoblastic leukemia (ALL). . Blood 90:239b, 1997. e-Pub 1997.
217. Weinkauff R, Starostik P, Hayes K, Huh YO, Hirsch-Ginsberg C, Bueso-Ramos C, Andreeff M, Keating M, Kantarjian H, Freireich E, Estey E, Albitar M. Use of peripheral blood blasts versus bone marrow blasts for diagnosis for acute leukemia. Blood 90:224b, 1997. e-Pub 1997.
218. Thomas D, Kantarjian H, Koller C, O’Brien S, Keating MJ, Beran M, Estey E, Pierce S, Freireich E. Review of 43 patients (pts) with adult lymphoblastic leukemia (ALL) in relapse after initial CR duration >2 years: Chracteristics, response and outcome with salvage therapy. . Blood 90:247b, 1997. e-Pub 1997.
219. Thomas D, Kantarjian H, O’Brien S, Keating MJ, Koller C, Beran M, Estey E, Pierce S, Freireich E. Refractory or relapsed Burkitt’s type adult lymphoblastic leukemia (ALL): Chracteristics and outcome with salvage therapy. Blood 90:247b, 1997. e-Pub 1997.
220. Starostik, P, O’Brien S, Manshouri T, Haidar M, Kantarjian H, Freireich E, E, Keating M, Albitar M. Allelotyping of chronic lymphocytic leukemia. Blood 90:90a, 1997. e-Pub 1997.
221. Starostik P, Manshouri T, O’Brien S, Freireich E, Kantarjian H, Lerner S, Keating M, Albitar M. The ATM gene is deleted in a subgroup of B-cell chronic lymphocytic leukemia. Blood 90:90a, 1997. e-Pub 1997.
222. Dabaja, BS, Kantarjian H, O’Brien S, Estey E, Keating M. Deletion or losses in chromosomes 5 or 7 in adults with acute lymphocytic leukemia (ALL): Incidence, associations and implications. . Blood 90:211b, 1997. e-Pub 1997.
223. Dabaja B, Kantarjian H, Pierce S, Keating M, Estey E. The outcome of FUO during induction therapy of AML/MDS. Blood 90:227b, 1997. e-Pub 1997.
224. O’Brien, S, Kantarjian H, Keating M, Beran M, Rios M, Robinson J, Kornblau S, Talpaz M. Homoharringtonine (HHT) and low-dose cytarabine (ara-C) in patients with late chronic phase (CP) chronic myelogenous leukemia (CML). . Blood 90:514a, 1997. e-Pub 1997.
225. Estey E, Thall P, Kantarjian H, Pierce S, Keating M. The value of CR in newly-diagnosed AML. . Blood 90:73a, 1997. e-Pub 1997.
226. Estey, E, Beran M, Pierce S, Kantarjian H, Keating M. ALL-trans retinoic acid (ATRA) may improve results of chemotherapy in poor prognosis non-APL AML and MDS: A randomized study. . Blood 90:416a, 1997. e-Pub 1997.
227. Estey E, Dahlberg S, Kantarjian H, Reed P, Pierce S, MacPherson B, Bianco J, Singer J, Keating M. Randomized trial of idarubicin + Ara-C + lisofylline in newly-diagnosed AML/MDS. . Blood 90:506a, 1997. e-Pub 1997.
228. Li, L, Keating MJ, Plunkett W, L-Y: Y. Fludarabine-mediated inhibition of DNA repair induces synergistic cytotoxicity with cisplatin in human K562 leukemia cells. Cancer Research 38(10):2, 1997. e-Pub 1997.
229. Fayad L, Kurzrock R, Keating M, O’Brien S, Kantarjian H, Andreeff M, Pierce S, Talpaz M, Freireich E, Estey. Treatment of hairy-cell leukemia (HCL) with 2-CdA: Long term follow-up at M.D. Anderson Cancer Center. Blood 90:530a, 1997. e-Pub 1997.
230. Fleming, R, Kantarjian H, Lichtiger B, Keating M, Estey E. Granulocyte transfusions from GM-CSF treated donors as infection prophylaxis in AML/MDS during induction. Blood 90:131b, 1997. e-Pub 1997.
231. Ravandi, F, Keating M, Pierce S, Estey E. Identification of a relatively favorable group within AML/MDS patients with chromosome 5 and/or 7 abnormalities. . Blood 90:64a, 1997. e-Pub 1997.
232. Rodriguez, JrCO, Legha JK, Keating MJ, Estey EH, Plunkett W, Gandhi V. Differential metabolism of arabinosylguanine in T-ALL vs. other leukemias: Strategies to increase triphosphate accumulation. Cancer Research 38:100, 1997. e-Pub 1997.
233. Romaguera, J, Khouri I, Hagemeister FB, Rodriguez MA, McLaughlin P, Sarris A, Younes A, Keating MJ, Koller C, O’Brien S, Riggs S, Kantarjian H, Champlin R, Cabanillas F. Indolent lymphoma and aggressive lymphoma HCVAD/ARA-C-MTX (HCVAD/A-M) with or without high dose chemotherapy and stem cell transfusion (SCT) as salvage for relapsed or refractory diffuse/nodular mantle cell lymphoma (MCL). . Blood 90:189a, 1997. e-Pub 1997.
234. Kornblau, SM, Thall P, Walterscheid M, Estrov Z, Keating M, Patel S, Kantarjian H, Estey E, Andreeff M. Acute myelogenous leukemia (AML) patients with lower levels of BCL2 expression and unfavorable cytogenetics have a very poor prognosis. Blood 90:216b, 1997. e-Pub 1997.
235. Sacchi, S, Kantarjian H, Smith T, O’Brien S, Pierce S, Kornblau S, Beran M, Keating M, Talpaz M. Early treatment decisions with interferon alpha (IFN-A) therapy in early chronic phase. . Blood 90:517a, 1997. e-Pub 1997.
236. Gandhi V, JrCO R, Kisor DF, Keating MJ, Plunkett W. Rationale and design of pharmacologically directed clinical trials of GW506U in refractory hematologic malignancies. . Blood 90:241b, 1997. e-Pub 1997.
237. Koller, CA, Kantarjian H, Feldman E, Estey E, O’Brien S, Rios MB, Keating M. A phase I/II trial of increasing doses of mitoxantrone with fludarabine and cytarabine (FAM regimen) in relapsed acute leukemia and chronic myelogenous leukemia in blastic phase (CML-BP). . Blood 90:243b, 1997. e-Pub 1997.
238. Koller, CA, Kantarjian HM, Thomas D, O’Brien S, Rios MB, Kornblau S, Murphy S, Keating M. Hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. . Blood 90:332a, 1997. e-Pub 1997.
239. Koehl, U, Li L, Nowak B, Ruiz van Haperen V, Kornhuber B, Schwabe D, O’Brien S, Keating M, Plunkett W, L-Y Y. Fludarabine and cyclophosphamide: Synergistic cytotoxicity associated with inhibition of interstrand cross-link removal. Cancer Research 38(10):2, 1997. e-Pub 1997.
240. Huang, P, Ballal K, Keating MJ, Plunkett W. Identification and characterization of the enzymatic components responsible for high molecular weight DNA fragmentation during apoptosis. Cancer Research 38(34):5, 1997. e-Pub 1997.
241. Kantarjian H, O’Brien S, Keating M, Estey E, Beran M, Koller C, Kornblau S, M-B R, Freireich E, Talpaz M. Interferon alpha (IFN-a) and low-dose cytosine arabinoside (ARA-C) therapy in Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML). Journal of Clinical Oncology 16:13a, 1997. e-Pub 1997.
242. Kantarjian, H, O’Brien S, Keating M, Rios MB, Talpaz M. Decitabine, a hypomethylating agent shows encouraging results in the treatment of chronic myelogenous leukemia (CML) in transformation. . Blood 90:81a, 1997. e-Pub 1997.
243. Kantarjian H, Manshouri T, Talpaz M, O’Brien S, Keating M, Cortes J, Pierce S, Andreeff M, Kornblau S, Albitar M. Multidrug resistance (MDR) expression in chronic myelogenous leukemia (CML). . Blood 90:502a, 1997. e-Pub 1997.
244. Kantarjian H, Manshouri PT, Estrov Z, Talpaz M, O’Brien S, Beran M, Pierce S, Estey E, Keating M, Albitar M. Significance of C-MPL expression in philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML). . Blood 90:278b, 1997. e-Pub 1997.

Book Chapters

1. Wierda WG, Keating MJ, O'Brien S. Chronic Lymphocytic Leukemias. In: Cancer: Principles and Practice of Oncology. 8. Lippincott Williams & Wilkins, 2278-2292, 2008.
2. Rai KR, Keating MJ. Chronic Lymphocytic Leukemia. In: Cancer Medicine 7. BC Decker Inc, 1786-1801, 2006.
3. Tsimberidou AM, Keating MJ. Hyperuricemic Syndromes in Cancer Patients. In: Contrib Nephrol. S. Karger AG, 47-60, 2005.
4. Qazilbash MH, Keating MJ. Chronic Leukemias. In: Bethesda Handbook of Clinical Oncology. Lippincott Williams & Wilkins, 325-330, 2005.
5. Bodey GP, Kontoyiannis D, Keating MJ. Infections in Patients with Chronic Lymphocytic Leukemia. In: Contemporary Hematology, Chronic Lymphocytic Leukemia: Molecular Genetics, Biology, Diagnosis, and Management. Humana Press Inc, 343-359, 2003.
6. Ferrajoli A, Keating MJ, O’Brien SM. Chemotherapy of Chronic Lymphocytic Leukemia. In: Contemporary Hematology, Chronic Lymphocytic Leukemia: Molecular Genetics, Biology, Diagnosis, and Management. Humana Press Inc, 241-254, 2003.
7. Tannir N, Keating M, O’Brien S. Diagnosis and Treatment of Chronic Lymphocytic Leukemia. In: Neoplastic Diseases of the Blood. 4. Cambridge University Press, 83-95, 2003.
8. Rai KR, Keating MJ. Chronic Lymphocytic Leukemia. In: Cancer Medicine 6. BC Decker Inc, 2135-2148, 2003.
9. Keating MJ. Chronic Lymphocytic Leukemia. In: Encyclopedia of Cancer. Academic Press, Elsevier Science, 497-503, 2002.
10. Giles FJ, Andreeff M, Keating MJ. Acute Myeloid Leukemia. In: Cancer Treatment. W.B. Saunders Company, 1280-1294, 2001.
11. Ravandi F, Keating MJ, O’Brien SM. Supportive Care in Chronic Lymphocytic Leukemia. In: Chronic Lymphoid Leukemias. Marcel Dekker Inc, 485-504, 2001.
12. Thomas DA, O’Brien SM, Keating MJ. Management of the Patient with Relapsed or Refractory Chronic Lymphocytic Leukemia. In: Chronic Lymphoid Leukemias. Marcel Dekker Inc, 275-333, 2001.
13. Khouri IF, Keating MJ, Champlin R. Hematopoietic stem cell transplantation for chronic lymphocytic leukemia. In: Curr Opin Hematol. 6. Lippincott Williams & Wilkins, in press, 1998.
14. Koehl, U, Yang LY, Li L, Nowak B, van Haperen V, Keating MJ, Plunkett W. Effect of Combined Treatment with 4-Hydroper oxycyclophosphamide and Fludarabine on Cytotoxicity and Repair of Damaged DNA. Experimental Approaches and Novel Therapies. In: Acute Leukemias VII. Springer-Verlag, 549-555, 1997.
15. Gandhi V, Estey EE, Seymour JF, Sampath D, Du M, Ayers M, Keating M, Plunkett W. Modulation of Ara-C Metabolism to Improve AML Response. Experimental Approaches and Novel Therapies. In: Acute Leukemias VII. Springer-Verlag, 577-583, 1997.
16. Deisseroth AB, Kantarjian H, Andreeff M, Talpaz M, Keating MJ, Khouri I, Champlin RB. Chronic Leukemias. In: Cancer: Principles and Practice of Oncology. Lippincott-Raven, 2321-2343, 1997.
17. McLaughlin P, Robertson LE, Keating MJ. Fludarabine phosphate in lymphoma: An important new therapeutic agent. In: Cancer Treat Res. Kluwer Academic Publishers, 3-14, 1996.

Letters to the Editor

1. Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Oken MM, Schiffer CA, Keating MJ, Boldt DH, Kempin SJ, Foon KA. Chronic lymphocytic leukemia: recommendations. Annals of Internal Medicine 110: 664-665, 1989.